Dr Emanuela Palmerini from the IRCCS Istituto Ortopedico Rizzoli in Bologna, Italy, discusses the current and future clinical treatment of tenosynovial giant cell tumor, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the management of tenosynovial giant cell tumor with Dr Emanuela Palmerini, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-11-20T10:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/fa51cdbb-70cf-4a16-8091-563422cecb11.mp3","mime_type":"audio/mpeg","size_in_bytes":38404265,"duration_in_seconds":3835}]},{"id":"ac268d20-2dd5-4a21-8565-d34d6d726738","title":"Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care — Prostate Cancer","url":"https://oncologytoday.researchtopractice.com/307","content_text":"Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with prostate cancer, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here. ","content_html":"Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with prostate cancer, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring discussions with specialists on optimal management and the potential role of investigational approaches for prostate cancer, moderated by Dr Neil Love. Produced by Research To Practice. ","date_published":"2024-11-20T08:15:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/ac268d20-2dd5-4a21-8565-d34d6d726738.mp3","mime_type":"audio/mpeg","size_in_bytes":34337264,"duration_in_seconds":3430}]},{"id":"b5dfdd24-e677-4cb4-9294-e346c60b598c","title":"Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care — Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia ","url":"https://oncologytoday.researchtopractice.com/306","content_text":"Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here. ","content_html":"Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring discussions on optimal management and investigational approaches for non-Hodgkin lymphoma and chronic lymphocytic leukemia, moderated by Dr Neil Love. Produced by Research To Practice. ","date_published":"2024-11-20T08:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/b5dfdd24-e677-4cb4-9294-e346c60b598c.mp3","mime_type":"audio/mpeg","size_in_bytes":33819816,"duration_in_seconds":3371}]},{"id":"5461d98c-a020-427b-893f-35a607666b74","title":"Optimizing Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer Harboring PI3K/AKT/PTEN Pathway Abnormalities","url":"https://oncologytoday.researchtopractice.com/303","content_text":"Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Hope S Rugo from the UCSF Helen Diller Family Comprehensive Cancer Center discuss treatment decision-making for HR-positive metastatic breast cancer in patients who harbor PI3K/AKT/PTEN pathway mutations, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here. ","content_html":"Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Hope S Rugo from the UCSF Helen Diller Family Comprehensive Cancer Center discuss treatment decision-making for HR-positive metastatic breast cancer in patients who harbor PI3K/AKT/PTEN pathway mutations, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the management of HR+ metastatic breast cancer with mutations in PI3K, AKT or PTEN with Drs Jhaveri and Rugo, moderated by Dr Neil Love. Produced by Research To Practice. ","date_published":"2024-11-18T09:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/5461d98c-a020-427b-893f-35a607666b74.mp3","mime_type":"audio/mpeg","size_in_bytes":34165882,"duration_in_seconds":3408}]},{"id":"e2601a55-799c-4471-a50e-7a38b134da0e","title":"Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care — Lung Cancer","url":"https://oncologytoday.researchtopractice.com/302","content_text":"Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with lung cancer, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here. ","content_html":"Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with lung cancer, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring discussions with specialists on optimal management and the potential role of investigational approaches for lung cancer, moderated by Dr Neil Love. Produced by Research To Practice. ","date_published":"2024-11-15T11:30:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/e2601a55-799c-4471-a50e-7a38b134da0e.mp3","mime_type":"audio/mpeg","size_in_bytes":39460680,"duration_in_seconds":3942}]},{"id":"7d0a9126-9951-4737-be2a-96ff05f8d310","title":"Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care — Breast Cancer","url":"https://oncologytoday.researchtopractice.com/301","content_text":"Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with HR-positive breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here.","content_html":"Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with HR-positive breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring discussions with specialists on optimal management and the potential role of investigational approaches for HR-positive breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. ","date_published":"2024-11-15T10:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/7d0a9126-9951-4737-be2a-96ff05f8d310.mp3","mime_type":"audio/mpeg","size_in_bytes":38407162,"duration_in_seconds":3832}]},{"id":"2a8d8caf-61b0-4e0f-8180-0fbfa348d4d8","title":"What Clinicians Want to Know About the Current and Future Role of EZH1/2 Inhibitors in the Care of Patients with Lymphoma","url":"https://oncologytoday.researchtopractice.com/300","content_text":"Dr Gilles Salles from the Memorial Sloan Kettering Cancer Center in New York, New York, reviews current and novel EZH1/2 inhibitor-based treatment strategies for follicular lymphoma, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here. ","content_html":"Dr Gilles Salles from the Memorial Sloan Kettering Cancer Center in New York, New York, reviews current and novel EZH1/2 inhibitor-based treatment strategies for follicular lymphoma, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on EZH1/2 inhibitors for the treatment of follicular lymphoma with Dr Gilles Salles, moderated by Dr Neil Love. Produced by Research To Practice. ","date_published":"2024-11-08T09:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/2a8d8caf-61b0-4e0f-8180-0fbfa348d4d8.mp3","mime_type":"audio/mpeg","size_in_bytes":33855336,"duration_in_seconds":3374}]},{"id":"fc8ffb1a-cdb0-4500-ae66-5f409e07fd60","title":"Special Edition — Key Presentations on Lung Cancer from Recent Major Conferences ","url":"https://oncologytoday.researchtopractice.com/299","content_text":"Dr Stephen V Liu from Georgetown University Hospital in Washington, DC, reviews recently presented data with and newly approved therapies for localized and advanced lung cancers, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here. ","content_html":"Dr Stephen V Liu from Georgetown University Hospital in Washington, DC, reviews recently presented data with and newly approved therapies for localized and advanced lung cancers, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on data from recent conference presentations and new approvals in lung cancer with Dr Stephen V Liu, moderated by Dr Neil Love. Produced by Research To Practice. ","date_published":"2024-11-06T10:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/fc8ffb1a-cdb0-4500-ae66-5f409e07fd60.mp3","mime_type":"audio/mpeg","size_in_bytes":32834280,"duration_in_seconds":3279}]},{"id":"a9a9a439-0b47-4950-a1dc-c146cd733c20","title":"The Implications of Recent Datasets for the Current and Future Management of Gastrointestinal Cancers — An ESMO Congress 2024 Review ","url":"https://oncologytoday.researchtopractice.com/298","content_text":"Dr Tanios Bekaii-Saab from Mayo Clinic in Phoenix, Arizona, and Dr Philip A Philip from the Henry Ford Cancer Institute in Detroit, Michigan, discuss recent research presentations on the treatment of gastrointestinal cancers, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here. ","content_html":"Dr Tanios Bekaii-Saab from Mayo Clinic in Phoenix, Arizona, and Dr Philip A Philip from the Henry Ford Cancer Institute in Detroit, Michigan, discuss recent research presentations on the treatment of gastrointestinal cancers, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion of GI cancers after the 2024 ESMO annual congress and other conferences, with Drs Bekaii-Saab and Philip, moderated by Dr Neil Love. Produced by Research To Practice. ","date_published":"2024-11-05T08:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/a9a9a439-0b47-4950-a1dc-c146cd733c20.mp3","mime_type":"audio/mpeg","size_in_bytes":37482187,"duration_in_seconds":3744}]},{"id":"81daf8a8-033d-44cd-89ac-efd0ed32998c","title":"Improving Outcomes with First-Line Endocrine-Based Therapy for Patients with HR-Positive, HER2-Negative Metastatic Breast Cancer","url":"https://oncologytoday.researchtopractice.com/297","content_text":"Prof Francois-Clement Bidard from Institut Curie in Paris and Dr Kevin Kalinsky from Winship Cancer Institute of Emory University in Atlanta discuss improving the outcomes of first-line endocrine-based therapy for patients with HR-positive, HER2-negative metastatic breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here.","content_html":"Prof Francois-Clement Bidard from Institut Curie in Paris and Dr Kevin Kalinsky from Winship Cancer Institute of Emory University in Atlanta discuss improving the outcomes of first-line endocrine-based therapy for patients with HR-positive, HER2-negative metastatic breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on first-line therapy for HR-positive, HER2-negative metastatic breast cancer with Prof Bidard and Dr Kalinsky, moderated by Dr Neil Love. Produced by Research To Practice. ","date_published":"2024-11-01T10:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/81daf8a8-033d-44cd-89ac-efd0ed32998c.mp3","mime_type":"audio/mpeg","size_in_bytes":57832224,"duration_in_seconds":3569}]},{"id":"841f45b4-6975-4eb1-959f-bc425b838078","title":"Practical Perspectives: Optimizing the Role of BTK Inhibitors in the Management of Mantle Cell Lymphoma","url":"https://oncologytoday.researchtopractice.com/296","content_text":"Dr Tycel Phillips from the City of Hope Comprehensive Cancer Center in Duarte, California, and Dr Michael Wang from the University of Texas MD Anderson Cancer Center in Houston discuss the current role of Bruton tyrosine kinase inhibitors for the management of newly diagnosed and relapsed/refractory mantle cell lymphoma, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here.","content_html":"Dr Tycel Phillips from the City of Hope Comprehensive Cancer Center in Duarte, California, and Dr Michael Wang from the University of Texas MD Anderson Cancer Center in Houston discuss the current role of Bruton tyrosine kinase inhibitors for the management of newly diagnosed and relapsed/refractory mantle cell lymphoma, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the use of Bruton tyrosine kinase inhibitors for mantle cell lymphoma with Drs Tycel Phillips and Michael Wang, moderated by Dr Neil Love. Produced by Research To Practice. ","date_published":"2024-10-29T11:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/841f45b4-6975-4eb1-959f-bc425b838078.mp3","mime_type":"audio/mpeg","size_in_bytes":34889016,"duration_in_seconds":3478}]},{"id":"542003be-4515-4ad3-9783-2003e8f0354f","title":"Potential Role of PROTAC ER Degraders in Therapy for HR-Positive Metastatic Breast Cancer","url":"https://oncologytoday.researchtopractice.com/295","content_text":"Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville discusses emerging evidence with proteolysis-targeting chimera estrogen receptor degraders for HR-positive metastatic breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here.","content_html":"Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville discusses emerging evidence with proteolysis-targeting chimera estrogen receptor degraders for HR-positive metastatic breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the optimal management of breast cancer with Dr Erika Hamilton, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-10-25T10:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/542003be-4515-4ad3-9783-2003e8f0354f.mp3","mime_type":"audio/mpeg","size_in_bytes":27535162,"duration_in_seconds":2745}]},{"id":"61a0ee77-ec6e-44bb-95e1-cc7f6d316a66","title":"Practical Perspectives: Current Management of Chronic Myeloid Leukemia","url":"https://oncologytoday.researchtopractice.com/294","content_text":"Drs Bhavana (Tina) Bhatnagar, Amanda Blackmon, Jorge Cortes, Michael J Mauro and Neil P Shah discuss recent updates on clinical treatment strategies for chronic myeloid leukemia, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here. ","content_html":"Drs Bhavana (Tina) Bhatnagar, Amanda Blackmon, Jorge Cortes, Michael J Mauro and Neil P Shah discuss recent updates on clinical treatment strategies for chronic myeloid leukemia, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the management of chronic myeloid leukemia with Drs Bhatnagar, Blackmon, Cortes, Mauro and Shah, moderated by Dr Neil Love. Produced by Research To Practice. ","date_published":"2024-10-23T09:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/61a0ee77-ec6e-44bb-95e1-cc7f6d316a66.mp3","mime_type":"audio/mpeg","size_in_bytes":65718216,"duration_in_seconds":6561}]},{"id":"79e45b5a-aa88-4188-9b23-ed598eb01893","title":"The Implications of Recent Datasets for the Current and Future Management of Small Cell Lung Cancer — A 2024 World Conference on Lung Cancer Review","url":"https://oncologytoday.researchtopractice.com/293","content_text":"Dr Jacob Sands from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent presentations on approved and investigational therapies in small cell lung cancer from the 2024 World Conference on Lung Cancer, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here.","content_html":"Dr Jacob Sands from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent presentations on approved and investigational therapies in small cell lung cancer from the 2024 World Conference on Lung Cancer, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent presentations on small cell lung cancer from the 2024 World Conference on Lung Cancer with Dr Jacob Sands, moderated by Dr Neil Love. Produced by Research To Practice. ","date_published":"2024-10-22T09:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/79e45b5a-aa88-4188-9b23-ed598eb01893.mp3","mime_type":"audio/mpeg","size_in_bytes":41501989,"duration_in_seconds":2566}]},{"id":"91c80db5-2448-459d-b4f2-aebc5058e6ef","title":"Practical Perspectives: Optimizing Diagnosis and Treatment for Patients with Desmoid Tumors","url":"https://oncologytoday.researchtopractice.com/292","content_text":"Dr Thierry Alcindor from Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr Mrinal Gounder from Memorial Sloan Kettering Cancer Center in New York, New York, summarize the treatment landscape for desmoid tumors and review novel options for targeted therapy, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here. ","content_html":"Dr Thierry Alcindor from Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr Mrinal Gounder from Memorial Sloan Kettering Cancer Center in New York, New York, summarize the treatment landscape for desmoid tumors and review novel options for targeted therapy, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on targeted therapies for desmoid tumors with Dr Thierry Alcindor and Dr Mrinal Gounder, moderated by Dr Neil Love. Produced by Research To Practice. ","date_published":"2024-10-18T10:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/91c80db5-2448-459d-b4f2-aebc5058e6ef.mp3","mime_type":"audio/mpeg","size_in_bytes":35637302,"duration_in_seconds":3561}]},{"id":"6e7e22b0-e9bf-427c-810e-7b942b52712b","title":"Peripheral T-Cell Lymphoma","url":"https://oncologytoday.researchtopractice.com/291","content_text":"Dr Stephen Horwitz from Memorial Sloan Kettering Cancer Center in New York, New York, discusses management strategies for previously untreated and relapsed peripheral T-cell lymphomas, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here.","content_html":"Dr Stephen Horwitz from Memorial Sloan Kettering Cancer Center in New York, New York, discusses management strategies for previously untreated and relapsed peripheral T-cell lymphomas, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the presentation and management of peripheral T-cell lymphomas with Dr Horwitz, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-10-16T11:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/6e7e22b0-e9bf-427c-810e-7b942b52712b.mp3","mime_type":"audio/mpeg","size_in_bytes":28033416,"duration_in_seconds":2792}]},{"id":"40443d82-ac38-4512-bcde-52a735750495","title":"The Implications of Recent Datasets for the Current and Future Use of Nontargeted Therapy for Metastatic Non-Small Cell Lung Cancer","url":"https://oncologytoday.researchtopractice.com/290","content_text":"Dr Edward Garon from UCLA Health Jonsson Comprehensive Cancer Center and Dr Luis Paz-Ares from the Spanish National Oncology Research Center in Madrid share their perspectives on recent datasets from the 2024 World Conference on Lung Cancer on the management of non-small cell lung cancer without actionable genomic alterations, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here.","content_html":"Dr Edward Garon from UCLA Health Jonsson Comprehensive Cancer Center and Dr Luis Paz-Ares from the Spanish National Oncology Research Center in Madrid share their perspectives on recent datasets from the 2024 World Conference on Lung Cancer on the management of non-small cell lung cancer without actionable genomic alterations, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on NSCLC from the 2024 World Conference on Lung Cancer with Drs Garon and Paz-Ares, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-10-15T09:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/40443d82-ac38-4512-bcde-52a735750495.mp3","mime_type":"audio/mpeg","size_in_bytes":58540509,"duration_in_seconds":3607}]},{"id":"4476b8af-6c98-4513-9ac8-32357540081e","title":"Meet The Professor: Optimizing the Management of Chronic Lymphocytic Leukemia — Part 1 of a 3-Part Series","url":"https://oncologytoday.researchtopractice.com/289","content_text":"Dr Matthew S Davids from Dana-Farber Cancer Institute in Boston, Massachusetts, reviews current available data and ongoing investigational treatment approaches for chronic lymphocytic leukemia, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here. ","content_html":"Dr Matthew S Davids from Dana-Farber Cancer Institute in Boston, Massachusetts, reviews current available data and ongoing investigational treatment approaches for chronic lymphocytic leukemia, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on current and emerging therapies for chronic lymphocytic leukemia with Dr Matthew S Davids, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-10-10T09:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/4476b8af-6c98-4513-9ac8-32357540081e.mp3","mime_type":"audio/mpeg","size_in_bytes":35492136,"duration_in_seconds":3538}]},{"id":"a5d3bb14-74e6-48f0-955f-3990743124f5","title":"The Implications of Recent Datasets for the Current and Future Management of Non-Small Cell Lung Cancer with Actionable Targets Beyond EGFR","url":"https://oncologytoday.researchtopractice.com/288","content_text":"Dr Ibiayi Dagogo-Jack from Massachusetts General Hospital in Boston and Dr Corey J Langer from the Abramson Cancer Center in Philadelphia, Pennsylvania, discuss the implications of recent datasets for the current and future management of non-small cell lung cancer with actionable targets beyond EGFR, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here.","content_html":"Dr Ibiayi Dagogo-Jack from Massachusetts General Hospital in Boston and Dr Corey J Langer from the Abramson Cancer Center in Philadelphia, Pennsylvania, discuss the implications of recent datasets for the current and future management of non-small cell lung cancer with actionable targets beyond EGFR, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion of recent data for the management of NSCLC with actionable targets beyond EGFR with Drs Dagogo-Jack and Langer, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-10-08T09:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/a5d3bb14-74e6-48f0-955f-3990743124f5.mp3","mime_type":"audio/mpeg","size_in_bytes":34975320,"duration_in_seconds":3493}]},{"id":"8bdf7e6f-5316-4f7d-a2c8-5cb031ebe728","title":"The Implications of Recent Datasets for the Current and Future Management of Non-Small Cell Lung Cancer with EGFR Mutations","url":"https://oncologytoday.researchtopractice.com/287","content_text":"Dr Joshua K Sabari from the NYU Langone Health Perlmutter Cancer Center and Dr Helena Yu from Memorial Sloan Kettering Cancer Center in New York, New York, summarize the treatment landscape for non-small cell lung cancer with EGFR mutations, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here. ","content_html":"Dr Joshua K Sabari from the NYU Langone Health Perlmutter Cancer Center and Dr Helena Yu from Memorial Sloan Kettering Cancer Center in New York, New York, summarize the treatment landscape for non-small cell lung cancer with EGFR mutations, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on therapies for patients with advanced non-small cell lung cancer and EGFR mutations with Drs Sabari and Yu, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-10-01T10:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/8bdf7e6f-5316-4f7d-a2c8-5cb031ebe728.mp3","mime_type":"audio/mpeg","size_in_bytes":35029320,"duration_in_seconds":3499}]},{"id":"6dae340a-d282-4550-9c94-069c75c0d54b","title":"Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast Cancer","url":"https://oncologytoday.researchtopractice.com/286","content_text":"Dr Tiffany Traina from the Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College in New York, New York, discusses optimizing the management of metastatic BRCA-negative, triple-negative breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here. ","content_html":"Dr Tiffany Traina from the Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College in New York, New York, discusses optimizing the management of metastatic BRCA-negative, triple-negative breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the management of metastatic BRCA-negative, triple-negative breast cancer with Dr Tiffany Traina, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-09-24T08:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/6dae340a-d282-4550-9c94-069c75c0d54b.mp3","mime_type":"audio/mpeg","size_in_bytes":30031162,"duration_in_seconds":2995}]},{"id":"bd97ab59-01a8-4243-a1de-c9b958aae93b","title":"Striving for Consensus: Optimizing the Current and Future Management of Biliary Tract Cancers","url":"https://oncologytoday.researchtopractice.com/285","content_text":"Dr Lipika Goyal from Stanford Cancer Center in Palo Alto, California, Dr James J Harding from Memorial Sloan Kettering Cancer Center in New York, New York, Dr Milind Javle from The University of Texas MD Anderson Cancer Center in Houston, Texas, and Dr Robin K (Katie) Kelley from UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, California, summarize the treatment landscape for patients with biliary tract cancers and review recent advancements in the field, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here. ","content_html":"Dr Lipika Goyal from Stanford Cancer Center in Palo Alto, California, Dr James J Harding from Memorial Sloan Kettering Cancer Center in New York, New York, Dr Milind Javle from The University of Texas MD Anderson Cancer Center in Houston, Texas, and Dr Robin K (Katie) Kelley from UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, California, summarize the treatment landscape for patients with biliary tract cancers and review recent advancements in the field, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on targeted therapies for biliary tract cancers with Drs Goyal, Harding, Javle and Kelley, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-09-20T14:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/bd97ab59-01a8-4243-a1de-c9b958aae93b.mp3","mime_type":"audio/mpeg","size_in_bytes":80953867,"duration_in_seconds":8092}]},{"id":"1d23221c-730f-4971-a8f8-0fe2c6fa7366","title":"Inside the Issue: Optimizing the Diagnosis and Treatment of Neuroendocrine Tumors","url":"https://oncologytoday.researchtopractice.com/284","content_text":"Dr Pamela Kunz from the Yale School of Medicine and Yale Cancer Center in New Haven, Connecticut, and Dr Simron Singh from the Odette Cancer Centre and Sunnybrook Health Sciences Centre in Toronto, Ontario, Canada, discuss optimizing the diagnosis and treatment of neuroendocrine tumors, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here. ","content_html":"Dr Pamela Kunz from the Yale School of Medicine and Yale Cancer Center in New Haven, Connecticut, and Dr Simron Singh from the Odette Cancer Centre and Sunnybrook Health Sciences Centre in Toronto, Ontario, Canada, discuss optimizing the diagnosis and treatment of neuroendocrine tumors, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the diagnosis and treatment of neuroendocrine tumors with Dr Pamela Kunz and Dr Simron Singh, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-09-17T10:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/1d23221c-730f-4971-a8f8-0fe2c6fa7366.mp3","mime_type":"audio/mpeg","size_in_bytes":35616182,"duration_in_seconds":3559}]},{"id":"dab29bd2-48cb-4912-add9-baf34973b045","title":"Inside the Issue: Integrating HER2-Targeted Strategies into the Management of Gastrointestinal Cancers","url":"https://oncologytoday.researchtopractice.com/283","content_text":"Dr Tanios Bekaii-Saab from the Mayo Clinic Cancer Center in Phoenix, Arizona, and Dr John Strickler from Duke University in Durham, North Carolina, review clinical data supporting the application of HER2-targeted therapies for patients with gastrointestinal cancers, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here. ","content_html":"Dr Tanios Bekaii-Saab from the Mayo Clinic Cancer Center in Phoenix, Arizona, and Dr John Strickler from Duke University in Durham, North Carolina, review clinical data supporting the application of HER2-targeted therapies for patients with gastrointestinal cancers, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on HER2-targeted therapies for gastrointestinal cancers, with Drs Tanios Bekaii-Saab and John Strickler, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-09-11T11:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/dab29bd2-48cb-4912-add9-baf34973b045.mp3","mime_type":"audio/mpeg","size_in_bytes":36621787,"duration_in_seconds":3658}]},{"id":"928b8695-09d8-4a6b-b23a-79d9a5a80f03","title":"Optimizing the Management of Dedifferentiated Liposarcoma","url":"https://oncologytoday.researchtopractice.com/282","content_text":"Dr Mrinal Gounder from Memorial Sloan Kettering Cancer Center in New York, New York, discusses recent updates on available and emerging treatment strategies for dedifferentiated liposarcoma and other sarcomas, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here.","content_html":"Dr Mrinal Gounder from Memorial Sloan Kettering Cancer Center in New York, New York, discusses recent updates on available and emerging treatment strategies for dedifferentiated liposarcoma and other sarcomas, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on dedifferentiated liposarcoma with Dr Mrinal Gounder, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-09-09T08:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/928b8695-09d8-4a6b-b23a-79d9a5a80f03.mp3","mime_type":"audio/mpeg","size_in_bytes":45148502,"duration_in_seconds":4513}]},{"id":"d8779e93-98a7-410b-9e40-58c1bcde3b5b","title":"Inside the Issue: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast Cancer","url":"https://oncologytoday.researchtopractice.com/281","content_text":"Prof Peter Schmid from the Barts Cancer Institute in London, United Kingdom, and Dr Sara Tolaney from the Dana-Farber Cancer Institute in Boston, Massachusetts, review clinical trials investigating the role of antibody-drug conjugate-mediated therapies in the treatment of metastatic breast cancer.\n\nCME information and select publications here","content_html":"Prof Peter Schmid from the Barts Cancer Institute in London, United Kingdom, and Dr Sara Tolaney from the Dana-Farber Cancer Institute in Boston, Massachusetts, review clinical trials investigating the role of antibody-drug conjugate-mediated therapies in the treatment of metastatic breast cancer.
\n\nCME information and select publications here
","summary":"Featuring a discussion on antibody-drug conjugates for metastatic breast cancer, with Prof Peter Schmid and Dr Sara Tolaney, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-09-06T08:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/d8779e93-98a7-410b-9e40-58c1bcde3b5b.mp3","mime_type":"audio/mpeg","size_in_bytes":37621402,"duration_in_seconds":3754}]},{"id":"55acdf87-56d0-4ae4-85ec-bc5702d224a3","title":"Current and Future Management of Non-Small Cell Lung Cancer with an EGFR Mutation","url":"https://oncologytoday.researchtopractice.com/280","content_text":"Dr Pasi Jänne from the Dana-Farber Cancer Institute in Boston, Massachusetts, Prof Tom John from the Peter MacCallum Cancer Centre in Melbourne, Australia, Dr Zofia Piotrowska from Massachusetts General Hospital in Boston, Massachusetts, and Dr Alexander Spira from the Virginia Cancer Specialists Research Program in Fairfax, discuss recent updates on available and emerging treatment strategies for non-small cell lung cancer with an EGFR mutation.\n\nCME information and select publications here","content_html":"Dr Pasi Jänne from the Dana-Farber Cancer Institute in Boston, Massachusetts, Prof Tom John from the Peter MacCallum Cancer Centre in Melbourne, Australia, Dr Zofia Piotrowska from Massachusetts General Hospital in Boston, Massachusetts, and Dr Alexander Spira from the Virginia Cancer Specialists Research Program in Fairfax, discuss recent updates on available and emerging treatment strategies for non-small cell lung cancer with an EGFR mutation.
\n\nCME information and select publications here
","summary":"Featuring a discussion on NSCLC with an EGFR mutation with Dr Pasi Jänne, Prof Tom John, Dr Zofia Piotrowska and Dr Alexander Spira, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-09-04T08:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/55acdf87-56d0-4ae4-85ec-bc5702d224a3.mp3","mime_type":"audio/mpeg","size_in_bytes":74065320,"duration_in_seconds":7402}]},{"id":"e985700e-4bba-46b3-ba5f-26f098648fd0","title":"Management of Metastatic Urothelial Bladder Cancer","url":"https://oncologytoday.researchtopractice.com/279","content_text":"Dr Michiel van der Heijden from the Netherlands Cancer Institute in Amsterdam discusses the management of metastatic urothelial bladder cancer, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here.","content_html":"Dr Michiel van der Heijden from the Netherlands Cancer Institute in Amsterdam discusses the management of metastatic urothelial bladder cancer, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the management of metastatic urothelial bladder cancer with Dr Michiel van der Heijden, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-08-30T08:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/e985700e-4bba-46b3-ba5f-26f098648fd0.mp3","mime_type":"audio/mpeg","size_in_bytes":18489344,"duration_in_seconds":1845}]},{"id":"85a489ec-7dbb-42fb-aa45-81e4d43d1345","title":"Special Edition — Key Presentations on Breast Cancer from the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting","url":"https://oncologytoday.researchtopractice.com/278","content_text":"Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, discusses recent advances in the treatment of breast cancer following the 2024 ASCO Annual Meeting, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here. ","content_html":"Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, discusses recent advances in the treatment of breast cancer following the 2024 ASCO Annual Meeting, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on breast cancer with Dr Priyanka Sharma, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-08-28T11:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/85a489ec-7dbb-42fb-aa45-81e4d43d1345.mp3","mime_type":"audio/mpeg","size_in_bytes":45667162,"duration_in_seconds":4558}]},{"id":"17bff86d-0365-4074-a730-636479e9cfff","title":"An interview with Professor Giuseppe Curigliano, MD, PhD — Management of Metastatic Breast Cancer","url":"https://oncologytoday.researchtopractice.com/277","content_text":"Prof Giuseppe Curigliano from the European Institute of Oncology in Milano, Italy discusses current questions and controversies in the management of metastatic breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here. ","content_html":"Prof Giuseppe Curigliano from the European Institute of Oncology in Milano, Italy discusses current questions and controversies in the management of metastatic breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion of questions and controversies in the management of metastatic breast cancer with Prof Giuseppe Curigliano, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-08-23T08:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/17bff86d-0365-4074-a730-636479e9cfff.mp3","mime_type":"audio/mpeg","size_in_bytes":27807562,"duration_in_seconds":2772}]},{"id":"94638989-38b0-4a81-9524-4a9f509939e0","title":"An interview with Angeles Alvarez Secord, MD, MHSc — Management of Ovarian and Endometrial Cancer","url":"https://oncologytoday.researchtopractice.com/276","content_text":"Dr Angeles Alvarez Secord from the Duke Cancer Institute in Durham, North Carolina, provides her perspectives on recent datasets from ASCO 2024 on the management of ovarian and endometrial cancers, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here. ","content_html":"Dr Angeles Alvarez Secord from the Duke Cancer Institute in Durham, North Carolina, provides her perspectives on recent datasets from ASCO 2024 on the management of ovarian and endometrial cancers, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the current and future management of gynecologic cancers, with Dr Angeles Alvarez Secord, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-08-21T10:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/94638989-38b0-4a81-9524-4a9f509939e0.mp3","mime_type":"audio/mpeg","size_in_bytes":31623228,"duration_in_seconds":3156}]},{"id":"e5ab696f-1978-4eee-9ef9-e99a25676192","title":"Inside the Issue: Integrating ALK-Targeted Therapy into the Management of Localized Non-Small Cell Lung Cancer","url":"https://oncologytoday.researchtopractice.com/275","content_text":"Prof Solange Peters from the Lausanne University Hospital in Lausanne, Switzerland, and Professor Ben Solomon from the Peter MacCallum Cancer Centre in Melbourne, Australia, discuss treatment approaches for ALK-rearranged non-small cell lung cancer in the localized disease setting, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here. ","content_html":"Prof Solange Peters from the Lausanne University Hospital in Lausanne, Switzerland, and Professor Ben Solomon from the Peter MacCallum Cancer Centre in Melbourne, Australia, discuss treatment approaches for ALK-rearranged non-small cell lung cancer in the localized disease setting, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the management of localized NSCLC with ALK rearrangements with Profs Solange Peters and Ben Solomon, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-08-20T10:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/e5ab696f-1978-4eee-9ef9-e99a25676192.mp3","mime_type":"audio/mpeg","size_in_bytes":36877800,"duration_in_seconds":3683}]},{"id":"477115ef-23d2-460a-976b-e540694fe135","title":"Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast Cancer","url":"https://oncologytoday.researchtopractice.com/274","content_text":"Dr Sara A Hurvitz from the Fred Hutchinson Cancer Center in Seattle, Washington, summarizes recent trials investigating the integration of antibody-drug conjugates for HR-positive and triple-negative metastatic breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here. ","content_html":"Dr Sara A Hurvitz from the Fred Hutchinson Cancer Center in Seattle, Washington, summarizes recent trials investigating the integration of antibody-drug conjugates for HR-positive and triple-negative metastatic breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on antibody-drug conjugate-mediated therapies for HR-positive breast cancer and TNBC, with Dr Sara Hurvitz, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-08-16T07:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/477115ef-23d2-460a-976b-e540694fe135.mp3","mime_type":"audio/mpeg","size_in_bytes":32657482,"duration_in_seconds":3257}]},{"id":"cfdbdeb6-38cc-4352-bef9-0bc10036992f","title":"Novel Agents and Strategies in Lung Cancer","url":"https://oncologytoday.researchtopractice.com/273","content_text":"Dr Melissa Johnson from Sarah Cannon Research Institute in Nashville, Tennessee, Dr Ticiana Leal from Winship Cancer Institute of Emory University in Atlanta, Georgia, and Dr Manish Patel from Florida Cancer Specialists & Research Institute in Sarasota, Florida, summarize recently presented advancements, including novel strategies, in the treatment of lung cancer, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here. ","content_html":"Dr Melissa Johnson from Sarah Cannon Research Institute in Nashville, Tennessee, Dr Ticiana Leal from Winship Cancer Institute of Emory University in Atlanta, Georgia, and Dr Manish Patel from Florida Cancer Specialists & Research Institute in Sarasota, Florida, summarize recently presented advancements, including novel strategies, in the treatment of lung cancer, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on treatments for lung cancer, with Drs Melissa Johnson, Ticiana Leal and Manish Patel, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-08-13T10:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/cfdbdeb6-38cc-4352-bef9-0bc10036992f.mp3","mime_type":"audio/mpeg","size_in_bytes":37073400,"duration_in_seconds":3703}]},{"id":"3d782682-056f-4651-9341-241f6136dfe7","title":"Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Multiple Myeloma","url":"https://oncologytoday.researchtopractice.com/272","content_text":"Dr Jesús G Berdeja from the Greco-Hainsworth Tennessee Oncology Centers for Research in Nashville and Dr Thomas Martin from UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco discuss the most relevant new data sets and advances in multiple myeloma, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here. ","content_html":"Dr Jesús G Berdeja from the Greco-Hainsworth Tennessee Oncology Centers for Research in Nashville and Dr Thomas Martin from UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco discuss the most relevant new data sets and advances in multiple myeloma, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion of the most relevant new data sets and advances in multiple myeloma with Drs Jesús G Berdeja and Thomas Martin, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-08-09T12:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/3d782682-056f-4651-9341-241f6136dfe7.mp3","mime_type":"audio/mpeg","size_in_bytes":37344456,"duration_in_seconds":3723}]},{"id":"a4c15ba6-d3cb-42e9-ba1d-b95461e42fe8","title":"Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Melanoma and Nonmelanoma Skin Cancers","url":"https://oncologytoday.researchtopractice.com/271","content_text":"Dr Evan J Lipson from the Sidney Kimmel Comprehensive Cancer Center in Baltimore, Maryland, summarizes major clinical advances over the past year for treating skin cancers, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here.","content_html":"Dr Evan J Lipson from the Sidney Kimmel Comprehensive Cancer Center in Baltimore, Maryland, summarizes major clinical advances over the past year for treating skin cancers, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on important clinical findings over the past year for patients with skin cancers with Dr Evan J Lipson, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-08-08T14:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/a4c15ba6-d3cb-42e9-ba1d-b95461e42fe8.mp3","mime_type":"audio/mpeg","size_in_bytes":35807225,"duration_in_seconds":3575}]},{"id":"ae8881ad-440f-44fb-b8dc-309a9d8d5cd2","title":"Individualizing the Selection of First-Line Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer","url":"https://oncologytoday.researchtopractice.com/270","content_text":"Dr Joyce O’Shaughnessy from Sarah Cannon Research Institute in Dallas, Texas, summarizes risk factors and targeted therapy options for patients with HR-positive metastatic breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here. ","content_html":"Dr Joyce O’Shaughnessy from Sarah Cannon Research Institute in Dallas, Texas, summarizes risk factors and targeted therapy options for patients with HR-positive metastatic breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on optimal therapies for patients with HR-positive metastatic breast cancer, with Dr Joyce O’Shaughnessy, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-08-06T09:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/ae8881ad-440f-44fb-b8dc-309a9d8d5cd2.mp3","mime_type":"audio/mpeg","size_in_bytes":45075082,"duration_in_seconds":4499}]},{"id":"0e2bb5f8-bff8-4ad0-b73c-5c7425d5a96b","title":"An interview with Matthew R Smith, MD, PhD — Management of Prostate Cancer","url":"https://oncologytoday.researchtopractice.com/269","content_text":"Dr Matthew R Smith from the Massachusetts General Hospital Cancer Center in Boston summarizes recent developments presented at ASCO 2024 for prostate cancer, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here. ","content_html":"Dr Matthew R Smith from the Massachusetts General Hospital Cancer Center in Boston summarizes recent developments presented at ASCO 2024 for prostate cancer, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recently presented findings from ASCO 2024 on therapies for prostate cancer, with Dr Matthew R Smith, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-08-02T10:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/0e2bb5f8-bff8-4ad0-b73c-5c7425d5a96b.mp3","mime_type":"audio/mpeg","size_in_bytes":32187824,"duration_in_seconds":3215}]},{"id":"fcf27be2-761c-4208-a9f5-dbf653142385","title":"Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Immunotherapy and Other Nontargeted Approaches for Lung Cancer","url":"https://oncologytoday.researchtopractice.com/268","content_text":"Dr Matthew Gubens from the University of California, San Francisco summarizes important 2023 data sets guiding the use of immunotherapy and other nontargeted approaches for patients with NSCLC and no actionable mutations, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here. ","content_html":"Dr Matthew Gubens from the University of California, San Francisco summarizes important 2023 data sets guiding the use of immunotherapy and other nontargeted approaches for patients with NSCLC and no actionable mutations, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on select data sets from 2023 on the management of NSCLC without actionable mutations with Dr Matthew Gubens, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-07-30T10:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/fcf27be2-761c-4208-a9f5-dbf653142385.mp3","mime_type":"audio/mpeg","size_in_bytes":36572280,"duration_in_seconds":3653}]},{"id":"3056a648-ef55-4090-a3fb-4661a47f6d02","title":"Optimizing the Identification of HER2-Low Breast Cancer","url":"https://oncologytoday.researchtopractice.com/267","content_text":"Dr Kimberly H Allison from the Stanford Cancer Institute in Stanford, California discusses the optimal identification, pathologic reporting and treatment of HER2-low breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here. ","content_html":"Dr Kimberly H Allison from the Stanford Cancer Institute in Stanford, California discusses the optimal identification, pathologic reporting and treatment of HER2-low breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on HER2-low breast cancer with Dr Kimberly H Allison, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-07-30T09:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/3056a648-ef55-4090-a3fb-4661a47f6d02.mp3","mime_type":"audio/mpeg","size_in_bytes":14364202,"duration_in_seconds":1428}]},{"id":"dd674d7b-968e-465a-aea9-dae0a6cdffaf","title":"Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Gynecologic Oncology","url":"https://oncologytoday.researchtopractice.com/266","content_text":"Dr Dana M Chase from the David Geffen School of Medicine at UCLA in Los Angeles, California, discusses select 2023 data sets on the management of ovarian, endometrial and cervical cancers, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here. ","content_html":"Dr Dana M Chase from the David Geffen School of Medicine at UCLA in Los Angeles, California, discusses select 2023 data sets on the management of ovarian, endometrial and cervical cancers, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on select data sets from 2023 on the management of gynecologic cancers with Dr Dana M Chase, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-07-26T11:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/dd674d7b-968e-465a-aea9-dae0a6cdffaf.mp3","mime_type":"audio/mpeg","size_in_bytes":35629548,"duration_in_seconds":3557}]},{"id":"659e5a75-6096-4ade-a058-abda1c620b22","title":"An interview with Jonathan W Goldman, MD — Management of Non-Small Cell Lung Cancer with an EGFR Mutation","url":"https://oncologytoday.researchtopractice.com/265","content_text":"Dr Jonathan W Goldman from UCLA Health in Santa Monica, California, summarizes recent developments presented at ASCO 2024 for patients with non-small cell lung cancer with an EGFR mutation, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here. ","content_html":"Dr Jonathan W Goldman from UCLA Health in Santa Monica, California, summarizes recent developments presented at ASCO 2024 for patients with non-small cell lung cancer with an EGFR mutation, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on findings presented at ASCO 2024 on therapies for NSCLC with an EGFR mutation with Dr Jonathan Goldman, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-07-24T13:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/659e5a75-6096-4ade-a058-abda1c620b22.mp3","mime_type":"audio/mpeg","size_in_bytes":28584120,"duration_in_seconds":2854}]},{"id":"6d7abd27-c3b0-4bd4-8364-97425a44d40f","title":"Investigator Perspectives on Available Research and Challenging Questions in Melanoma and Nonmelanoma Skin Cancers: A Post-ASCO 2024 Annual Review","url":"https://oncologytoday.researchtopractice.com/264","content_text":"Dr Nikhil I Khushalani from Moffitt Cancer Center in Tampa, Florida and Dr Jason J Luke from UPMC Hillman Cancer Center in Pittsburgh, Pennsylvania discuss recently presented findings from ASCO on the management of melanoma and nonmelanoma skin cancers, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here. ","content_html":"Dr Nikhil I Khushalani from Moffitt Cancer Center in Tampa, Florida and Dr Jason J Luke from UPMC Hillman Cancer Center in Pittsburgh, Pennsylvania discuss recently presented findings from ASCO on the management of melanoma and nonmelanoma skin cancers, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on results presented at ASCO 2024 on therapies for skin cancers, with Drs Nikhil I Khushalani and Jason Luke, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-07-19T12:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/6d7abd27-c3b0-4bd4-8364-97425a44d40f.mp3","mime_type":"audio/mpeg","size_in_bytes":39740825,"duration_in_seconds":3969}]},{"id":"ae32d2a6-ff21-47be-a8a0-d907d2b099c2","title":"Investigator Perspectives on Available Research and Challenging Questions in Renal Cell Carcinoma: A Post-ASCO Annual Review","url":"https://oncologytoday.researchtopractice.com/263","content_text":"Dr Rana R McKay from Moores Cancer Center in La Jolla, California, and Prof Thomas Powles from Barts Cancer Institute in London, United Kingdom, discuss recent updates on available and novel treatment strategies for renal cell carcinoma, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here.","content_html":"Dr Rana R McKay from Moores Cancer Center in La Jolla, California, and Prof Thomas Powles from Barts Cancer Institute in London, United Kingdom, discuss recent updates on available and novel treatment strategies for renal cell carcinoma, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the optimal management of renal cell carcinoma with Dr Rana R McKay and Prof Thomas Powles, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-07-17T12:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/ae32d2a6-ff21-47be-a8a0-d907d2b099c2.mp3","mime_type":"audio/mpeg","size_in_bytes":37487024,"duration_in_seconds":3745}]},{"id":"f6395141-0d44-4009-a165-4aa461f2031f","title":"RTP Live from Chicago: Investigator Perspectives on Recent Advances and Challenging Questions in the Management of Colorectal Cancer","url":"https://oncologytoday.researchtopractice.com/262","content_text":"Dr Scott Kopetz from The University of Texas MD Anderson Cancer Center in Houston, and Dr John Strickler from Duke University in Durham, North Carolina, discuss recent updates on available and novel treatment strategies for colorectal cancer, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here. ","content_html":"Dr Scott Kopetz from The University of Texas MD Anderson Cancer Center in Houston, and Dr John Strickler from Duke University in Durham, North Carolina, discuss recent updates on available and novel treatment strategies for colorectal cancer, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the optimal management of colorectal cancer with Dr Scott Kopetz and Dr John Strickler, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-07-12T14:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/f6395141-0d44-4009-a165-4aa461f2031f.mp3","mime_type":"audio/mpeg","size_in_bytes":61217503,"duration_in_seconds":3756}]},{"id":"f675624d-bf5c-4b6b-8abd-34411ff41b52","title":"RTP Live from Chicago: Investigator Perspectives on the Role of Bispecific Antibodies in the Management of Lymphoma","url":"https://oncologytoday.researchtopractice.com/261","content_text":"Dr Joshua Brody from the Tisch Cancer Institute at Mount Sinai in New York, New York, Dr Ian W Flinn from OneOncology in Nashville, Tennessee, and Dr Tycel Phillips from the City of Hope Comprehensive Cancer Center in Duarte, California, discuss recent updates on available and novel treatment strategies for various lymphomas, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here. ","content_html":"Dr Joshua Brody from the Tisch Cancer Institute at Mount Sinai in New York, New York, Dr Ian W Flinn from OneOncology in Nashville, Tennessee, and Dr Tycel Phillips from the City of Hope Comprehensive Cancer Center in Duarte, California, discuss recent updates on available and novel treatment strategies for various lymphomas, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the optimal management of lymphoma with Dr Joshua Brody, Dr Ian W Flinn and Dr Tycel Phillips, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-07-12T12:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/f675624d-bf5c-4b6b-8abd-34411ff41b52.mp3","mime_type":"audio/mpeg","size_in_bytes":60097204,"duration_in_seconds":3649}]},{"id":"4b482e23-2778-49f3-a0fe-523974df76e1","title":"What Clinicians Want to Know About the Management of Triple-Negative Breast Cancer","url":"https://oncologytoday.researchtopractice.com/260","content_text":"Dr Kevin Kalinsky from Winship Cancer Institute of Emory University in Atlanta, Georgia, and Dr Heather McArthur from UT Southwestern Medical Center in Dallas, Texas, summarize the evolution of biomarker-driven treatment approaches for triple-negative breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.\n\nCME information and select publications here. ","content_html":"Dr Kevin Kalinsky from Winship Cancer Institute of Emory University in Atlanta, Georgia, and Dr Heather McArthur from UT Southwestern Medical Center in Dallas, Texas, summarize the evolution of biomarker-driven treatment approaches for triple-negative breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the selection and sequencing of optimal therapies for TNBC with Dr Kevin Kalinsky and Dr Heather McArthur, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-07-10T10:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/4b482e23-2778-49f3-a0fe-523974df76e1.mp3","mime_type":"audio/mpeg","size_in_bytes":38460202,"duration_in_seconds":3838}]},{"id":"bb96d66a-c514-48ea-8cfc-58b9e2b76765","title":"Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Myelofibrosis","url":"https://oncologytoday.researchtopractice.com/259","content_text":"Dr Aaron T Gerds from the Cleveland Clinic Taussig Cancer Institute in Cleveland, Ohio, discusses recent updates on available and novel treatment strategies for myelofibrosis, moderated by Dr Neil Love. Produced by Research To Practice.\n\nCME information and select publications here. ","content_html":"Dr Aaron T Gerds from the Cleveland Clinic Taussig Cancer Institute in Cleveland, Ohio, discusses recent updates on available and novel treatment strategies for myelofibrosis, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the optimal management of myelofibrosis with Dr Aaron T Gerds, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-07-01T10:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/bb96d66a-c514-48ea-8cfc-58b9e2b76765.mp3","mime_type":"audio/mpeg","size_in_bytes":36173016,"duration_in_seconds":3606}]},{"id":"a05158cc-30f8-4316-866c-e721989df417","title":"Clinical Update on the Current Management of Advanced Urothelial Bladder Cancer","url":"https://oncologytoday.researchtopractice.com/258","content_text":"Dr Petros Grivas from the Fred Hutchinson Cancer Center in Seattle, Washington, discusses the current management of advanced urothelial bladder cancer, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here. ","content_html":"Dr Petros Grivas from the Fred Hutchinson Cancer Center in Seattle, Washington, discusses the current management of advanced urothelial bladder cancer, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion of the current management of advanced urothelial bladder cancer with Dr Petros Grivas, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-06-17T14:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/a05158cc-30f8-4316-866c-e721989df417.mp3","mime_type":"audio/mpeg","size_in_bytes":60291248,"duration_in_seconds":5021}]},{"id":"7cfefb9c-244e-48d2-b966-22c18ee809ba","title":"Striving for Consensus: Exploring the Current Role of Ovarian Suppression in the Management of Breast Cancer","url":"https://oncologytoday.researchtopractice.com/257","content_text":"Dr William J Gradishar from Northwestern Medicine Feinberg School of Medicine in Chicago, Illinois, Dr Virginia Kaklamani from UT Health San Antonio MD Anderson Cancer Center in Texas, Dr Erica Mayer from Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr Seth Wander from Massachusetts General Hospital in Boston, discuss key findings and practical considerations with ovarian function suppression for hormone receptor-positive breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here. ","content_html":"Dr William J Gradishar from Northwestern Medicine Feinberg School of Medicine in Chicago, Illinois, Dr Virginia Kaklamani from UT Health San Antonio MD Anderson Cancer Center in Texas, Dr Erica Mayer from Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr Seth Wander from Massachusetts General Hospital in Boston, discuss key findings and practical considerations with ovarian function suppression for hormone receptor-positive breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on ovarian suppression for HR-positive breast cancer with Drs Gradishar, Kaklamani, Mayer and Wander moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-06-12T14:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/7cfefb9c-244e-48d2-b966-22c18ee809ba.mp3","mime_type":"audio/mpeg","size_in_bytes":93569482,"duration_in_seconds":9349}]},{"id":"64710efc-2894-40de-b239-b41c9c78050c","title":"Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Targeted Therapy for Non-Small Cell Lung Cancer","url":"https://oncologytoday.researchtopractice.com/256","content_text":"Dr Justin F Gainor from Massachusetts General Hospital in Boston and Dr Karen Reckamp from Cedars-Sinai Center in Los Angeles, California, summarize recently presented data on targeted therapy strategies for non-small cell lung cancer harboring actionable therapeutic targets, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here.","content_html":"Dr Justin F Gainor from Massachusetts General Hospital in Boston and Dr Karen Reckamp from Cedars-Sinai Center in Los Angeles, California, summarize recently presented data on targeted therapy strategies for non-small cell lung cancer harboring actionable therapeutic targets, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on treatments for NSCLC harboring targetable oncogenic alterations with Dr Justin F Gainor and Dr Karen Reckamp, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-06-11T11:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/64710efc-2894-40de-b239-b41c9c78050c.mp3","mime_type":"audio/mpeg","size_in_bytes":43819560,"duration_in_seconds":3648}]},{"id":"f1f840a3-fb38-4715-ac91-1ec416a0ee02","title":"Second Opinion: Urologic Oncology Investigators Discuss How They Apply Clinical Research in the Care of Patients with Urothelial Bladder Cancer","url":"https://oncologytoday.researchtopractice.com/255","content_text":"Dr Matthew Galsky from The Tisch Cancer Institute in New York and Dr Ashish Kamat from The University of Texas MD Anderson Cancer Center in Houston summarize recent clinical advances in the management of urothelial bladder cancer, including data from the 2024 AUA annual meeting, moderated by Dr Neil Love. Produced by Research To Practice.\n\nCME information and select publications here.","content_html":"Dr Matthew Galsky from The Tisch Cancer Institute in New York and Dr Ashish Kamat from The University of Texas MD Anderson Cancer Center in Houston summarize recent clinical advances in the management of urothelial bladder cancer, including data from the 2024 AUA annual meeting, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on treatment for urothelial bladder cancer, including data presented at the 2024 AUA annual meeting, with Drs Matthew Galsky and Ashish Kamat, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-06-07T11:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/f1f840a3-fb38-4715-ac91-1ec416a0ee02.mp3","mime_type":"audio/mpeg","size_in_bytes":45056768,"duration_in_seconds":3751}]},{"id":"4b9a56af-8735-4489-98d7-958800ae884f","title":"Key Presentations on Lymphoma from Recent Major Conferences","url":"https://oncologytoday.researchtopractice.com/254","content_text":"Dr Andrew D Zelenetz from Memorial Sloan Kettering Cancer Center in New York City discusses recent updates on available and emerging treatment strategies for various lymphomas, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here. ","content_html":"Dr Andrew D Zelenetz from Memorial Sloan Kettering Cancer Center in New York City discusses recent updates on available and emerging treatment strategies for various lymphomas, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on follicular lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma and Hodgkin lymphoma with Dr Andrew D Zelenetz, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-05-28T12:15:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/4b9a56af-8735-4489-98d7-958800ae884f.mp3","mime_type":"audio/mpeg","size_in_bytes":55374744,"duration_in_seconds":4605}]},{"id":"94437fab-cdc4-40a7-bdf4-8794813f6d51","title":"Bispecific Antibodies in the Management of Multiple Myeloma","url":"https://oncologytoday.researchtopractice.com/253","content_text":"Dr Joshua Richter from the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai in New York, New York, discusses the role of bispecific antibodies in multiple myeloma.\n\nCME information and select publications here.","content_html":"Dr Joshua Richter from the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai in New York, New York, discusses the role of bispecific antibodies in multiple myeloma.
\n\nCME information and select publications here.
","summary":"Featuring a discussion of the role of bispecific antibodies in multiple myeloma with Dr Joshua Richter, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-05-24T11:45:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/94437fab-cdc4-40a7-bdf4-8794813f6d51.mp3","mime_type":"audio/mpeg","size_in_bytes":30451799,"duration_in_seconds":2528}]},{"id":"0102fc87-e75c-4baa-8703-73a19a9302db","title":"Recent Advances in the Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","url":"https://oncologytoday.researchtopractice.com/252","content_text":"Dr Elias Jabbour from the University of Texas MD Anderson Cancer Center in Houston discusses recent advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here. ","content_html":"Dr Elias Jabbour from the University of Texas MD Anderson Cancer Center in Houston discusses recent advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia with Dr Elias Jabbour, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-05-24T11:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/0102fc87-e75c-4baa-8703-73a19a9302db.mp3","mime_type":"audio/mpeg","size_in_bytes":24518280,"duration_in_seconds":2034}]},{"id":"2f17c989-4425-4521-aed0-8ea5495ae159","title":"Understanding the Risk of Recurrence and Related Management for Patients with Localized HER2-Positive Breast Cancer","url":"https://oncologytoday.researchtopractice.com/251","content_text":"Dr Adam M Brufsky from UPMC Hillman Cancer Center in Pittsburgh summarizes the history of and modern advances in treating localized HER2-positive breast cancers, including strategies for monitoring and managing treatment-related toxicities.\n\nCME information and select publications here. ","content_html":"Dr Adam M Brufsky from UPMC Hillman Cancer Center in Pittsburgh summarizes the history of and modern advances in treating localized HER2-positive breast cancers, including strategies for monitoring and managing treatment-related toxicities.
\n\nCME information and select publications here.
","summary":"Featuring a discussion discussion on evolving treatments for patients with localized HER2-expressing breast cancer with Dr Adam M Brufsky, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-05-20T14:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/2f17c989-4425-4521-aed0-8ea5495ae159.mp3","mime_type":"audio/mpeg","size_in_bytes":55172890,"duration_in_seconds":4591}]},{"id":"c72f1c9c-1596-45c3-b8e6-c95ba00b6a87","title":"Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Acute Myeloid Leukemia","url":"https://oncologytoday.researchtopractice.com/250","content_text":"Drs Naval Daver and Courtney D DiNardo, both from The University of Texas MD Anderson Cancer Center in Houston, summarize the clinical progress in diagnosing and treating acute myeloid leukemia over the past year, as well as practical considerations for patients with the disease, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here.","content_html":"Drs Naval Daver and Courtney D DiNardo, both from The University of Texas MD Anderson Cancer Center in Houston, summarize the clinical progress in diagnosing and treating acute myeloid leukemia over the past year, as well as practical considerations for patients with the disease, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent developments in the diagnosis and treatment of acute myeloid leukemia with Drs Naval Daver and Courtney DiNardo, moderated by Dr Neil Love. Produced by Research To Practice. ","date_published":"2024-05-13T10:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/c72f1c9c-1596-45c3-b8e6-c95ba00b6a87.mp3","mime_type":"audio/mpeg","size_in_bytes":52396061,"duration_in_seconds":3734}]},{"id":"99c0bb78-f3fa-4d24-96fa-98567ad2e666","title":"Virtual Case Library: Metastatic Triple-Negative Breast Cancer","url":"https://oncologytoday.researchtopractice.com/249","content_text":"Drs Rita Nanda, Sara M Tolaney, Julia Foldi, Laura Huppert and Saba Shaikh discuss available and emerging research, patient cases from participating junior clinical investigators and senior clinical investigator perspectives on relevant research data informing clinical decision-making for patients with metastatic triple-negative breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here. ","content_html":"Drs Rita Nanda, Sara M Tolaney, Julia Foldi, Laura Huppert and Saba Shaikh discuss available and emerging research, patient cases from participating junior clinical investigators and senior clinical investigator perspectives on relevant research data informing clinical decision-making for patients with metastatic triple-negative breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion of clinical decision-making for patients with mTNBC, with Drs Nanda, Tolaney, Foldi, Huppert and Shaikh moderated by Dr Neil Love. Produced by Research To Practice. ","date_published":"2024-05-08T14:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/99c0bb78-f3fa-4d24-96fa-98567ad2e666.mp3","mime_type":"audio/mpeg","size_in_bytes":95848714,"duration_in_seconds":7980}]},{"id":"9b3ed58a-99d1-4319-a369-95e5d5f56afe","title":"Role of HER2-Directed Therapy in the Treatment of HER2-Expressing Urothelial Bladder Cancer — Part 3 of a Special 3-Part Edition","url":"https://oncologytoday.researchtopractice.com/248","content_text":"Dr Matthew D Galsky from Icahn School of Medicine at Mount Sinai in New York, New York, summarizes treatment options for patients with HER2-altered genitourinary cancers and reviews recent emerging clinical trial data in the field, moderated by Dr Neil Love. Produced by Research To Practice.\n\nCME information and select publications here. ","content_html":"Dr Matthew D Galsky from Icahn School of Medicine at Mount Sinai in New York, New York, summarizes treatment options for patients with HER2-altered genitourinary cancers and reviews recent emerging clinical trial data in the field, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on HER2-targeted therapies for patients with genitourinary cancers with Dr Matthew D Galsky, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-05-06T08:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/9b3ed58a-99d1-4319-a369-95e5d5f56afe.mp3","mime_type":"audio/mpeg","size_in_bytes":56610784,"duration_in_seconds":4041}]},{"id":"c923c224-c51c-459c-9241-d5f6ece95a8f","title":"Year in Review: Novel Treatments and Strategies in Gastroesophageal Cancer","url":"https://oncologytoday.researchtopractice.com/247","content_text":"Prof Eric Van Cutsem from University Hospitals Leuven in Leuven, Belgium, discusses recent updates on available and novel treatment strategies for gastroesophageal cancer, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here. ","content_html":"Prof Eric Van Cutsem from University Hospitals Leuven in Leuven, Belgium, discusses recent updates on available and novel treatment strategies for gastroesophageal cancer, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the optimal management of gastroesophageal cancer with Prof Eric Van Cutsem, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-05-03T11:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/c923c224-c51c-459c-9241-d5f6ece95a8f.mp3","mime_type":"audio/mpeg","size_in_bytes":50147442,"duration_in_seconds":3579}]},{"id":"b2790ffd-3ae0-40c6-9d67-6b951d8168f1","title":"Meet The Professor: Optimizing the Management of Myelofibrosis — Part 2 of a 2-Part Series","url":"https://oncologytoday.researchtopractice.com/246","content_text":"Dr Ruben A Mesa from Wake Forest University School of Medicine in Winston-Salem, North Carolina, discusses recent updates on available and novel treatment strategies for myelofibrosis, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here. ","content_html":"Dr Ruben A Mesa from Wake Forest University School of Medicine in Winston-Salem, North Carolina, discusses recent updates on available and novel treatment strategies for myelofibrosis, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the optimal management of myelofibrosis with Dr Ruben A Mesa, moderated by Dr Neil Love. Produced by Research To Practice. ","date_published":"2024-05-01T16:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/b2790ffd-3ae0-40c6-9d67-6b951d8168f1.mp3","mime_type":"audio/mpeg","size_in_bytes":51168201,"duration_in_seconds":3647}]},{"id":"2c02caba-814b-4e95-85fe-59d38c256b05","title":"Striving for Consensus: Current and Future Management of Paroxysmal Nocturnal Hemoglobinuria","url":"https://oncologytoday.researchtopractice.com/245","content_text":"Dr Carlos de Castro, Prof Alexander Röth and Dr Ilene Weitz summarize the biology of paroxysmal nocturnal hemoglobinuria, current treatment approaches, and practical considerations for patients with the disease, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here. ","content_html":"Dr Carlos de Castro, Prof Alexander Röth and Dr Ilene Weitz summarize the biology of paroxysmal nocturnal hemoglobinuria, current treatment approaches, and practical considerations for patients with the disease, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on paroxysmal nocturnal hemoglobinuria, with Dr Carlos de Castro, Prof Alexander Röth and Dr Ilene Weitz, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-04-26T11:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/2c02caba-814b-4e95-85fe-59d38c256b05.mp3","mime_type":"audio/mpeg","size_in_bytes":81661031,"duration_in_seconds":5825}]},{"id":"8b3649f9-94ad-45f4-84d7-5fee3876d060","title":"Special Edition – Prostate Cancer Updates from a CME Program Held at the 2024 Genitourinary Cancers Symposium","url":"https://oncologytoday.researchtopractice.com/244","content_text":"Dr Emmanuel Antonarakis from the University of Minnesota in Minneapolis reviews research findings presented at the 2024 Genitourinary Cancers Symposium and provides his perspectives on current and novel treatment approaches for prostate cancer, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here. ","content_html":"Dr Emmanuel Antonarakis from the University of Minnesota in Minneapolis reviews research findings presented at the 2024 Genitourinary Cancers Symposium and provides his perspectives on current and novel treatment approaches for prostate cancer, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring an overview of recent clinical data presented at the 2024 Genitourinary Cancers Symposium with Dr Emmanuel Antonarakis, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-04-24T11:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/8b3649f9-94ad-45f4-84d7-5fee3876d060.mp3","mime_type":"audio/mpeg","size_in_bytes":50314534,"duration_in_seconds":3591}]},{"id":"e97d241a-a066-4270-af66-33af80a9b864","title":"Key Presentations on Myeloproliferative Neoplasms from Recent Major Conferences","url":"https://oncologytoday.researchtopractice.com/243","content_text":"Dr Naveen Pemmaraju from The University of Texas MD Anderson Cancer Center in Houston discusses updated findings from ASH 2023 on management approaches for myelofibrosis and polycythemia vera, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here.","content_html":"Dr Naveen Pemmaraju from The University of Texas MD Anderson Cancer Center in Houston discusses updated findings from ASH 2023 on management approaches for myelofibrosis and polycythemia vera, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring presentations from the 2023 ASH annual meeting on the management of myelofibrosis and other myeloproliferative neoplasms moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-04-23T16:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/e97d241a-a066-4270-af66-33af80a9b864.mp3","mime_type":"audio/mpeg","size_in_bytes":54269241,"duration_in_seconds":3868}]},{"id":"ad81eedc-4dbc-4dc6-8829-8ae795806e02","title":"Role of HER2-Directed Therapy in the Treatment of HER2-Expressing Gastrointestinal Cancers — Part 2 of a Special 3-Part Edition","url":"https://oncologytoday.researchtopractice.com/242","content_text":"Dr Kanwal Raghav from The University of Texas MD Anderson Cancer Center in Houston discusses the role of HER2-directed therapy in the treatment of gastrointestinal tumors beyond gastroesophageal cancer, moderated by Dr Neil Love. Produced by Research To Practice.\n\nCME information and select publications here.","content_html":"Dr Kanwal Raghav from The University of Texas MD Anderson Cancer Center in Houston discusses the role of HER2-directed therapy in the treatment of gastrointestinal tumors beyond gastroesophageal cancer, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the role of HER2-directed therapy in the treatment of gastrointestinal tumors, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-04-15T12:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/ad81eedc-4dbc-4dc6-8829-8ae795806e02.mp3","mime_type":"audio/mpeg","size_in_bytes":31390092,"duration_in_seconds":2239}]},{"id":"65a1c764-6aa9-404f-a552-a0285acc630b","title":"Key Presentations on Chronic Lymphocytic Leukemia from Recent Major Conferences","url":"https://oncologytoday.researchtopractice.com/241","content_text":"Dr Bita Fakhri from Stanford University in Stanford, California, discusses recent updates from ASH 2023 for the management of chronic lymphocytic leukemia and Richter’s syndrome, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here. ","content_html":"Dr Bita Fakhri from Stanford University in Stanford, California, discusses recent updates from ASH 2023 for the management of chronic lymphocytic leukemia and Richter’s syndrome, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring updates for the management of CLL and Richter’s transformation from ASH 2023 with Dr Bita Fakhri, moderated by Dr Neil Love. Produced by Research To Practice","date_published":"2024-04-12T16:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/65a1c764-6aa9-404f-a552-a0285acc630b.mp3","mime_type":"audio/mpeg","size_in_bytes":79914506,"duration_in_seconds":5700}]},{"id":"77c8a047-4537-420f-8493-66fdb8386edd","title":"Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Colorectal Cancer","url":"https://oncologytoday.researchtopractice.com/240","content_text":"Professor Thierry André from the Hôpital Saint-Antoine in Paris, France, and Dr Arvind Dasari from MD Anderson Cancer Center in Houston, Texas, discuss recent developments regarding available and novel treatment strategies for colorectal cancer, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here. ","content_html":"Professor Thierry André from the Hôpital Saint-Antoine in Paris, France, and Dr Arvind Dasari from MD Anderson Cancer Center in Houston, Texas, discuss recent developments regarding available and novel treatment strategies for colorectal cancer, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the optimal management of colorectal cancer with Professor Thierry André and Dr Arvind Dasari, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-04-05T11:15:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/77c8a047-4537-420f-8493-66fdb8386edd.mp3","mime_type":"audio/mpeg","size_in_bytes":57267335,"duration_in_seconds":3522}]},{"id":"5e6236fc-d197-4b13-abf2-ffee9f29b2c9","title":"Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Urothelial Bladder Cancer","url":"https://oncologytoday.researchtopractice.com/239","content_text":"Dr Shilpa Gupta from the Taussig Cancer Institute in Cleveland, Ohio, and Prof Thomas Powles from the Barts Cancer Institute in London, United Kingdom, discuss clinical decision-making with numerous treatment strategies for urothelial bladder cancer, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here. ","content_html":"Dr Shilpa Gupta from the Taussig Cancer Institute in Cleveland, Ohio, and Prof Thomas Powles from the Barts Cancer Institute in London, United Kingdom, discuss clinical decision-making with numerous treatment strategies for urothelial bladder cancer, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the management of urothelial bladder cancer with Dr Shilpa Gupta and Prof Thomas Powles, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-04-05T11:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/5e6236fc-d197-4b13-abf2-ffee9f29b2c9.mp3","mime_type":"audio/mpeg","size_in_bytes":59627401,"duration_in_seconds":3656}]},{"id":"6b27fcb8-2415-42f9-b0e1-a4bf2f3c8c9b","title":"The Emerging Role of B7-H3-Targeted Antibody-Drug Conjugates","url":"https://oncologytoday.researchtopractice.com/238","content_text":"Dr Manish Patel from the Florida Cancer Specialists & Research Institute in Sarasota, Florida, discusses drug development, early-phase clinical trials and the emerging field of B7-H3-targeted antibody-drug conjugates for solid tumors, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here.","content_html":"Dr Manish Patel from the Florida Cancer Specialists & Research Institute in Sarasota, Florida, discusses drug development, early-phase clinical trials and the emerging field of B7-H3-targeted antibody-drug conjugates for solid tumors, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on early research and available data with B7-H3-targeted antibody-drug conjugates with Dr Manish Patel, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-04-03T11:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/6b27fcb8-2415-42f9-b0e1-a4bf2f3c8c9b.mp3","mime_type":"audio/mpeg","size_in_bytes":72519666,"duration_in_seconds":4442}]},{"id":"7a61c358-909f-42bd-bd6d-3ac133cb1422","title":"Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Prostate Cancer","url":"https://oncologytoday.researchtopractice.com/237","content_text":"Dr Andrew J Armstrong from the Duke Cancer Institute Center in Durham, North Carolina and Dr Maha Hussain from Robert H Lurie Comprehensive Cancer Center in Chicago summarize recent data sets from 2023 on hormonal therapies and other emerging treatment approaches for patients with prostate cancer, moderated by Dr Neil Love. Produced by Research To Practice.\n\nCME information and select publications here.","content_html":"Dr Andrew J Armstrong from the Duke Cancer Institute Center in Durham, North Carolina and Dr Maha Hussain from Robert H Lurie Comprehensive Cancer Center in Chicago summarize recent data sets from 2023 on hormonal therapies and other emerging treatment approaches for patients with prostate cancer, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on clinical data from the past year on the management of prostate cancer with Drs Andrew Armstrong and Maha Hussain, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-03-27T14:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/7a61c358-909f-42bd-bd6d-3ac133cb1422.mp3","mime_type":"audio/mpeg","size_in_bytes":60240316,"duration_in_seconds":3697}]},{"id":"f9c4411d-f122-44fd-a804-7c9d9d63d1fc","title":"Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Lymphoma","url":"https://oncologytoday.researchtopractice.com/236","content_text":"Dr Andrew M Evens from the Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Sonali M Smith from the University of Chicago in Illinois discuss clinical decision-making with numerous treatment strategies for lymphoma, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here.","content_html":"Dr Andrew M Evens from the Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Sonali M Smith from the University of Chicago in Illinois discuss clinical decision-making with numerous treatment strategies for lymphoma, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the management of lymphoma with Dr Andrew M Evens and Dr Sonali M Smith, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-03-26T15:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/f9c4411d-f122-44fd-a804-7c9d9d63d1fc.mp3","mime_type":"audio/mpeg","size_in_bytes":58931396,"duration_in_seconds":3613}]},{"id":"e400ac8a-70a3-46c1-8835-4661f56fe7de","title":"Overcoming Endocrine Resistance in ER-Positive Metastatic Breast Cancer","url":"https://oncologytoday.researchtopractice.com/235","content_text":"Dr Seth Wander from Harvard Medical School in Boston, Massachusetts, discusses mechanisms underlying endocrine resistance in breast cancer and optimal therapeutic approaches for patients who experience disease progression while or after receiving endocrine therapy, moderated by Dr Neil Love. Produced by Research To Practice.\n\nCME information and select publications here.","content_html":"Dr Seth Wander from Harvard Medical School in Boston, Massachusetts, discusses mechanisms underlying endocrine resistance in breast cancer and optimal therapeutic approaches for patients who experience disease progression while or after receiving endocrine therapy, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Dr Seth Wander from Harvard Medical School in Boston, Massachusetts, discusses mechanisms underlying endocrine resistance in breast cancer and optimal therapeutic approaches for patients who experience disease progression while or after receiving endocrine therapy.","date_published":"2024-03-25T15:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/e400ac8a-70a3-46c1-8835-4661f56fe7de.mp3","mime_type":"audio/mpeg","size_in_bytes":76639448,"duration_in_seconds":4785}]},{"id":"8fb083a6-5a38-4bfd-96d9-c28b0bcebb2f","title":"Consensus or Controversy? Immune Checkpoint Inhibitors in the Management of Hepatobiliary Cancers — A 2024 Post-ASCO Gastrointestinal Cancers Symposium Review","url":"https://oncologytoday.researchtopractice.com/234","content_text":"Dr Robin K (Katie) Kelley from the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, California, and Dr Mark Yarchoan from the Johns Hopkins Sidney Kimmel Cancer Center in Baltimore, Maryland, discuss clinical decision-making with numerous treatment strategies for hepatocellular carcinoma and biliary tract cancers.\n\nCME information and select publications here.","content_html":"Dr Robin K (Katie) Kelley from the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, California, and Dr Mark Yarchoan from the Johns Hopkins Sidney Kimmel Cancer Center in Baltimore, Maryland, discuss clinical decision-making with numerous treatment strategies for hepatocellular carcinoma and biliary tract cancers.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the management of hepatobiliary cancers with Dr Robin K (Katie) Kelley and Dr Mark Yarchoan, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-03-21T13:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/8fb083a6-5a38-4bfd-96d9-c28b0bcebb2f.mp3","mime_type":"audio/mpeg","size_in_bytes":60069947,"duration_in_seconds":3701}]},{"id":"32fc3332-9644-49eb-9eb2-d1ece6154d52","title":"Promising Therapeutic Strategies for Patients with Progressive Metastatic Non-Small Cell Lung Cancer","url":"https://oncologytoday.researchtopractice.com/233","content_text":"Dr Melissa Johnson from Sarah Cannon Research Institute in Nashville, Tennessee, discusses available data with antibody-drug conjugates with established and investigational targets in patients with non-small cell lung cancer, moderated by Dr Neil Love. Produced by Research To Practice.\n\nCME information and select publications here.","content_html":"Dr Melissa Johnson from Sarah Cannon Research Institute in Nashville, Tennessee, discusses available data with antibody-drug conjugates with established and investigational targets in patients with non-small cell lung cancer, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the role of approved and investigational antibody drug conjugates for non-small cell lung cancer, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-03-19T13:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/32fc3332-9644-49eb-9eb2-d1ece6154d52.mp3","mime_type":"audio/mpeg","size_in_bytes":60344309,"duration_in_seconds":3769}]},{"id":"8ed67a48-0c54-402d-830d-65b7bd6e3737","title":"Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in HER2-Positive and Triple-Negative Breast Cancer","url":"https://oncologytoday.researchtopractice.com/232","content_text":"Dr Ian E Krop from the Yale Cancer Center in New Haven, Connecticut, and Dr Priyanka Sharma from the University of Kansas Cancer Center in Westwood, Kansas, discuss patient cases and treatment strategies for HER2-positive and triple-negative breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here.","content_html":"Dr Ian E Krop from the Yale Cancer Center in New Haven, Connecticut, and Dr Priyanka Sharma from the University of Kansas Cancer Center in Westwood, Kansas, discuss patient cases and treatment strategies for HER2-positive and triple-negative breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the management of HER2-positive and triple-negative breast cancer with Dr Ian E Krop and Dr Priyanka Sharma, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-03-15T10:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/8ed67a48-0c54-402d-830d-65b7bd6e3737.mp3","mime_type":"audio/mpeg","size_in_bytes":63083481,"duration_in_seconds":3937}]},{"id":"d508a905-b1b7-4d27-8ba3-b0dbac2a665a","title":"Virtual Case Library: Metastatic Urothelial Bladder Cancer","url":"https://oncologytoday.researchtopractice.com/231","content_text":"Drs Petros Grivas, Vadim S Koshkin, Kriti Mittal, Mamta Parikh and Scott T Tagawa discuss available and emerging research, patient cases from participating junior clinical investigators and the perspectives of senior clinical investigator faculty on data informing their decision-making for patients with metastatic urothelial bladder cancer, moderated by Dr Neil Love. Produced by Research To Practice.\n\nCME information and select publications here.","content_html":"Drs Petros Grivas, Vadim S Koshkin, Kriti Mittal, Mamta Parikh and Scott T Tagawa discuss available and emerging research, patient cases from participating junior clinical investigators and the perspectives of senior clinical investigator faculty on data informing their decision-making for patients with metastatic urothelial bladder cancer, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a roundtable discussion of patient cases and relevant recent research on metastatic urothelial bladder cancer, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-03-13T15:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/d508a905-b1b7-4d27-8ba3-b0dbac2a665a.mp3","mime_type":"audio/mpeg","size_in_bytes":93939313,"duration_in_seconds":7694}]},{"id":"76dc83ce-a64c-45da-bd5f-d8a1967310a6","title":"Understanding the Current and Future Role of Oral SERDs (Selective Estrogen Receptor Degraders) in the Management of ER-Positive Metastatic Breast Cancer","url":"https://oncologytoday.researchtopractice.com/230","content_text":"Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York City discusses available and emerging data with oral SERDs for patients with ER-positive metastatic breast cancer.\n\nCME information and select publications here.","content_html":"Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York City discusses available and emerging data with oral SERDs for patients with ER-positive metastatic breast cancer.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on available and investigational oral SERDs in the management of ER-positive metastatic breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-03-11T11:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/76dc83ce-a64c-45da-bd5f-d8a1967310a6.mp3","mime_type":"audio/mpeg","size_in_bytes":36119961,"duration_in_seconds":2252}]},{"id":"0c8ddb9a-3691-4cd8-903f-9b6ccabd3286","title":"Meet The Professor: Optimizing the Management of Myelofibrosis — Part 1 of a 2-Part Series","url":"https://oncologytoday.researchtopractice.com/229","content_text":"Dr Stephen T Oh from Washington University School of Medicine in St Louis, Missouri, discusses current and emerging monitoring and management strategies for myelofibrosis, moderated by Dr Neil Love. Produced by Research To Practice.\n\nCME information and select publications here.","content_html":"Dr Stephen T Oh from Washington University School of Medicine in St Louis, Missouri, discusses current and emerging monitoring and management strategies for myelofibrosis, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on optimal management approaches for myelofibrosis with Dr Stephen T Oh, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-03-08T10:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/0c8ddb9a-3691-4cd8-903f-9b6ccabd3286.mp3","mime_type":"audio/mpeg","size_in_bytes":57775443,"duration_in_seconds":3604}]},{"id":"68a90834-cbaa-4bef-9f31-b1807f729c6d","title":"Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Gastroesophageal Cancers","url":"https://oncologytoday.researchtopractice.com/228","content_text":"Dr Yelena Y Janjigian from Memorial Sloan Kettering Cancer Center in New York and Dr Zev Wainberg from UCLA Jonsson Comprehensive Cancer Center in Los Angeles discuss the management of gastroesophageal cancers and review emerging data sets in the field, moderated by Dr Neil Love. Produced by Research To Practice.\n\nCME information and select publications here.","content_html":"Dr Yelena Y Janjigian from Memorial Sloan Kettering Cancer Center in New York and Dr Zev Wainberg from UCLA Jonsson Comprehensive Cancer Center in Los Angeles discuss the management of gastroesophageal cancers and review emerging data sets in the field, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on gastroesophageal cancers with Dr Yelena Y Janjigian and Dr Zev Wainberg, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-03-06T12:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/68a90834-cbaa-4bef-9f31-b1807f729c6d.mp3","mime_type":"audio/mpeg","size_in_bytes":45668005,"duration_in_seconds":3756}]},{"id":"a48eb2da-9f4f-457c-8b74-273518384401","title":"Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Chronic Lymphocytic Leukemia","url":"https://oncologytoday.researchtopractice.com/227","content_text":"Dr Lindsey Roeker from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Jeff Sharman of the US Oncology Network in Eugene, Oregon, discuss relevant datasets from 2023 on the management of chronic lymphocytic leukemia, moderated by Dr Neil Love. Produced by Research To Practice.\n\nCME information and select publications here.","content_html":"Dr Lindsey Roeker from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Jeff Sharman of the US Oncology Network in Eugene, Oregon, discuss relevant datasets from 2023 on the management of chronic lymphocytic leukemia, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on select datasets from 2023 on the management of chronic lymphocytic leukemia with Dr Lindsey Roeker\r\nand Dr Jeff Sharman, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-02-26T14:30:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/a48eb2da-9f4f-457c-8b74-273518384401.mp3","mime_type":"audio/mpeg","size_in_bytes":56547944,"duration_in_seconds":3481}]},{"id":"d3450b21-8a01-4af8-8f14-a35d43dcd87a","title":"Consensus or Controversy? Investigator Perspectives on the Current and Future Role of Immune Checkpoint Inhibitors in the Management of Hepatobiliary Cancers","url":"https://oncologytoday.researchtopractice.com/226","content_text":"Dr Ahmed Omar Kaseb from the University of Texas MD Anderson Cancer Center in Houston, Texas, and Prof Arndt Vogel from Schwartz Reisman Liver Research Centre in Toronto, Ontario, discuss the optimal selection and sequencing of checkpoint inhibitor therapy for patients with hepatobiliary cancers, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here.","content_html":"Dr Ahmed Omar Kaseb from the University of Texas MD Anderson Cancer Center in Houston, Texas, and Prof Arndt Vogel from Schwartz Reisman Liver Research Centre in Toronto, Ontario, discuss the optimal selection and sequencing of checkpoint inhibitor therapy for patients with hepatobiliary cancers, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the management of hepatobiliary cancers with Dr Ahmed Omar Kaseb and Prof Arndt Vogel, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-02-23T15:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/d3450b21-8a01-4af8-8f14-a35d43dcd87a.mp3","mime_type":"audio/mpeg","size_in_bytes":58039151,"duration_in_seconds":3625}]},{"id":"5a5637f0-8be8-4cd7-8e2e-e828e5eddc82","title":"Meet The Professor: Optimizing the Management of Ovarian Cancer — Part 4 of a 4-Part Series","url":"https://oncologytoday.researchtopractice.com/225","content_text":"Dr Bradley J Monk from the Florida Cancer Specialists & Research Institute in West Palm Beach, Florida, discusses real-world patient cases and treatment strategies for ovarian cancer.\n\nCME information and select publications here.","content_html":"Dr Bradley J Monk from the Florida Cancer Specialists & Research Institute in West Palm Beach, Florida, discusses real-world patient cases and treatment strategies for ovarian cancer.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the optimal management of ovarian cancer with Dr Bradley J Monk, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-02-16T12:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/5a5637f0-8be8-4cd7-8e2e-e828e5eddc82.mp3","mime_type":"audio/mpeg","size_in_bytes":57413710,"duration_in_seconds":3584}]},{"id":"cb2db1b1-2cf7-473c-a24c-e22cfbeaf962","title":"Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Hormone Receptor-Positive Breast Cancer","url":"https://oncologytoday.researchtopractice.com/224","content_text":"Dr Stephanie L Graff from the Legorreta Cancer Center at Brown University in Providence, Rhode Island, and Dr Erica Mayer from Dana-Farber Cancer Institute in Boston discuss treatment decision-making involving approved and investigational strategies for the management of hormone receptor-positive breast cancer.\n\nCME information and select publications here.","content_html":"Dr Stephanie L Graff from the Legorreta Cancer Center at Brown University in Providence, Rhode Island, and Dr Erica Mayer from Dana-Farber Cancer Institute in Boston discuss treatment decision-making involving approved and investigational strategies for the management of hormone receptor-positive breast cancer.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the management of hormone receptor-positive breast cancer with Dr Stephanie L Graff and Dr Erica Mayer, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-01-31T12:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/cb2db1b1-2cf7-473c-a24c-e22cfbeaf962.mp3","mime_type":"audio/mpeg","size_in_bytes":62223097,"duration_in_seconds":3884}]},{"id":"f655e626-eb09-41fa-a271-b03e72aecad4","title":"Meet The Professor: Optimizing the Management of Ovarian Cancer — Part 3 of a 4-Part Series","url":"https://oncologytoday.researchtopractice.com/223","content_text":"Dr Antonio González-Martín from the Clínica Universidad de Navarra in Madrid, Spain, discusses real-world patient cases and treatment strategies for ovarian cancer, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here.","content_html":"Dr Antonio González-Martín from the Clínica Universidad de Navarra in Madrid, Spain, discusses real-world patient cases and treatment strategies for ovarian cancer, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the optimal management of ovarian cancer with Dr Antonio González-Martín, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-01-23T09:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/f655e626-eb09-41fa-a271-b03e72aecad4.mp3","mime_type":"audio/mpeg","size_in_bytes":51651278,"duration_in_seconds":3689}]},{"id":"cb47eb12-1715-494d-97b3-84ca9b1ecef8","title":"Meet The Professor: Optimizing the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes — Part 3 of a 3-Part Series","url":"https://oncologytoday.researchtopractice.com/222","content_text":"Dr Richard M Stone from Dana-Farber Cancer Institute in Boston discusses the optimal selection and sequencing of systemic therapies for patients with acute myeloid leukemia and myelodysplastic syndromes, moderated by Dr Neil Love. Produced by Research To Practice.\n\nCME information and select publications here.","content_html":"Dr Richard M Stone from Dana-Farber Cancer Institute in Boston discusses the optimal selection and sequencing of systemic therapies for patients with acute myeloid leukemia and myelodysplastic syndromes, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the management of acute myeloid leukemia and myelodysplastic syndromes with Dr Richard M Stone, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2024-01-16T16:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/cb47eb12-1715-494d-97b3-84ca9b1ecef8.mp3","mime_type":"audio/mpeg","size_in_bytes":50759766,"duration_in_seconds":3618}]},{"id":"3c24afe5-1c47-424d-8df6-2f06fa8c4ebb","title":"Role of HER2-Directed Therapy in the Treatment of HER2-Expressing Gynecologic Cancers — Part 1 of a Special 3-Part Edition","url":"https://oncologytoday.researchtopractice.com/221","content_text":"Dr David M O’Malley from The Ohio State University and the James Comprehensive Cancer Center in Columbus, Ohio discusses the role of HER2-directed therapy in the treatment of gynecologic cancers.\n\nCME information and select publications here.","content_html":"Dr David M O’Malley from The Ohio State University and the James Comprehensive Cancer Center in Columbus, Ohio discusses the role of HER2-directed therapy in the treatment of gynecologic cancers.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the role of HER2-directed therapy in the treatment of gynecologic cancers with Dr David M O’Malley moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2023-12-19T14:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/3c24afe5-1c47-424d-8df6-2f06fa8c4ebb.mp3","mime_type":"audio/mpeg","size_in_bytes":55056553,"duration_in_seconds":3928}]},{"id":"d6266240-3d5a-43df-9a05-7d54326676d3","title":"Inside the Issue: Targeted and Immunotherapeutic Approaches for Biliary Tract Cancers","url":"https://oncologytoday.researchtopractice.com/220","content_text":"Dr Lipika Goyal from The Stanford Cancer Center and Dr Milind Javle from The University of Texas MD Anderson Cancer Center in Houston discuss targeted and immunotherapeutic approaches for biliary tract cancers, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here.","content_html":"Dr Lipika Goyal from The Stanford Cancer Center and Dr Milind Javle from The University of Texas MD Anderson Cancer Center in Houston discuss targeted and immunotherapeutic approaches for biliary tract cancers, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion of targeted and immunotherapeutic approaches for biliary tract cancers with Drs Lipika Goyal and Milind Javle, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2023-12-13T14:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/d6266240-3d5a-43df-9a05-7d54326676d3.mp3","mime_type":"audio/mpeg","size_in_bytes":57912934,"duration_in_seconds":3617}]},{"id":"d988c9e3-1a2d-49f4-90fc-65f69550c094","title":"Implications of Recent Data Sets for the Current and Future Management of Lung Cancer","url":"https://oncologytoday.researchtopractice.com/219","content_text":"Dr Luis Paz-Ares from the National Oncology Research Center in Madrid, Spain, Dr Zofia Piotrowska from Massachusetts General Hospital in Boston, and Dr David R Spigel from the Sarah Cannon Research Institute in Nashville, Tennessee, discuss key presentations from the 2023 ESMO Congress for the management of lung cancer, moderated by Neil Love. Produced by Research To Practice. \n\nCME information and select publications here. ","content_html":"Dr Luis Paz-Ares from the National Oncology Research Center in Madrid, Spain, Dr Zofia Piotrowska from Massachusetts General Hospital in Boston, and Dr David R Spigel from the Sarah Cannon Research Institute in Nashville, Tennessee, discuss key presentations from the 2023 ESMO Congress for the management of lung cancer, moderated by Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on presentations on lung cancer from the 2023 ESMO Congress with Drs Luis Paz-Ares, Zofia Piotrowska and David Spigel, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2023-12-08T14:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/d988c9e3-1a2d-49f4-90fc-65f69550c094.mp3","mime_type":"audio/mpeg","size_in_bytes":88313525,"duration_in_seconds":5416}]},{"id":"75d3bb91-f3f1-40f3-822c-675fb7efcfbe","title":"Meet The Professor: Optimizing the Management of Gastroesophageal Cancers — Part 3 of a 3-Part Series","url":"https://oncologytoday.researchtopractice.com/218","content_text":"Featuring a discussion on optimizing the management of gastroesophageal cancers with Dr Samuel J Klempner, moderated by Dr Neil Love. Produced by Research To Practice.\n\nCME information and select publications here.","content_html":"Featuring a discussion on optimizing the management of gastroesophageal cancers with Dr Samuel J Klempner, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Dr Samuel J Klempner from Massachusetts General Hospital in Boston discusses optimizing the management of gastroesophageal cancers.","date_published":"2023-12-05T01:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/75d3bb91-f3f1-40f3-822c-675fb7efcfbe.mp3","mime_type":"audio/mpeg","size_in_bytes":60314191,"duration_in_seconds":3714}]},{"id":"f0e3bd52-63bc-4726-a898-0c2c5351724f","title":"Implications of Recent Data Sets for the Current and Future Management of Breast Cancer","url":"https://oncologytoday.researchtopractice.com/217","content_text":"Dr Aditya Bardia from Massachusetts General Hospital and Dr Sara M Tolaney from the Dana-Farber Cancer Institute, both in Boston, Massachusetts, discuss key presentations on the management of breast cancer from the 2023 ESMO Congress, moderated by Dr Neil Love. Produced by Research To Practice.\n\nCME information and select publications here.","content_html":"Dr Aditya Bardia from Massachusetts General Hospital and Dr Sara M Tolaney from the Dana-Farber Cancer Institute, both in Boston, Massachusetts, discuss key presentations on the management of breast cancer from the 2023 ESMO Congress, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on key presentations on breast cancer from the 2023 ESMO Congress with Dr Aditya Bardia and Dr Sara M Tolaney, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2023-11-29T12:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/f0e3bd52-63bc-4726-a898-0c2c5351724f.mp3","mime_type":"audio/mpeg","size_in_bytes":60569900,"duration_in_seconds":3780}]},{"id":"9f021442-cc09-411f-83c5-dee9d6810eb3","title":"Implications of Recent Data Sets for the Current and Future Management of Gynecologic Cancers","url":"https://oncologytoday.researchtopractice.com/216","content_text":"Dr Richard Penson from Massachusetts General Hospital in Boston, Massachusetts and Dr Krishnansu Tewari from the University of California, Irvine, discuss updated data from the 2023 ESMO Congress on optimal management approaches for gynecologic cancers. \n\nCME information and select publications here.","content_html":"Dr Richard Penson from Massachusetts General Hospital in Boston, Massachusetts and Dr Krishnansu Tewari from the University of California, Irvine, discuss updated data from the 2023 ESMO Congress on optimal management approaches for gynecologic cancers.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on updated datasets in the management of gynecologic cancers from the 2023 ESMO Congress, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2023-11-20T08:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/9f021442-cc09-411f-83c5-dee9d6810eb3.mp3","mime_type":"audio/mpeg","size_in_bytes":60104831,"duration_in_seconds":3690}]},{"id":"782d27c6-398e-4f6e-9e9b-e2624cfb1b60","title":"Meet The Professor: Optimizing the Management of Gastroesophageal Cancers — Part 2 of a 3-Part Series","url":"https://oncologytoday.researchtopractice.com/215","content_text":"Prof Eric Van Cutsem from the University Hospitals Leuven in Leuven, Belgium, discusses optimizing the management of gastroesophageal cancers, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here.","content_html":"Prof Eric Van Cutsem from the University Hospitals Leuven in Leuven, Belgium, discusses optimizing the management of gastroesophageal cancers, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on optimizing the management of gastroesophageal cancers with Prof Eric Van Cutsem, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2023-11-14T10:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/782d27c6-398e-4f6e-9e9b-e2624cfb1b60.mp3","mime_type":"audio/mpeg","size_in_bytes":52719597,"duration_in_seconds":3763}]},{"id":"a086ba93-ead4-45d6-ab88-dc5e47cfe14a","title":"Meet The Professor: Optimizing the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes — Part 2 of a 3-Part Series","url":"https://oncologytoday.researchtopractice.com/214","content_text":"Dr Gail J Roboz from Weill Cornell Medicine in New York discusses the optimal management of acute myeloid leukemia and myelodysplastic syndromes, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here.","content_html":"Dr Gail J Roboz from Weill Cornell Medicine in New York discusses the optimal management of acute myeloid leukemia and myelodysplastic syndromes, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the management of acute myeloid leukemia and myelodysplastic syndromes with Dr Gail J Roboz, moderated by Dr Neil Love. ","date_published":"2023-11-10T14:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/a086ba93-ead4-45d6-ab88-dc5e47cfe14a.mp3","mime_type":"audio/mpeg","size_in_bytes":59024794,"duration_in_seconds":3682}]},{"id":"7d299170-80bf-41b4-be2f-3dfb671d23e3","title":"Meet The Professor: Optimizing the Management of Ovarian Cancer — Part 2 of a 4-Part Series","url":"https://oncologytoday.researchtopractice.com/213","content_text":"Dr David M O’Malley from the Ohio State University and the James Cancer Center in Columbus, Ohio, discusses optimizing the management of ovarian cancer moderated by Dr Neil Love. Produced by Research To Practice.\n\nCME information and select publications here","content_html":"Dr David M O’Malley from the Ohio State University and the James Cancer Center in Columbus, Ohio, discusses optimizing the management of ovarian cancer moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here
","summary":"Featuring a discussion on optimizing the management of ovarian cancer with Dr David M O'Malley, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2023-11-01T10:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/7d299170-80bf-41b4-be2f-3dfb671d23e3.mp3","mime_type":"audio/mpeg","size_in_bytes":61264447,"duration_in_seconds":3825}]},{"id":"d7a521f3-0e41-4f5b-ace1-6efdebd3bbf5","title":"Inside the Issue: Optimizing the Management of Nonmelanoma Skin Cancer","url":"https://oncologytoday.researchtopractice.com/212","content_text":"Dr Nikhil Khushalani from the Moffitt Cancer Center in Tampa, Florida, and Dr Anna Pavlick from the Weill Cornell Medicine Meyer Cancer Center in New York, New York, discuss available and novel treatment strategies for cutaneous squamous cell carcinoma and basal cell carcinoma.\n\nCME information and select publications here","content_html":"Dr Nikhil Khushalani from the Moffitt Cancer Center in Tampa, Florida, and Dr Anna Pavlick from the Weill Cornell Medicine Meyer Cancer Center in New York, New York, discuss available and novel treatment strategies for cutaneous squamous cell carcinoma and basal cell carcinoma.
\n\nCME information and select publications here
","summary":"Featuring a discussion on the optimal management of nonmelanoma skin cancers with Dr Nikhil I Khushalani and Dr Anna C Pavlick moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2023-10-24T13:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/d7a521f3-0e41-4f5b-ace1-6efdebd3bbf5.mp3","mime_type":"audio/mpeg","size_in_bytes":51206805,"duration_in_seconds":3654}]},{"id":"192ce83d-6499-4f1d-aece-85c4b5877c5a","title":"Meet The Professor: Optimizing the Management of Gastroesophageal Cancers — Part 1 of a 3-Part Series","url":"https://oncologytoday.researchtopractice.com/211","content_text":"Featuring a discussion on current and emerging strategies for the treatment of upper GI cancers with Dr Peter C Enzinger, moderated by Dr Neil Love. Produced by Research To Practice.\n\nCME information and select publications here","content_html":"Featuring a discussion on current and emerging strategies for the treatment of upper GI cancers with Dr Peter C Enzinger, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here
","summary":"Dr Peter Enzinger discusses the optimal management of upper GI cancers for patients with and without targetable mutations, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2023-10-20T12:45:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/192ce83d-6499-4f1d-aece-85c4b5877c5a.mp3","mime_type":"audio/mpeg","size_in_bytes":52872897,"duration_in_seconds":3774}]},{"id":"6e021335-fa8c-466a-9c9e-d334eb390102","title":"Meet The Professor: Optimizing the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes — Part 1 of a 3-Part Series","url":"https://oncologytoday.researchtopractice.com/210","content_text":"Dr Naval Daver from The University of Texas MD Anderson Cancer Center in Houston, Texas, discusses current and emerging optimal management approaches for patients with acute myeloid leukemia and myelodysplastic syndromes.\n\nCME information and select publications here","content_html":"Dr Naval Daver from The University of Texas MD Anderson Cancer Center in Houston, Texas, discusses current and emerging optimal management approaches for patients with acute myeloid leukemia and myelodysplastic syndromes.
\n\nCME information and select publications here
","summary":"Featuring a discussion on the management of acute myeloid leukemia and myelodysplastic syndromes with Dr Naval Daver, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2023-10-20T12:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/6e021335-fa8c-466a-9c9e-d334eb390102.mp3","mime_type":"audio/mpeg","size_in_bytes":51865716,"duration_in_seconds":3697}]},{"id":"7af625b0-7991-4480-b641-f18621e4f59c","title":"What Clinicians Want to Know About the Management of Relapsed/Refractory Mantle Cell Lymphoma","url":"https://oncologytoday.researchtopractice.com/209","content_text":"Dr Toby A Eyre from the Oxford University Hospitals NHS Foundation Trust in Oxford, United Kingdom, and Dr Brad S Kahl from Siteman Cancer Center in St Louis, Missouri, discuss the management of relapsed/refractory mantle cell lymphoma.\n\nCME information and select publications here","content_html":"Dr Toby A Eyre from the Oxford University Hospitals NHS Foundation Trust in Oxford, United Kingdom, and Dr Brad S Kahl from Siteman Cancer Center in St Louis, Missouri, discuss the management of relapsed/refractory mantle cell lymphoma.
\n\nCME information and select publications here
","summary":"Featuring a discussion on the management of relapsed/refractory mantle cell lymphoma with Dr Toby A Eyre and Dr Brad S Kahl, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2023-10-18T11:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/7af625b0-7991-4480-b641-f18621e4f59c.mp3","mime_type":"audio/mpeg","size_in_bytes":51710956,"duration_in_seconds":3685}]},{"id":"5758b10f-4b6e-49b0-be17-47af476e848e","title":"Key Presentations on Multiple Myeloma from Recent Major Oncology/Hematology Conferences","url":"https://oncologytoday.researchtopractice.com/208","content_text":"Dr Joseph Mikhael from the City of Hope Cancer Center in Phoenix, Arizona, discusses recent updates and future directions in the management of newly diagnosed and relapsed/refractory multiple myeloma.\n\nCME information and select publications here","content_html":"Dr Joseph Mikhael from the City of Hope Cancer Center in Phoenix, Arizona, discusses recent updates and future directions in the management of newly diagnosed and relapsed/refractory multiple myeloma.
\n\nCME information and select publications here
","summary":"Featuring a discussion on recent updates in the optimal management of newly diagnosed and relapsed/refractory multiple myeloma moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2023-10-17T12:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/5758b10f-4b6e-49b0-be17-47af476e848e.mp3","mime_type":"audio/mpeg","size_in_bytes":67008471,"duration_in_seconds":4778}]},{"id":"8220ecbc-a622-4324-820e-30942f87bd67","title":"Inside the Issue: Integrating Targeted and Immunotherapy into the Management of Localized Non-Small Cell Lung Cancer","url":"https://oncologytoday.researchtopractice.com/207","content_text":"Dr Jamie Chaft and Dr John Heymach discuss the optimal integration of targeted therapy and immunotherapy into the care of patients with localized non-small cell lung cancer. \n\nCME information and select publications here","content_html":"Dr Jamie Chaft and Dr John Heymach discuss the optimal integration of targeted therapy and immunotherapy into the care of patients with localized non-small cell lung cancer.
\n\nCME information and select publications here
","summary":"Featuring a discussion on the roles of targeted therapy and immunotherapy in the management of localized non-small cell lung cancer, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2023-10-13T10:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/8220ecbc-a622-4324-820e-30942f87bd67.mp3","mime_type":"audio/mpeg","size_in_bytes":51733835,"duration_in_seconds":3692}]},{"id":"bd3bd734-d61a-4579-8ef3-508cf64169ac","title":"Management of Metastatic Pancreatic Cancer with Dr Michael Pishvaian","url":"https://oncologytoday.researchtopractice.com/206","content_text":"Dr Michael Pishvaian from the Johns Hopkins University School of Medicine in Washington, DC, discusses recent updates on available and novel treatment strategies for pancreatic cancer.\n\nCME information and select publications here","content_html":"Dr Michael Pishvaian from the Johns Hopkins University School of Medicine in Washington, DC, discusses recent updates on available and novel treatment strategies for pancreatic cancer.
\n\nCME information and select publications here
","summary":"Featuring a discussion on the optimal management of pancreatic cancer with Dr Michael Pishvaian, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2023-10-12T10:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/bd3bd734-d61a-4579-8ef3-508cf64169ac.mp3","mime_type":"audio/mpeg","size_in_bytes":48612580,"duration_in_seconds":3469}]},{"id":"301bb1ff-5ccf-41ba-831f-fd2d2248f55e","title":"Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma with Dr Matthew Matasar","url":"https://oncologytoday.researchtopractice.com/205","content_text":"Dr Matthew Matasar from the Rutgers Cancer Institute of New Jersey in New York, New York, discusses the current and future role of CD20 x CD3 bispecific antibodies in the management of non-Hodgkin lymphoma.\n\nCME information and select publications here","content_html":"Dr Matthew Matasar from the Rutgers Cancer Institute of New Jersey in New York, New York, discusses the current and future role of CD20 x CD3 bispecific antibodies in the management of non-Hodgkin lymphoma.
\n\nCME information and select publications here
","summary":"Featuring a discussion of the role of CD20 x CD3 bispecific antibodies in the management of non-Hodgkin lymphoma moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2023-10-11T11:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/301bb1ff-5ccf-41ba-831f-fd2d2248f55e.mp3","mime_type":"audio/mpeg","size_in_bytes":39062574,"duration_in_seconds":2782}]},{"id":"cad622d3-f150-43e8-b94e-8575b34392cc","title":"Meet The Professor: Optimizing the Management of Ovarian Cancer — Part 1 of a 4-Part Series","url":"https://oncologytoday.researchtopractice.com/204","content_text":"Dr Kathleen Moore from OU Health Stephenson Cancer Center in Oklahoma City discusses treatment decision-making for real-world cases and approved and investigational treatment strategies for the management of ovarian cancer.\n\nCME information and select publications here","content_html":"Dr Kathleen Moore from OU Health Stephenson Cancer Center in Oklahoma City discusses treatment decision-making for real-world cases and approved and investigational treatment strategies for the management of ovarian cancer.
\n\nCME information and select publications here
","summary":"Featuring a discussion on the management of ovarian cancer with Dr Kathleen Moore, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2023-10-09T10:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/cad622d3-f150-43e8-b94e-8575b34392cc.mp3","mime_type":"audio/mpeg","size_in_bytes":52174148,"duration_in_seconds":3722}]},{"id":"3a47157c-fff5-4b48-a634-c819fb593e65","title":"What Clinicians Want to Know About Anti-CD38 Antibodies in the Management of Multiple Myeloma","url":"https://oncologytoday.researchtopractice.com/203","content_text":"Professor Philippe Moreau from the University Hospital of Nantes in France discusses anti-CD38 antibody-based treatment approaches for newly diagnosed and relapsed/refractory multiple myeloma moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here","content_html":"Professor Philippe Moreau from the University Hospital of Nantes in France discusses anti-CD38 antibody-based treatment approaches for newly diagnosed and relapsed/refractory multiple myeloma moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here
","summary":"Featuring a discussion on the role of anti-CD38 antibodies in the management of multiple myeloma with Professor Philippe Moreau, moderated by Dr Neil Love. ","date_published":"2023-10-06T11:30:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/3a47157c-fff5-4b48-a634-c819fb593e65.mp3","mime_type":"audio/mpeg","size_in_bytes":28608216,"duration_in_seconds":2850}]},{"id":"fe822d9a-ac27-421c-b10e-39c60de590d2","title":"Practical Perspectives: Investigators Discuss Current Management and Actual Cases of Relapsed/Refractory Metastatic Colorectal Cancer","url":"https://oncologytoday.researchtopractice.com/202","content_text":"Dr Kristen K Ciombor from the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, and Dr J Randolph Hecht from UCLA’s David Geffen School of Medicine in Santa Monica, California, discuss the current management and actual cases of relapsed/refractory metastatic colorectal cancer moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here ","content_html":"Dr Kristen K Ciombor from the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, and Dr J Randolph Hecht from UCLA’s David Geffen School of Medicine in Santa Monica, California, discuss the current management and actual cases of relapsed/refractory metastatic colorectal cancer moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here
","summary":"Featuring a discussion on the current management and actual cases of relapsed/refractory metastatic colorectal cancer with Drs Kristen K Ciombor and J Randolph Hecht, moderated by Dr Neil Love.","date_published":"2023-10-06T10:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/fe822d9a-ac27-421c-b10e-39c60de590d2.mp3","mime_type":"audio/mpeg","size_in_bytes":54849610,"duration_in_seconds":3915}]},{"id":"c537718f-bbbb-4e77-b2cc-1c7b0c3397e2","title":"Blastic Plasmacytoid Dendritic Cell Neoplasm","url":"https://oncologytoday.researchtopractice.com/201","content_text":"Dr Naveen Pemmaraju from the University of Texas MD Anderson Cancer Center in Houston, Texas, discusses current and emerging management approaches for blastic plasmacytoid dendritic cell neoplasms moderated by Dr Neil Love.\n\nCME information and select publications here","content_html":"Dr Naveen Pemmaraju from the University of Texas MD Anderson Cancer Center in Houston, Texas, discusses current and emerging management approaches for blastic plasmacytoid dendritic cell neoplasms moderated by Dr Neil Love.
\n\nCME information and select publications here
","summary":"Featuring a discussion on the presentation and management of blastic plasmacytoid dendritic cell neoplasms with Dr Naveen Pemmaraju, moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2023-10-04T10:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/c537718f-bbbb-4e77-b2cc-1c7b0c3397e2.mp3","mime_type":"audio/mpeg","size_in_bytes":20423016,"duration_in_seconds":2031}]},{"id":"c87567b2-4009-4d1b-8661-344ca3d2503d","title":"Inside the Issue: Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast Cancer","url":"https://oncologytoday.researchtopractice.com/200","content_text":"Dr Hope Rugo from the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, California, and Dr Tiffany Traina from Memorial Sloan Kettering Cancer Center in New York, New York, discuss current and emerging optimal management approaches for metastatic triple-negative breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here","content_html":"Dr Hope Rugo from the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, California, and Dr Tiffany Traina from Memorial Sloan Kettering Cancer Center in New York, New York, discuss current and emerging optimal management approaches for metastatic triple-negative breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here
","summary":"Featuring a discussion on the management of metastatic triple-negative breast cancer with Drs Hope Rugo and Tiffany Traina, moderated by Dr Neil Love. ","date_published":"2023-09-29T11:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/c87567b2-4009-4d1b-8661-344ca3d2503d.mp3","mime_type":"audio/mpeg","size_in_bytes":38964682,"duration_in_seconds":3888}]},{"id":"27db21e3-2c37-4be1-8919-9935e2a65251","title":"Emerging Role of CELMoDs (Cereblon E3 Ligase Modulators) and Other Novel Approaches to Targeting Protein Degradation Pathways in Multiple Myeloma","url":"https://oncologytoday.researchtopractice.com/199","content_text":"Dr Paul G Richardson from Dana-Farber Cancer Institute in Boston discusses the emerging role of CELMoDs and other novel approaches to targeting protein degradation pathways in the treatment of multiple myeloma, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here","content_html":"Dr Paul G Richardson from Dana-Farber Cancer Institute in Boston discusses the emerging role of CELMoDs and other novel approaches to targeting protein degradation pathways in the treatment of multiple myeloma, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here
","summary":"Featuring a discussion on the emerging role of CELMoDs and other novel approaches to targeting protein degradation pathways in multiple myeloma, with Dr Paul G Richardson, moderated by Dr Neil Love.","date_published":"2023-09-27T11:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/27db21e3-2c37-4be1-8919-9935e2a65251.mp3","mime_type":"audio/mpeg","size_in_bytes":23610216,"duration_in_seconds":2350}]},{"id":"3191b2c2-6efe-4fee-a94f-8f77cc1b2b28","title":"Novel Agents and Strategies in the Treatment of Ovarian Cancer","url":"https://oncologytoday.researchtopractice.com/198","content_text":"Dr Debra L Richardson from OU Health Stephenson Cancer Center in Oklahoma City discusses novel agents and strategies for ovarian cancer moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here","content_html":"Dr Debra L Richardson from OU Health Stephenson Cancer Center in Oklahoma City discusses novel agents and strategies for ovarian cancer moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here
","summary":"Featuring a discussion on novel agents and strategies in the treatment of ovarian cancer with Dr Debra L Richardson, moderated by Dr Neil Love. ","date_published":"2023-09-25T12:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/3191b2c2-6efe-4fee-a94f-8f77cc1b2b28.mp3","mime_type":"audio/mpeg","size_in_bytes":13053948,"duration_in_seconds":1299}]},{"id":"5e5b4018-abd1-4e2a-9c4c-177eaf5ef73b","title":"What Clinicians Want to Know About Toxicity Considerations Associated with BTK Inhibitors","url":"https://oncologytoday.researchtopractice.com/197","content_text":"Dr Nicole Lamanna from the Columbia University Herbert Irving Comprehensive Cancer Center in New York, New York, and Dr William G Wierda from The University of Texas MD Anderson Cancer Center in Houston, Texas, discuss the spectrum of toxicities associated with BTK inhibitors and strategies for their mitigation and management for patients with chronic lymphocytic leukemia and mantle cell lymphoma, moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here","content_html":"Dr Nicole Lamanna from the Columbia University Herbert Irving Comprehensive Cancer Center in New York, New York, and Dr William G Wierda from The University of Texas MD Anderson Cancer Center in Houston, Texas, discuss the spectrum of toxicities associated with BTK inhibitors and strategies for their mitigation and management for patients with chronic lymphocytic leukemia and mantle cell lymphoma, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here
","summary":"Featuring a discussion on clinically relevant BTK inhibitor-associated adverse events and their management with Dr Nicole Lamanna and Dr William G Wierda, moderated by Dr Neil Love.","date_published":"2023-09-22T10:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/5e5b4018-abd1-4e2a-9c4c-177eaf5ef73b.mp3","mime_type":"audio/mpeg","size_in_bytes":37743816,"duration_in_seconds":3763}]},{"id":"b36c4313-f025-411b-a614-2ab6386e3aff","title":"Optimizing the Management of Metastatic Pancreatic Cancer ","url":"https://oncologytoday.researchtopractice.com/196","content_text":"Dr Eileen M O’Reilly from Memorial Sloan Kettering Cancer Center in New York City and Dr Zev A Wainberg from the UCLA Jonsson Comprehensive Cancer Center in Los Angeles discuss approved and novel treatment approaches for metastatic pancreatic cancer moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here","content_html":"Dr Eileen M O’Reilly from Memorial Sloan Kettering Cancer Center in New York City and Dr Zev A Wainberg from the UCLA Jonsson Comprehensive Cancer Center in Los Angeles discuss approved and novel treatment approaches for metastatic pancreatic cancer moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here
","summary":"Featuring a discussion on the management of metastatic pancreatic cancer with Dr Eileen M O’Reilly and Dr Zev Wainberg, moderated by Dr Neil Love.","date_published":"2023-09-15T10:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/b36c4313-f025-411b-a614-2ab6386e3aff.mp3","mime_type":"audio/mpeg","size_in_bytes":38316907,"duration_in_seconds":3828}]},{"id":"012458f5-da5c-48dd-ae5e-6f3a35b5b7c5","title":"The Current and Future Role of CD20 x CD3 Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma","url":"https://oncologytoday.researchtopractice.com/195","content_text":"Dr Martin Hutchings from Rigshospitalet, Copenhagen University Hospital in Copenhagen, Denmark, and Dr Loretta Nastoupil from The University of Texas MD Anderson Cancer Center in Houston, Texas, discuss the current and future role of CD20 x CD3 bispecific antibodies in the management of non-Hodgkin lymphoma moderated by Dr Neil Love. Produced by Research To Practice.\n\nCME information and select publications here","content_html":"Dr Martin Hutchings from Rigshospitalet, Copenhagen University Hospital in Copenhagen, Denmark, and Dr Loretta Nastoupil from The University of Texas MD Anderson Cancer Center in Houston, Texas, discuss the current and future role of CD20 x CD3 bispecific antibodies in the management of non-Hodgkin lymphoma moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here
","summary":"Featuring a discussion of the current and future role of CD20 x CD3 bispecific antibodies in the management of non-Hodgkin lymphoma with Dr Martin Hutchings and Dr Loretta Nastoupil, moderated by Dr Neil Love.","date_published":"2023-09-13T10:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/012458f5-da5c-48dd-ae5e-6f3a35b5b7c5.mp3","mime_type":"audio/mpeg","size_in_bytes":36526499,"duration_in_seconds":3641}]},{"id":"ed232d31-5801-4db6-9ca4-333f3629dfd0","title":"Meet The Professor: Optimizing the Management of Melanoma","url":"https://oncologytoday.researchtopractice.com/194","content_text":"Prof Georgina Long from the University of Sydney in Sydney, New South Wales, Australia, discusses optimizing the management of melanoma moderated by Dr Neil Love. Produced by Research To Practice. \n\nCME information and select publications here","content_html":"Prof Georgina Long from the University of Sydney in Sydney, New South Wales, Australia, discusses optimizing the management of melanoma moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here
","summary":"Featuring a discussion on optimizing the management of melanoma with Prof Georgina Long, moderated by Dr Neil Love. ","date_published":"2023-09-11T11:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/ed232d31-5801-4db6-9ca4-333f3629dfd0.mp3","mime_type":"audio/mpeg","size_in_bytes":37859945,"duration_in_seconds":3781}]},{"id":"404893ec-cb10-4293-82b7-862bed2ddbc6","title":"Striving for Consensus: Current and Future Management of Metastatic Non-Small Cell Lung Cancer in Patients Who Experience Disease Progression on Immune Checkpoint Inhibitor Therapy","url":"https://oncologytoday.researchtopractice.com/193","content_text":"Dr Corey Langer, Dr Ticiana Leal, Dr Karen Reckamp and Dr Jacob Sands discuss the optimal current management of relapsed NSCLC and provide perspectives on the future of care for patients with this disease, moderated by Dr Neil Love. Produced by Research To Practice.\n\nCME information and select publications here","content_html":"Dr Corey Langer, Dr Ticiana Leal, Dr Karen Reckamp and Dr Jacob Sands discuss the optimal current management of relapsed NSCLC and provide perspectives on the future of care for patients with this disease, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here
","summary":"Featuring a discussion on current and potential future management approaches for patients with relapsed NSCLC with Dr Corey Langer, Dr Ticiana Leal, Dr Karen Reckamp and Dr Jacob Sands, moderated by Dr Neil Love. ","date_published":"2023-09-08T14:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/404893ec-cb10-4293-82b7-862bed2ddbc6.mp3","mime_type":"audio/mpeg","size_in_bytes":98211000,"duration_in_seconds":9817}]},{"id":"c9e84fd6-ec42-4b1c-a913-2ca8b2313877","title":"The Implications of Recent Data Sets for the Management of Hepatocellular Carcinoma","url":"https://oncologytoday.researchtopractice.com/192","content_text":"Dr Ghassan Abou-Alfa from Memorial Sloan Kettering Cancer Center in New York and Dr Daneng Li from City of Hope Comprehensive Cancer Center in Duarte, California, discuss the implications of recent data sets for the management of hepatocellular carcinoma moderated by Dr Neil Love. Produced by Research To Practice.\n\nCME information and select publications here","content_html":"Dr Ghassan Abou-Alfa from Memorial Sloan Kettering Cancer Center in New York and Dr Daneng Li from City of Hope Comprehensive Cancer Center in Duarte, California, discuss the implications of recent data sets for the management of hepatocellular carcinoma moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here
","summary":"Featuring a discussion on the implications of recent data sets for the management of hepatocellular carcinoma, with Drs Ghassan Abou-Alfa and Daneng Li, moderated by Dr Neil Love.","date_published":"2023-09-05T13:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/c9e84fd6-ec42-4b1c-a913-2ca8b2313877.mp3","mime_type":"audio/mpeg","size_in_bytes":37276267,"duration_in_seconds":3724}]},{"id":"5d2f773c-c442-4c65-bfda-f90cb3cc1e5b","title":"Exploring the Current and Future Management of High-Risk, Hormone-Sensitive Nonmetastatic Prostate Cancer","url":"https://oncologytoday.researchtopractice.com/191","content_text":"Dr Neal Shore from the Carolina Urologic Research Center in Myrtle Beach, South Carolina, and Dr Mary-Ellen Taplin from the Dana-Farber Cancer Institute in Boston, Massachusetts, discuss the current and future management of high-risk, hormone-sensitive nonmetastatic prostate cancer, moderated by Dr Neil Love. Produced by Research To Practice.\n\nCME information and select publications here","content_html":"Dr Neal Shore from the Carolina Urologic Research Center in Myrtle Beach, South Carolina, and Dr Mary-Ellen Taplin from the Dana-Farber Cancer Institute in Boston, Massachusetts, discuss the current and future management of high-risk, hormone-sensitive nonmetastatic prostate cancer, moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here
","summary":"Featuring a discussion on the management of high-risk, hormone-sensitive nonmetastatic prostate cancer with Dr Neal Shore and Dr Mary-Ellen Taplin.","date_published":"2023-09-01T11:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/5d2f773c-c442-4c65-bfda-f90cb3cc1e5b.mp3","mime_type":"audio/mpeg","size_in_bytes":36640987,"duration_in_seconds":3660}]},{"id":"cc219fc3-2617-4bd9-9da5-8d68ffa5d283","title":"Role of BTK Inhibitors in Therapy for Mantle Cell Lymphoma","url":"https://oncologytoday.researchtopractice.com/190","content_text":"Featuring a discussion on BTK inhibitors for the management of mantle cell lymphoma with Dr Michael Wang, moderated by Dr Neil Love.\n\nCME information and select publications here.","content_html":"Featuring a discussion on BTK inhibitors for the management of mantle cell lymphoma with Dr Michael Wang, moderated by Dr Neil Love.
\n\nCME information and select publications here.
","summary":"Dr Michael Wang from The University of Texas MD Anderson Cancer Center in Houston, Texas, discusses BTK inhibitors and their role in the treatment of mantle cell lymphoma.","date_published":"2023-08-30T14:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/cc219fc3-2617-4bd9-9da5-8d68ffa5d283.mp3","mime_type":"audio/mpeg","size_in_bytes":40871925,"duration_in_seconds":2547}]},{"id":"59dd7b71-4939-4475-b4a2-8be5fe7d4909","title":"Meet The Professor: Optimizing the Management of Soft Tissue Sarcoma and Related Connective Tissue Disorders — Part 2 of a 2-Part Series","url":"https://oncologytoday.researchtopractice.com/189","content_text":"Dr Richard F Riedel from Duke Cancer Institute in Durham, North Carolina, discusses approved and novel treatment approaches for soft tissue sarcoma, moderated by Dr Neil Love.\n\nCME information and select publications here.","content_html":"Dr Richard F Riedel from Duke Cancer Institute in Durham, North Carolina, discusses approved and novel treatment approaches for soft tissue sarcoma, moderated by Dr Neil Love.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the management of soft tissue sarcomas with Dr Richard F Riedel moderated by Dr Neil Love. Produced by Research To Practice.","date_published":"2023-08-29T10:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/59dd7b71-4939-4475-b4a2-8be5fe7d4909.mp3","mime_type":"audio/mpeg","size_in_bytes":37148582,"duration_in_seconds":3713}]},{"id":"73b5057d-2c2e-48cf-be65-480218386fa1","title":"Special Edition — Key Presentations on Chronic Lymphocytic Leukemia and Lymphoma from Recent Major Oncology/Hematology Conferences ","url":"https://oncologytoday.researchtopractice.com/188","content_text":"Dr Jeremy Abramson from Massachusetts General Hospital in Boston discusses key presentations on chronic lymphocytic leukemia and lymphomas from recent oncology/hematology conferences.\n\nCME information and select publications here","content_html":"Dr Jeremy Abramson from Massachusetts General Hospital in Boston discusses key presentations on chronic lymphocytic leukemia and lymphomas from recent oncology/hematology conferences.
\n\nCME information and select publications here
","summary":"Featuring a discussion of key presentations on chronic lymphocytic leukemia and lymphomas from recent oncology/hematology conferences, with Dr Jeremy Abramson, moderated by Dr Neil Love.","date_published":"2023-08-28T11:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/73b5057d-2c2e-48cf-be65-480218386fa1.mp3","mime_type":"audio/mpeg","size_in_bytes":21763379,"duration_in_seconds":2165}]},{"id":"49eafd29-67a9-4766-ac7c-2b631fd4a01a","title":"Special Edition — Key Presentations on Genitourinary Cancers from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting ","url":"https://oncologytoday.researchtopractice.com/187","content_text":"Dr Rana McKay from UC San Diego Moores Cancer Center in La Jolla, California discusses key presentations on genitourinary cancers from the 2023 ASCO Annual Meeting. \n\nCME information and select publications here","content_html":"Dr Rana McKay from UC San Diego Moores Cancer Center in La Jolla, California discusses key presentations on genitourinary cancers from the 2023 ASCO Annual Meeting.
\n\nCME information and select publications here
","summary":"Featuring a discussion on key presentations on genitourinary cancers from the 2023 ASCO Annual Meeting with Dr Rana McKay, moderated by Dr Neil Love. ","date_published":"2023-08-25T09:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/49eafd29-67a9-4766-ac7c-2b631fd4a01a.mp3","mime_type":"audio/mpeg","size_in_bytes":48410143,"duration_in_seconds":4837}]},{"id":"b50d845b-4abc-4e52-a296-d2d2e9267518","title":"Current and Future Management of ER-Positive Metastatic Breast Cancer After Disease Progression on a CDK4/6 Inhibitor","url":"https://oncologytoday.researchtopractice.com/186","content_text":"Dr Aditya Bardia from Massachusetts General Hospital in Boston, Massachusetts, and Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, discuss approved and novel treatment approaches for ER-positive metastatic breast cancer that has progressed on prior CDK4/6 inhibitor therapy.\n\nCME information and select publications here.","content_html":"Dr Aditya Bardia from Massachusetts General Hospital in Boston, Massachusetts, and Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, discuss approved and novel treatment approaches for ER-positive metastatic breast cancer that has progressed on prior CDK4/6 inhibitor therapy.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the management of ER-positive metastatic breast cancer after disease progression on CDK4/6 inhibitor therapy, with Dr Aditya Bardia and Dr Erika Hamilton. ","date_published":"2023-08-23T12:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/b50d845b-4abc-4e52-a296-d2d2e9267518.mp3","mime_type":"audio/mpeg","size_in_bytes":36831525,"duration_in_seconds":3675}]},{"id":"ebb0d628-ce1f-481c-ac99-d75550c55bde","title":"Integrating Bispecific Antibodies into the Management of Multiple Myeloma — Patient Selection and Toxicity Management","url":"https://oncologytoday.researchtopractice.com/185","content_text":"Dr Hans Lee from The University of Texas MD Anderson Cancer Center in Houston, Texas, and Dr Saad Zafar Usmani from Memorial Sloan Kettering Cancer Center in New York, New York, discuss approved and novel bispecific antibodies and their current and potential roles in the treatment of multiple myeloma.\n\nCME information and select publications here.","content_html":"Dr Hans Lee from The University of Texas MD Anderson Cancer Center in Houston, Texas, and Dr Saad Zafar Usmani from Memorial Sloan Kettering Cancer Center in New York, New York, discuss approved and novel bispecific antibodies and their current and potential roles in the treatment of multiple myeloma.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on BCMA- and non-BCMA-targeted bispecific antibodies in the management of multiple myeloma with Dr Hans Lee and Dr Saad Zafar Usmani, moderated by Dr Neil Love.","date_published":"2023-08-22T14:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/ebb0d628-ce1f-481c-ac99-d75550c55bde.mp3","mime_type":"audio/mpeg","size_in_bytes":36609299,"duration_in_seconds":3650}]},{"id":"2a9829f7-4b5e-48e0-b382-99ae407f238b","title":"Special Edition — Key Presentations on Lung Cancer from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting","url":"https://oncologytoday.researchtopractice.com/184","content_text":"Dr Matthew Gubens from the University of California in San Francisco, California, discusses key presentations on lung cancer from the 2023 ASCO Annual Meeting moderated by Dr Neil Love. Produced by Research To Practice.\n\nCME information and select publications here","content_html":"Dr Matthew Gubens from the University of California in San Francisco, California, discusses key presentations on lung cancer from the 2023 ASCO Annual Meeting moderated by Dr Neil Love. Produced by Research To Practice.
\n\nCME information and select publications here
","summary":"Featuring a discussion on key presentations on lung cancer from the 2023 ASCO Annual Meeting, with Dr Matthew Gubens, moderated by Dr Neil Love.","date_published":"2023-08-21T10:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/2a9829f7-4b5e-48e0-b382-99ae407f238b.mp3","mime_type":"audio/mpeg","size_in_bytes":19094571,"duration_in_seconds":1905}]},{"id":"2dccb7c3-a2c0-445f-ad7d-574063ed3331","title":"Special Nursing Edition — What I Tell My Patients About New Treatments and Clinical Trials in Chronic Lymphocytic Leukemia","url":"https://oncologytoday.researchtopractice.com/183","content_text":"Dr Kerry Rogers from the Ohio State University in Columbus, Ohio, discusses the education and care of patients with chronic lymphocytic leukemia.\n\nNCPD information and select publications here","content_html":"Dr Kerry Rogers from the Ohio State University in Columbus, Ohio, discusses the education and care of patients with chronic lymphocytic leukemia.
\n\nNCPD information and select publications here
","summary":"Featuring a discussion on the education and care of patients with chronic lymphocytic leukemia with Dr Kerry Rogers, moderated by Dr Neil Love.","date_published":"2023-08-18T10:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/2dccb7c3-a2c0-445f-ad7d-574063ed3331.mp3","mime_type":"audio/mpeg","size_in_bytes":66686310,"duration_in_seconds":4161}]},{"id":"1b00a01c-8127-445f-a77e-15bc8a53d1e5","title":"Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Melanoma and Nonmelanoma Skin Cancers ","url":"https://oncologytoday.researchtopractice.com/182","content_text":"Featuring perspectives from Dr Omid Hamid and Dr Evan J Lipson moderated by Dr Neil Love. Produced by Research to Practice.\n\nCME information and select publications here. ","content_html":"Featuring perspectives from Dr Omid Hamid and Dr Evan J Lipson moderated by Dr Neil Love. Produced by Research to Practice.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the most impactful updates from 2022 in the management of melanoma and nonmelanoma skin cancers with Dr Omid Hamid and Dr Evan J Lipson, moderated by Dr Neil Love.","date_published":"2023-08-16T10:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/1b00a01c-8127-445f-a77e-15bc8a53d1e5.mp3","mime_type":"audio/mpeg","size_in_bytes":61139948,"duration_in_seconds":3818}]},{"id":"55fdb47d-36e1-4d19-871c-5908cbe4979e","title":"Special Edition — Key Presentations from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Gastrointestinal Cancers Issue","url":"https://oncologytoday.researchtopractice.com/181","content_text":"Dr Philip Philip from Henry Ford Cancer - Detroit in Michigan discusses key presentations on GI cancers from the 2023 ASCO Annual Meeting moderated by Dr Neil Love. Produced by Research to Practice.\n\nCME information and select publications here","content_html":"Dr Philip Philip from Henry Ford Cancer - Detroit in Michigan discusses key presentations on GI cancers from the 2023 ASCO Annual Meeting moderated by Dr Neil Love. Produced by Research to Practice.
\n\nCME information and select publications here
","summary":"Featuring a discussion on key presentations related to gastrointestinal cancers from the 2023 ASCO Annual Meeting, with Dr Philip Philip, moderated by Dr Neil Love.","date_published":"2023-08-15T15:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/55fdb47d-36e1-4d19-871c-5908cbe4979e.mp3","mime_type":"audio/mpeg","size_in_bytes":46998729,"duration_in_seconds":2935}]},{"id":"abf05135-93f2-4f83-bb43-af81e68719f2","title":"Special Edition — Key Presentations on Gynecologic Cancers from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting","url":"https://oncologytoday.researchtopractice.com/180","content_text":"Dr Floor Backes from The James Cancer Hospital and Solove Research Institute in Columbus, Ohio, discusses recent updates from ASCO 2023 on the management of gynecologic cancers.\n\nCME information and select publications here","content_html":"Dr Floor Backes from The James Cancer Hospital and Solove Research Institute in Columbus, Ohio, discusses recent updates from ASCO 2023 on the management of gynecologic cancers.
\n\nCME information and select publications here
","summary":"Featuring a discussion on recent updates in the management of gynecologic cancers from the ASCO 2023 Annual Meeting, with Dr Floor Backes, moderated by Dr Neil Love. ","date_published":"2023-08-11T10:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/abf05135-93f2-4f83-bb43-af81e68719f2.mp3","mime_type":"audio/mpeg","size_in_bytes":41439362,"duration_in_seconds":2586}]},{"id":"41313c50-cd58-481e-89c9-27c767557c74","title":"Ready for Prime Time? Determining the Current and Future Role of PARP Inhibitor-Based Combinations in the Management of Prostate Cancer — A Clinical Investigator Think Tank","url":"https://oncologytoday.researchtopractice.com/179","content_text":"Drs Neeraj Agarwal, Emmanuel Antonarakis, Karim Fizazi and Susan Slovin discuss the current and future role of PARP inhibitors in the management of prostate cancer. \n\nCME information and select publications here.","content_html":"Drs Neeraj Agarwal, Emmanuel Antonarakis, Karim Fizazi and Susan Slovin discuss the current and future role of PARP inhibitors in the management of prostate cancer.
\n\nCME information and select publications here.
","summary":"Featuring a roundtable discussion on the current and future role of PARP inhibitor-based therapy in the management of prostate cancer, with Drs Neeraj Agarwal, Emmanuel Antonarakis, Karim Fizazi and Susan Slovin, moderated by Dr Neil Love. ","date_published":"2023-08-11T08:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/41313c50-cd58-481e-89c9-27c767557c74.mp3","mime_type":"audio/mpeg","size_in_bytes":101409824,"duration_in_seconds":10137}]},{"id":"7b4dd1b1-797a-41a2-881b-181aba16e56d","title":"Optimizing the Management of Metastatic Urothelial Bladder Cancer","url":"https://oncologytoday.researchtopractice.com/178","content_text":"Dr Terence Friedlander from the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, California, and Dr Petros Grivas from the Fred Hutchinson Cancer Research Center in Seattle, Washington, discuss available and novel treatment strategies for metastatic urothelial bladder cancer moderated by Dr Neil Love. \n\nCME informationa and select publications here.","content_html":"Dr Terence Friedlander from the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, California, and Dr Petros Grivas from the Fred Hutchinson Cancer Research Center in Seattle, Washington, discuss available and novel treatment strategies for metastatic urothelial bladder cancer moderated by Dr Neil Love.
\n\nCME informationa and select publications here.
","summary":"Featuring a discussion on treatment approaches for metastatic urothelial bladder cancer with Dr Terence Friedlander and Dr Petros Grivas, moderated by Dr Neil Love. ","date_published":"2023-08-09T12:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/7b4dd1b1-797a-41a2-881b-181aba16e56d.mp3","mime_type":"audio/mpeg","size_in_bytes":59609200,"duration_in_seconds":3723}]},{"id":"593f0322-f029-4216-8ea7-cafb24182e31","title":"Special Edition — Current and Future Management of Breast Cancer","url":"https://oncologytoday.researchtopractice.com/177","content_text":"Dr Heather McArthur from the UT Southwestern Medical Center in Dallas, Texas discusses key presentations on breast cancer from the 2023 ASCO Annual meeting.\n\nCME information and select publications here.","content_html":"Dr Heather McArthur from the UT Southwestern Medical Center in Dallas, Texas discusses key presentations on breast cancer from the 2023 ASCO Annual meeting.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on key presentations on breast cancer from the 2023 ASCO Annual meeting, with Dr Heather McArthur, moderated by Dr Neil Love.","date_published":"2023-08-08T12:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/593f0322-f029-4216-8ea7-cafb24182e31.mp3","mime_type":"audio/mpeg","size_in_bytes":82042888,"duration_in_seconds":5122}]},{"id":"c09fb39e-6800-4bdc-a793-b04d8c082f7f","title":"Special Edition — Key Presentations from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Ovarian Cancer Issue","url":"https://oncologytoday.researchtopractice.com/175","content_text":"Dr David O’Malley from The James Cancer Center in Columbus, Ohio, discusses recent advances in the management of ovarian cancer, including presentations from ASCO 2023.\n\nCME information and select publications here","content_html":"Dr David O’Malley from The James Cancer Center in Columbus, Ohio, discusses recent advances in the management of ovarian cancer, including presentations from ASCO 2023.
\n\nCME information and select publications here
","summary":"Featuring a discussion on recent therapeutic advances in ovarian cancer and presentations from the 2023 ASCO Annual Meeting, with Dr David O’Malley, moderated by Dr Neil Love.","date_published":"2023-08-03T12:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/c09fb39e-6800-4bdc-a793-b04d8c082f7f.mp3","mime_type":"audio/mpeg","size_in_bytes":55201692,"duration_in_seconds":3446}]},{"id":"55046ba5-9f57-4709-bf4c-76dd86cdf68c","title":"Special Nursing Edition — What I Tell My Patients About New Treatments and Clinical Trials in Colorectal and Gastroesophageal Cancers ","url":"https://oncologytoday.researchtopractice.com/174","content_text":"Dr Tanios Bekaii-Saab from the Mayo Clinic in Phoenix, Arizona, discusses the role of novel therapeutic management approaches for patients with colorectal and gastroesophageal cancers.\n\nNCPD information and select publications here","content_html":"Dr Tanios Bekaii-Saab from the Mayo Clinic in Phoenix, Arizona, discusses the role of novel therapeutic management approaches for patients with colorectal and gastroesophageal cancers.
\n\nNCPD information and select publications here
","summary":"Featuring a discussion on the management of colorectal and gastroesophageal cancers with Dr Tanios Bekaii-Saab, moderated by Dr Neil Love.","date_published":"2023-08-02T16:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/55046ba5-9f57-4709-bf4c-76dd86cdf68c.mp3","mime_type":"audio/mpeg","size_in_bytes":56302453,"duration_in_seconds":3516}]},{"id":"b64c95b0-f7bc-44a8-89ed-c4b7b73e114f","title":" Novel Agents, Approaches and Strategies in the Management of Higher-Risk Myelodysplastic Syndromes","url":"https://oncologytoday.researchtopractice.com/176","content_text":"Featuring perspectives from Dr Guillermo Garcia-Manero and Dr David Sallman.\n\nCME information and select publications here","content_html":"Featuring perspectives from Dr Guillermo Garcia-Manero and Dr David Sallman.
\n\nCME information and select publications here
","summary":"Featuring perspectives from Dr Guillermo Garcia-Manero and Dr David Sallman, moderated by Dr Neil Love. Produced by Research to Practice.","date_published":"2023-08-02T09:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/b64c95b0-f7bc-44a8-89ed-c4b7b73e114f.mp3","mime_type":"audio/mpeg","size_in_bytes":60689813,"duration_in_seconds":3786}]},{"id":"5f506597-a978-4515-b7a1-9d8474565c91","title":"Immune Thrombocytopenia Edition with Dr Hanny Al-Samkari","url":"https://oncologytoday.researchtopractice.com/171","content_text":"Dr Hanny Al-Samkari from Harvard Medical School in Boston, Massachusetts, discusses the presentation and management of immune thrombocytopenia.\n\nCME information and select publications here","content_html":"Dr Hanny Al-Samkari from Harvard Medical School in Boston, Massachusetts, discusses the presentation and management of immune thrombocytopenia.
\n\nCME information and select publications here
","summary":"Featuring a discussion on the biology and treatment of immune thrombocytopenia with Dr Hanny Al-Samkari, moderated by Dr Neil Love.","date_published":"2023-07-28T12:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/5f506597-a978-4515-b7a1-9d8474565c91.mp3","mime_type":"audio/mpeg","size_in_bytes":28317686,"duration_in_seconds":1763}]},{"id":"d2aef2d8-afb6-45ae-9f39-a97454130b14","title":"Paroxysmal Nocturnal Hemoglobinuria Edition with Dr Carlos de Castro","url":"https://oncologytoday.researchtopractice.com/167","content_text":"Dr Carlos de Castro from Duke Cancer Institute in Durham, North Carolina discusses the presentation, diagnosis and management of paroxysmal nocturnal hemoglobinuria.\n\nCME information and select publications here","content_html":"Dr Carlos de Castro from Duke Cancer Institute in Durham, North Carolina discusses the presentation, diagnosis and management of paroxysmal nocturnal hemoglobinuria.
\n\nCME information and select publications here
","summary":"Featuring a discussion on the biology and treatment of paroxysmal nocturnal hemoglobinuria with Dr Carlos de Castro, moderated by Dr Neil Love. ","date_published":"2023-07-25T13:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/d2aef2d8-afb6-45ae-9f39-a97454130b14.mp3","mime_type":"audio/mpeg","size_in_bytes":41236800,"duration_in_seconds":2570}]},{"id":"f20550f0-3044-4bcf-ba6a-6d32128131cc","title":"Special Edition — Management of Hepatobiliary Cancers","url":"https://oncologytoday.researchtopractice.com/170","content_text":"Dr Robin “Katie” Kelley from the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, California discusses recent updates from ASCO 2023 on the management of hepatobiliary cancers, moderated by Dr Neil Love.\n\nCME information and select publications here","content_html":"Dr Robin “Katie” Kelley from the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, California discusses recent updates from ASCO 2023 on the management of hepatobiliary cancers, moderated by Dr Neil Love.
\n\nCME information and select publications here
","summary":"Dr Robin “Katie” Kelley discusses recent updates from ASCO 2023 on the management of hepatobiliary cancers moderated by Dr Neil Love. Produced by Research to Practice.","date_published":"2023-07-24T11:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/f20550f0-3044-4bcf-ba6a-6d32128131cc.mp3","mime_type":"audio/mpeg","size_in_bytes":51182073,"duration_in_seconds":3196}]},{"id":"e2e32e07-8e08-440d-aad0-5cee703e9753","title":"Special Edition — Management of Urothelial Bladder Cancer ","url":"https://oncologytoday.researchtopractice.com/169","content_text":"Dr Matthew Galsky discusses recent updates from ASCO 2023 on the management of urothelial bladder cancer\nmoderated by Dr Neil Love. Produced by Research to Practice.\n\nCME information and select publications here","content_html":"Dr Matthew Galsky discusses recent updates from ASCO 2023 on the management of urothelial bladder cancer
\nmoderated by Dr Neil Love. Produced by Research to Practice.
CME information and select publications here
","summary":"Dr Matthew Galsky from The Tisch Cancer Institute in New York, New York, discusses recent updates from ASCO 2023 on the management of urothelial bladder cancer, moderated by Dr Neil Love.","date_published":"2023-07-21T16:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/e2e32e07-8e08-440d-aad0-5cee703e9753.mp3","mime_type":"audio/mpeg","size_in_bytes":54390368,"duration_in_seconds":3397}]},{"id":"1f4a5f75-cb51-4a37-88b5-1aa969f3bc31","title":"Special Edition — Current and Future Management of Breast Cancer","url":"https://oncologytoday.researchtopractice.com/168","content_text":"Featuring a discussion on recent presentations in breast cancer from the 2023 ASCO annual meeting with Dr Kevin Kalinsky moderated by Dr Neil Love. Produced by Research to Practice.\n\nCME information and select publications [here","content_html":"Featuring a discussion on recent presentations in breast cancer from the 2023 ASCO annual meeting with Dr Kevin Kalinsky moderated by Dr Neil Love. Produced by Research to Practice.
\n\nCME information and select publications [here
","summary":"Featuring a discussion on recent presentations in breast cancer from the 2023 ASCO annual meeting with Dr Kevin Kalinsky, moderated by Dr Neil Love.","date_published":"2023-07-21T13:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/1f4a5f75-cb51-4a37-88b5-1aa969f3bc31.mp3","mime_type":"audio/mpeg","size_in_bytes":56591158,"duration_in_seconds":3532}]},{"id":"55ae57df-b00f-43fd-bd75-9637069543a6","title":"Special Nursing Edition — What I Tell My Patients About New Treatments and Clinical Trials in Urothelial Bladder Cancer","url":"https://oncologytoday.researchtopractice.com/166","content_text":"Dr Elizabeth Plimack from Fox Chase Cancer Center in Philadelphia, Pennsylvania, discusses available and emerging therapies for patients with urothelial bladder cancer.\n\nCME information and select publications here","content_html":"Dr Elizabeth Plimack from Fox Chase Cancer Center in Philadelphia, Pennsylvania, discusses available and emerging therapies for patients with urothelial bladder cancer.
\n\nCME information and select publications here
","summary":"Featuring a discussion on the presentation and management of urothelial bladder cancer with Dr Elizabeth Plimack, moderated by Dr Neil Love. ","date_published":"2023-07-20T09:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/55ae57df-b00f-43fd-bd75-9637069543a6.mp3","mime_type":"audio/mpeg","size_in_bytes":50190944,"duration_in_seconds":3134}]},{"id":"fb3831d1-57b9-4181-959c-4d63705fe09b","title":"The Implications of New Research Findings for the Management of Endometrial Cancer","url":"https://oncologytoday.researchtopractice.com/165","content_text":"Featuring perspectives from Dr Bradley J Monk and Dr Matthew A Powell moderated by Dr Neil Love. Produced by Research to Practice.\n\nCME information and select publications here.","content_html":"Featuring perspectives from Dr Bradley J Monk and Dr Matthew A Powell moderated by Dr Neil Love. Produced by Research to Practice.
\n\nCME information and select publications here.
","summary":"Featuring perspectives from Dr Bradley J Monk and Dr Matthew A Powell, moderated by Dr Neil Love.","date_published":"2023-07-14T08:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/fb3831d1-57b9-4181-959c-4d63705fe09b.mp3","mime_type":"audio/mpeg","size_in_bytes":58736522,"duration_in_seconds":3667}]},{"id":"21a12bea-b062-49e6-8d5f-8a57c1032cc3","title":"Meet The Professor: The Current and Future Management of Hodgkin and Non-Hodgkin Lymphoma","url":"https://oncologytoday.researchtopractice.com/164","content_text":"Dr Ian W Flinn discusses the management of Hodgkin and non-Hodgkin lymphoma.\n\nCME information and select publications here","content_html":"Dr Ian W Flinn discusses the management of Hodgkin and non-Hodgkin lymphoma.
\n\nCME information and select publications here
","summary":"Featuring a discussion on the management of Hodgkin and non-Hodgkin lymphoma with Dr Ian W Flinn, moderated by Dr Neil Love.","date_published":"2023-07-06T12:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/21a12bea-b062-49e6-8d5f-8a57c1032cc3.mp3","mime_type":"audio/mpeg","size_in_bytes":58895082,"duration_in_seconds":3674}]},{"id":"f02acd7e-1bd6-463e-bb89-b5a8e4dcc6a6","title":"Meet The Professor: Optimizing the Management of Soft Tissue Sarcoma and Related Connective Tissue Disorders — Part 1 of a 2 - Part Series","url":"https://oncologytoday.researchtopractice.com/163","content_text":"Dr Brian Van Tine discusses new and future research in the management of soft tissue sarcoma and related connective tissue disorders.\n\nCME information and select publications here","content_html":"Dr Brian Van Tine discusses new and future research in the management of soft tissue sarcoma and related connective tissue disorders.
\n\nCME information and select publications here
","summary":"Featuring a discussion on the management of soft tissue sarcoma and related connective tissue disorders with Dr Brian Van Tine, moderated by Dr Neil Love.","date_published":"2023-06-16T12:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/f02acd7e-1bd6-463e-bb89-b5a8e4dcc6a6.mp3","mime_type":"audio/mpeg","size_in_bytes":58954700,"duration_in_seconds":3683}]},{"id":"736f8390-6835-420a-9b1a-7e2c9bac7754","title":"Key Presentations from the 64th American Society of Hematology (ASH) Annual Meeting: Multiple Myeloma Edition","url":"https://oncologytoday.researchtopractice.com/162","content_text":"Dr Jacob Laubach from the Dana-Farber Cancer Institute discusses key presentations in multiple myeloma from the 2022 ASH Annual Meeting.\n\nCME information and select publications here.","content_html":"Dr Jacob Laubach from the Dana-Farber Cancer Institute discusses key presentations in multiple myeloma from the 2022 ASH Annual Meeting.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on newly presented data in multiple myeloma from the 2022 ASH Annual Meeting, with Dr Jacob Laubach, moderated by Dr Neil Love.","date_published":"2023-04-19T08:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/736f8390-6835-420a-9b1a-7e2c9bac7754.mp3","mime_type":"audio/mpeg","size_in_bytes":71766620,"duration_in_seconds":4478}]},{"id":"9cf4448d-bc96-488c-a14b-44bb3fb3f2d6","title":"Key Presentations from the 64th American Society of Hematology (ASH) Annual Meeting: Chronic Lymphocytic Leukemia Edition","url":"https://oncologytoday.researchtopractice.com/161","content_text":"Dr John Allan from Weill Cornell Medicine in New York City discusses the most important chronic lymphocytic leukemia studies presented at ASH 2022.\n\nCME information and select publications here.","content_html":"Dr John Allan from Weill Cornell Medicine in New York City discusses the most important chronic lymphocytic leukemia studies presented at ASH 2022.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on chronic lymphocytic leukemia studies presented at ASH 2022 with Dr John Allan, moderated by Dr Neil Love.","date_published":"2023-04-12T09:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/9cf4448d-bc96-488c-a14b-44bb3fb3f2d6.mp3","mime_type":"audio/mpeg","size_in_bytes":74043379,"duration_in_seconds":4620}]},{"id":"38b2afc7-aef1-46d6-a94e-1d5184a1dc2d","title":"Key Presentations in Hodgkin and Non-Hodgkin Lymphomas from the 2022 ASH Annual Meeting with Dr Matthew Lunning","url":"https://oncologytoday.researchtopractice.com/160","content_text":"Dr Matthew Lunning from the University of Nebraska Medical Center in Omaha, Nebraska, discusses the most important lymphoma studies presented at the 2022 ASH Annual Meeting.\n\nCME information and select publications here.","content_html":"Dr Matthew Lunning from the University of Nebraska Medical Center in Omaha, Nebraska, discusses the most important lymphoma studies presented at the 2022 ASH Annual Meeting.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on lymphoma studies presented at ASH 2022, with Dr Matthew Lunning, moderated by Dr Neil Love.","date_published":"2023-03-02T14:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/38b2afc7-aef1-46d6-a94e-1d5184a1dc2d.mp3","mime_type":"audio/mpeg","size_in_bytes":84691119,"duration_in_seconds":5286}]},{"id":"dfea81ad-8e4c-46b7-ba98-ab68741d5c58","title":"Management of Desmoid Tumors with Dr Mrinal Gounder","url":"https://oncologytoday.researchtopractice.com/159","content_text":"Dr Mrinal Gounder from Memorial Sloan Kettering Cancer Center in New York City discusses the management of desmoid tumors.\n\nCME information and select publications here.","content_html":"Dr Mrinal Gounder from Memorial Sloan Kettering Cancer Center in New York City discusses the management of desmoid tumors.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the management of desmoid tumors with Dr Mrinal Gounder, moderated by Dr Neil Love.","date_published":"2023-02-28T12:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/dfea81ad-8e4c-46b7-ba98-ab68741d5c58.mp3","mime_type":"audio/mpeg","size_in_bytes":52137584,"duration_in_seconds":3257}]},{"id":"37103412-1367-4b6b-8d09-91eedaa91b59","title":"Management of HER2-Altered Non-Small Cell Lung Cancer","url":"https://oncologytoday.researchtopractice.com/158","content_text":"Dr Bob Li from Memorial Sloan Kettering Cancer Center in New York City discusses the current and future roles of targeted therapy for HER2-altered non-small cell lung cancer.\n\nCME information and select publications here.","content_html":"Dr Bob Li from Memorial Sloan Kettering Cancer Center in New York City discusses the current and future roles of targeted therapy for HER2-altered non-small cell lung cancer.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on targeted therapy for HER2-altered non-small cell lung cancer with Dr Bob Li, moderated by Dr Neil Love.","date_published":"2023-02-21T11:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/37103412-1367-4b6b-8d09-91eedaa91b59.mp3","mime_type":"audio/mpeg","size_in_bytes":76760265,"duration_in_seconds":4795}]},{"id":"ee4ffdee-6b82-4991-9438-4b6e1f192c14","title":"Management of Metastatic Non-Small Cell Lung Cancer without an Actionable Mutation","url":"https://oncologytoday.researchtopractice.com/157","content_text":"Dr Edward Garon from the UCLA Jonsson Comprehensive Cancer Center in Los Angeles, California, discusses the management of NSCLC in patients who do not have actionable activating mutations.\n\nCME information and select publications here.","content_html":"Dr Edward Garon from the UCLA Jonsson Comprehensive Cancer Center in Los Angeles, California, discusses the management of NSCLC in patients who do not have actionable activating mutations.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on new and emerging data in the management of NSCLC without an actionable mutation, with Dr Edward Garon, moderated by Dr Neil Love.","date_published":"2023-02-13T10:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/ee4ffdee-6b82-4991-9438-4b6e1f192c14.mp3","mime_type":"audio/mpeg","size_in_bytes":47568143,"duration_in_seconds":2970}]},{"id":"072fe345-6c0e-4448-b78e-6cc3e70e99cd","title":"Key Presentations on Myeloproliferative Neoplasms from the 2022 ASH Annual Meeting — With Dr Srdan Verstovsek","url":"https://oncologytoday.researchtopractice.com/156","content_text":"Dr Srdan Verstovsek from the University of Texas MD Anderson Cancer Center in Houston, Texas, discusses new data with myeloproliferative neoplasms presented at the 2022 ASH Annual Meeting.\n\nCME information and select publications here.","content_html":"Dr Srdan Verstovsek from the University of Texas MD Anderson Cancer Center in Houston, Texas, discusses new data with myeloproliferative neoplasms presented at the 2022 ASH Annual Meeting.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on newly presented data with myelofibrosis, polycythemia vera and essential thrombocythemia with Dr Srdan Verstovsek, moderated by Dr Neil Love.","date_published":"2023-02-09T09:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/072fe345-6c0e-4448-b78e-6cc3e70e99cd.mp3","mime_type":"audio/mpeg","size_in_bytes":75984576,"duration_in_seconds":4742}]},{"id":"f819f034-ab0e-43ef-99ff-2ffc9cdb3967","title":"Advances in Diffuse Large B-Cell Lymphoma with Dr Gilles Salles","url":"https://oncologytoday.researchtopractice.com/155","content_text":"Dr Gilles Salles from Memorial Sloan Kettering Cancer Center in New York City discusses recent data from clinical trials evaluating targeted therapies for diffuse large B-cell lymphoma.\n\nCME information and select publications here.","content_html":"Dr Gilles Salles from Memorial Sloan Kettering Cancer Center in New York City discusses recent data from clinical trials evaluating targeted therapies for diffuse large B-cell lymphoma.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent data with targeted therapies for the treatment of diffuse large B-cell lymphoma with Dr Gilles Salles, moderated by Dr Neil Love.","date_published":"2023-02-06T14:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/f819f034-ab0e-43ef-99ff-2ffc9cdb3967.mp3","mime_type":"audio/mpeg","size_in_bytes":41888571,"duration_in_seconds":2611}]},{"id":"edcd2640-65b4-4455-9755-ab12b4b3e39c","title":"Key Presentations in Acute Myeloid Leukemia and Myelodysplastic Syndromes from the 2022 ASH Annual Meeting with Dr Richard Stone","url":"https://oncologytoday.researchtopractice.com/154","content_text":"Dr Richard Stone from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses new data in acute myeloid leukemia and myelodysplastic syndromes presented at the 2022 ASH Annual Meeting.\n\nCME information and select publications here.","content_html":"Dr Richard Stone from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses new data in acute myeloid leukemia and myelodysplastic syndromes presented at the 2022 ASH Annual Meeting.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on newly presented data in acute myeloid leukemia and myelodysplastic syndromes from the 2022 ASH Annual Meeting with Dr Richard Stone, moderated by Dr Neil Love.","date_published":"2023-02-02T09:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/edcd2640-65b4-4455-9755-ab12b4b3e39c.mp3","mime_type":"audio/mpeg","size_in_bytes":67338915,"duration_in_seconds":4201}]},{"id":"73758cf3-5ab1-4faa-beb2-1b0b569d3512","title":"Special Edition — Management of ER-Positive Breast Cancer with Drs Erica Mayer and Ruth O'Regan","url":"https://oncologytoday.researchtopractice.com/153","content_text":"Dr Erica Mayer from the Dana-Farber Cancer Institute in Boston, Massachusetts and Dr Ruth O'Regan from the University of Rochester in Rochester, New York discuss new developments in ER-positive breast cancer.\n\nCME information and select publications here.","content_html":"Dr Erica Mayer from the Dana-Farber Cancer Institute in Boston, Massachusetts and Dr Ruth O'Regan from the University of Rochester in Rochester, New York discuss new developments in ER-positive breast cancer.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on ER-positive breast cancer with Drs Erica Mayer and Ruth O’Regan, moderated by Dr Neil Love.","date_published":"2023-01-31T09:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/73758cf3-5ab1-4faa-beb2-1b0b569d3512.mp3","mime_type":"audio/mpeg","size_in_bytes":96034035,"duration_in_seconds":5997}]},{"id":"4cab4a70-6176-4dec-8ada-92ad3cf52656","title":"HER2-Positive Metastatic Breast Cancer with Professor Giuseppe Curigliano","url":"https://oncologytoday.researchtopractice.com/152","content_text":"Professor Giuseppe Curigliano from the European Institute of Oncology in Milan, Italy discusses recent therapeutic advances in HER2-positive metastatic breast cancer.\n\nCME information and select publications here.","content_html":"Professor Giuseppe Curigliano from the European Institute of Oncology in Milan, Italy discusses recent therapeutic advances in HER2-positive metastatic breast cancer.
\n\nCME information and select publications here.
","summary":"Featuring a discussion of recent advances in the treatment of HER2-positive metastatic breast cancer with Professor Giuseppe Curigliano, moderated by Dr Neil Love.","date_published":"2023-01-26T09:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/4cab4a70-6176-4dec-8ada-92ad3cf52656.mp3","mime_type":"audio/mpeg","size_in_bytes":45161323,"duration_in_seconds":2817}]},{"id":"51fcfa3c-ad95-4532-a927-5e59e1b80dd8","title":"Management of Gastroesophageal Cancers with Dr Manish Shah","url":"https://oncologytoday.researchtopractice.com/151","content_text":"Dr Manish Shah from Weill Cornell Medicine in New York City discusses current approaches to the management of upper GI malignancies and the potential future role of novel therapies for patients with these cancers. \n\nCME information and select publications here.","content_html":"Dr Manish Shah from Weill Cornell Medicine in New York City discusses current approaches to the management of upper GI malignancies and the potential future role of novel therapies for patients with these cancers.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on current and emerging strategies for the treatment of upper GI malignancies with Dr Manish Shah, moderated by Dr Neil Love. ","date_published":"2023-01-12T09:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/51fcfa3c-ad95-4532-a927-5e59e1b80dd8.mp3","mime_type":"audio/mpeg","size_in_bytes":41583604,"duration_in_seconds":2596}]},{"id":"ab8f989c-35c1-4ff2-bd7a-265271e710b7","title":"Managing Metastatic Urothelial Bladder Cancer with Dr Scott Tagawa","url":"https://oncologytoday.researchtopractice.com/150","content_text":"Dr Scott Tagawa from Weill Cornell Medicine Sandra and Edward Meyer Cancer Center in New York, New York discusses current treatments and management strategies for metastatic urothelial bladder cancer.\n\nCME information and select publications here.","content_html":"Dr Scott Tagawa from Weill Cornell Medicine Sandra and Edward Meyer Cancer Center in New York, New York discusses current treatments and management strategies for metastatic urothelial bladder cancer.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on current treatments for metastatic urothelial bladder cancer with Dr Scott Tagawa, moderated by Dr Neil Love.","date_published":"2023-01-05T08:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/ab8f989c-35c1-4ff2-bd7a-265271e710b7.mp3","mime_type":"audio/mpeg","size_in_bytes":53797888,"duration_in_seconds":3360}]},{"id":"1a45bec0-3f5e-4fba-a964-5ca9f59ef9ad","title":"Role of PARP Inhibition in Ovarian Cancer with Dr Thomas Herzog","url":"https://oncologytoday.researchtopractice.com/149","content_text":"Dr Thomas Herzog from the University of Cincinnati Medical Center in Cincinnati, Ohio, discusses updates and recent changes in the use of PARP inhibitors for ovarian cancer.\n\nCME information and select publications here.","content_html":"Dr Thomas Herzog from the University of Cincinnati Medical Center in Cincinnati, Ohio, discusses updates and recent changes in the use of PARP inhibitors for ovarian cancer.
\n\nCME information and select publications here.
","summary":"Featuring a discussion of the current role of PARP inhibitors in the care of patients with ovarian cancer with Dr Thomas Herzog, moderated by Dr Neil Love.","date_published":"2022-12-21T09:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/1a45bec0-3f5e-4fba-a964-5ca9f59ef9ad.mp3","mime_type":"audio/mpeg","size_in_bytes":48033003,"duration_in_seconds":2998}]},{"id":"17c8cdc4-b570-4016-92fb-210782cfbff6","title":"Novel Immunotherapeutic Strategies in Melanoma with Dr Omid Hamid","url":"https://oncologytoday.researchtopractice.com/148","content_text":"Dr Omid Hamid from the Angeles Clinic and Research Institute in Los Angeles, California, discusses novel immunotherapies and combination treatments for patients with metastatic melanoma.\n\nCME information and select publications here.","content_html":"Dr Omid Hamid from the Angeles Clinic and Research Institute in Los Angeles, California, discusses novel immunotherapies and combination treatments for patients with metastatic melanoma.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on novel immunotherapies and combination treatments for patients with metastatic melanoma with Dr Omid Hamid, moderated by Dr Neil Love. ","date_published":"2022-12-13T07:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/17c8cdc4-b570-4016-92fb-210782cfbff6.mp3","mime_type":"audio/mpeg","size_in_bytes":47894740,"duration_in_seconds":2990}]},{"id":"7df265ac-5ba9-4cba-a11f-c7c8fb541e73","title":"Thyroid Cancer with Dr Eric Sherman","url":"https://oncologytoday.researchtopractice.com/147","content_text":"Dr Eric Sherman from Memorial Sloan Kettering Cancer Center in New York City discusses recent therapeutic advances in thyroid cancer.\n\nCME information and select publications here.","content_html":"Dr Eric Sherman from Memorial Sloan Kettering Cancer Center in New York City discusses recent therapeutic advances in thyroid cancer.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent advances in the treatment of thyroid cancer with Dr Eric Sherman, moderated by Dr Neil Love. ","date_published":"2022-12-08T06:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/7df265ac-5ba9-4cba-a11f-c7c8fb541e73.mp3","mime_type":"audio/mpeg","size_in_bytes":66248529,"duration_in_seconds":4138}]},{"id":"2d8d4607-213f-4963-abc3-3b4d5ff0c03d","title":"Amyloid Light Chain (AL) Amyloidosis with Dr Jeffrey Zonder","url":"https://oncologytoday.researchtopractice.com/146","content_text":"Dr Jeffrey Zonder from Karmanos Cancer Institute in Detroit, Michigan discusses the biology, presentation and current management of AL amyloidosis and emerging data with novel therapies.\n\nCME information and select publications here.","content_html":"Dr Jeffrey Zonder from Karmanos Cancer Institute in Detroit, Michigan discusses the biology, presentation and current management of AL amyloidosis and emerging data with novel therapies.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the biology, presentation and management of AL amyloidosis with Dr Jeffrey Zonder, moderated by Dr Neil Love.","date_published":"2022-12-06T08:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/2d8d4607-213f-4963-abc3-3b4d5ff0c03d.mp3","mime_type":"audio/mpeg","size_in_bytes":40705512,"duration_in_seconds":2537}]},{"id":"97749e06-4de1-4bb2-b579-7000324d432f","title":"Novel Agents and Strategies in Myelofibrosis with Dr Ruben Mesa","url":"https://oncologytoday.researchtopractice.com/145","content_text":"Dr Ruben Mesa from the Mays Cancer Center in San Antonio, Texas, discusses therapeutic advances in the management of patients with myelofibrosis.\n\nCME information and select publications here.","content_html":"Dr Ruben Mesa from the Mays Cancer Center in San Antonio, Texas, discusses therapeutic advances in the management of patients with myelofibrosis.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on current treatments and future directions in the care of patients with myelofibrosis with Dr Ruben Mesa, moderated by Dr Neil Love. ","date_published":"2022-12-01T08:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/97749e06-4de1-4bb2-b579-7000324d432f.mp3","mime_type":"audio/mpeg","size_in_bytes":39939096,"duration_in_seconds":2489}]},{"id":"43797835-788b-4072-a528-493b9b3586f1","title":"Management of Renal Cell Carcinoma with Dr Toni Choueiri","url":"https://oncologytoday.researchtopractice.com/144","content_text":"Dr Toni Choueiri from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent therapeutic advances in the care of patients with renal cell carcinoma.\n\nCME information and select publications here.","content_html":"Dr Toni Choueiri from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent therapeutic advances in the care of patients with renal cell carcinoma.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent advances in the treatment of renal cell carcinoma with Dr Toni Choueiri, moderated by Dr Neil Love.","date_published":"2022-11-29T09:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/43797835-788b-4072-a528-493b9b3586f1.mp3","mime_type":"audio/mpeg","size_in_bytes":38877248,"duration_in_seconds":2427}]},{"id":"ec5013d8-8430-40ee-a750-f80fca742bc6","title":"Management of Hepatocellular Carcinoma with Prof Arndt Vogel","url":"https://oncologytoday.researchtopractice.com/143","content_text":"Professor Arndt Vogel from Hannover Medical School in Germany discusses major clinical trials and recent changes in the treatment of advanced hepatocellular carcinoma.\n\nCME information and select publications [here]","content_html":"Professor Arndt Vogel from Hannover Medical School in Germany discusses major clinical trials and recent changes in the treatment of advanced hepatocellular carcinoma.
\n\nCME information and select publications [here]
","summary":"Featuring a discussion on recent advances in the clinical management of advanced HCC with Professor Arndt Vogel, moderated by Dr Neil Love. ","date_published":"2022-11-21T10:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/ec5013d8-8430-40ee-a750-f80fca742bc6.mp3","mime_type":"audio/mpeg","size_in_bytes":57003847,"duration_in_seconds":3560}]},{"id":"480a5b69-1f7b-484e-8e02-8942f3f4968c","title":"Novel Agents and Strategies in AML with Dr Eytan Stein","url":"https://oncologytoday.researchtopractice.com/142","content_text":"Dr Eytan Stein from Memorial Sloan Kettering Cancer Center in New York City discusses novel agents and strategies in the treatment of acute myeloid leukemia.\n\nCME information and select publications here.","content_html":"Dr Eytan Stein from Memorial Sloan Kettering Cancer Center in New York City discusses novel agents and strategies in the treatment of acute myeloid leukemia.
\n\nCME information and select publications here.
","summary":"Featuring a discussion of novel agents and strategies in acute myeloid leukemia with Dr Eytan Stein, moderated by Dr Neil Love.\r\n","date_published":"2022-11-17T08:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/480a5b69-1f7b-484e-8e02-8942f3f4968c.mp3","mime_type":"audio/mpeg","size_in_bytes":27397821,"duration_in_seconds":1705}]},{"id":"ab4fa454-234c-4c9a-b918-b05f8ecdc124","title":"Higher-Risk Myelodysplastic Syndromes with Dr Amy DeZern","url":"https://oncologytoday.researchtopractice.com/141","content_text":"Dr Amy DeZern from The Sidney Kimmel Comprehensive Cancer Center in Baltimore, Maryland, discusses recent therapeutic advances in higher-risk myelodysplastic syndromes.\n\nCME information and select publications here.","content_html":"Dr Amy DeZern from The Sidney Kimmel Comprehensive Cancer Center in Baltimore, Maryland, discusses recent therapeutic advances in higher-risk myelodysplastic syndromes.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on higher-risk myelodysplastic syndromes with Dr Amy DeZern, moderated by Dr Neil Love.","date_published":"2022-11-15T09:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/ab4fa454-234c-4c9a-b918-b05f8ecdc124.mp3","mime_type":"audio/mpeg","size_in_bytes":42070763,"duration_in_seconds":2622}]},{"id":"74f83e17-c6ad-41f8-98bc-d86689440856","title":"Key Presentations Related to Gastrointestinal Cancers from Recent Major Oncology Conferences — With Dr Rachna Shroff","url":"https://oncologytoday.researchtopractice.com/140","content_text":"Dr Rachna Shroff from the University of Arizona Cancer Center in Tucson, Arizona, discusses data and the practical implications from key gastrointestinal cancer presentations made at recent major oncology conferences.\n\nCME information and select publications here.","content_html":"Dr Rachna Shroff from the University of Arizona Cancer Center in Tucson, Arizona, discusses data and the practical implications from key gastrointestinal cancer presentations made at recent major oncology conferences.
\n\nCME information and select publications here.
","summary":"Featuring a discussion of key presentations related to gastrointestinal cancers from recent major oncology conferences, with Dr Rachna Shroff, moderated by Dr Neil Love.","date_published":"2022-11-10T09:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/74f83e17-c6ad-41f8-98bc-d86689440856.mp3","mime_type":"audio/mpeg","size_in_bytes":39649558,"duration_in_seconds":2476}]},{"id":"34d7b4c2-363a-4d1e-a78c-be8eda71aa30","title":"Management of MET-Altered Non-Small Cell Lung Cancer with Dr Rebecca Heist","url":"https://oncologytoday.researchtopractice.com/139","content_text":"Dr Rebecca Heist from Massachusetts General Hospital Cancer Center in Boston, Massachusetts discusses recent therapeutic advances in the management of MET-altered non-small cell lung cancer.\n\nCME information and select publications here.","content_html":"Dr Rebecca Heist from Massachusetts General Hospital Cancer Center in Boston, Massachusetts discusses recent therapeutic advances in the management of MET-altered non-small cell lung cancer.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent advances in the treatment of non-small cell lung cancer harboring MET alteration with Dr Rebecca Heist, moderated by Dr. Neil Love.","date_published":"2022-11-07T11:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/34d7b4c2-363a-4d1e-a78c-be8eda71aa30.mp3","mime_type":"audio/mpeg","size_in_bytes":37584763,"duration_in_seconds":2346}]},{"id":"33d795f8-df17-4fa0-a629-7027418bc70c","title":"Current Management of Myelofibrosis with Dr Brady Stein","url":"https://oncologytoday.researchtopractice.com/138","content_text":"Dr Brady Stein from Northwestern University Feinberg School of Medicine in Chicago, Illinois, discusses recent therapeutic advances in myelofibrosis.\n\nCME information and select publications here.","content_html":"Dr Brady Stein from Northwestern University Feinberg School of Medicine in Chicago, Illinois, discusses recent therapeutic advances in myelofibrosis.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent advances in the treatment of myelofibrosis with Dr Brady Stein, moderated by Dr Neil Love.","date_published":"2022-11-03T10:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/33d795f8-df17-4fa0-a629-7027418bc70c.mp3","mime_type":"audio/mpeg","size_in_bytes":56572809,"duration_in_seconds":3529}]},{"id":"2ac35f48-6b27-421d-82d5-d697f726607c","title":"Neuroendocrine Tumors with Dr Pamela Kunz","url":"https://oncologytoday.researchtopractice.com/137","content_text":"Dr Pamela Kunz from the Yale Cancer Center in Palo Alto, California, discusses recent therapeutic advances in neuroendocrine tumors.\n\nCME information and select publications here.","content_html":"Dr Pamela Kunz from the Yale Cancer Center in Palo Alto, California, discusses recent therapeutic advances in neuroendocrine tumors.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent advances in understanding and treating neuroendocrine tumors with Dr Pamela Kunz, moderated by Dr Neil Love.","date_published":"2022-11-01T11:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/2ac35f48-6b27-421d-82d5-d697f726607c.mp3","mime_type":"audio/mpeg","size_in_bytes":36754227,"duration_in_seconds":2296}]},{"id":"374f467f-ea71-4568-bb91-d87d24f1f9a5","title":"BRAF-Mutant Metastatic Melanoma with Prof Axel Hauschild","url":"https://oncologytoday.researchtopractice.com/136","content_text":"Professor Axel Hauschild from Kiel University in Kiel, Germany, discusses recent therapeutic advances in the treatment of metastatic melanoma with BRAF mutations.\n\nCME information and select publications here.","content_html":"Professor Axel Hauschild from Kiel University in Kiel, Germany, discusses recent therapeutic advances in the treatment of metastatic melanoma with BRAF mutations.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent advances in the treatment of metastatic melanoma with BRAF mutations with Prof Axel Hauschild, moderated by Dr Neil Love.","date_published":"2022-10-27T11:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/374f467f-ea71-4568-bb91-d87d24f1f9a5.mp3","mime_type":"audio/mpeg","size_in_bytes":52327033,"duration_in_seconds":3267}]},{"id":"18a3cb1e-9f21-4677-8529-129c56e2ab67","title":"Management of RET Fusion-Positive Non-Small Cell Lung Cancer with Dr Justin Gainor","url":"https://oncologytoday.researchtopractice.com/135","content_text":"Dr Justin Gainor from Massachusetts General Hospital in Boston, Massachusetts, discusses recent therapeutic advances in non-small cell lung cancer with RET fusions.\n\nCME information and select publications here.","content_html":"Dr Justin Gainor from Massachusetts General Hospital in Boston, Massachusetts, discusses recent therapeutic advances in non-small cell lung cancer with RET fusions.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent advances in the care of patients with RET-rearranged non-small cell lung cancer with Dr Justin Gainor, moderated by Dr Neil Love.","date_published":"2022-10-25T12:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/18a3cb1e-9f21-4677-8529-129c56e2ab67.mp3","mime_type":"audio/mpeg","size_in_bytes":44590346,"duration_in_seconds":2784}]},{"id":"40ff366a-575e-4d04-9d82-ec12ec6662c4","title":"Management of Nonmetastatic Urothelial Bladder Cancer with Prof Sia Daneshmand","url":"https://oncologytoday.researchtopractice.com/134","content_text":"Professor Sia Daneshmand from the USC/Norris Comprehensive Cancer Center in Los Angeles, California, discusses recent advances in and perspectives on the management of nonmetastatic urothelial bladder cancer.\n\nCME information and select publications here.","content_html":"Professor Sia Daneshmand from the USC/Norris Comprehensive Cancer Center in Los Angeles, California, discusses recent advances in and perspectives on the management of nonmetastatic urothelial bladder cancer.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on current management and novel therapies for nonmetastatic urothelial bladder cancer with Prof Sia Daneshmand, moderated by Dr Neil Love.","date_published":"2022-10-20T08:30:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/40ff366a-575e-4d04-9d82-ec12ec6662c4.mp3","mime_type":"audio/mpeg","size_in_bytes":45160567,"duration_in_seconds":2820}]},{"id":"b6cb1b81-4d67-4a65-a8bf-152d362b3018","title":"Management of Small Cell Lung Cancer with Dr Benjamin Levy","url":"https://oncologytoday.researchtopractice.com/133","content_text":"Dr Benjamin Levy from the Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial in Washington, DC, discusses recent therapeutic advances in the care of patients with small cell lung cancer.\n\nCME information and select publications here.","content_html":"Dr Benjamin Levy from the Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial in Washington, DC, discusses recent therapeutic advances in the care of patients with small cell lung cancer.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent advances in the care of patients with small cell lung cancer with Dr Benjamin Levy, moderated by Dr Neil Love.","date_published":"2022-10-06T12:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/b6cb1b81-4d67-4a65-a8bf-152d362b3018.mp3","mime_type":"audio/mpeg","size_in_bytes":46169145,"duration_in_seconds":2883}]},{"id":"d14dd3b8-a20f-4f9f-9601-4815bc500e64","title":"BCMA-Directed Therapies for Multiple Myeloma with Dr Amrita Krishnan","url":"https://oncologytoday.researchtopractice.com/132","content_text":"Dr Amrita Krishnan from City of Hope in Duarte, California, discusses recent therapeutic advances in BCMA-directed therapies for multiple myeloma.\n\nCME information and select publications here.","content_html":"Dr Amrita Krishnan from City of Hope in Duarte, California, discusses recent therapeutic advances in BCMA-directed therapies for multiple myeloma.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent advances in the treatment of multiple myeloma with BCMA-directed therapies with Dr Amrita Krishnan, moderated by Dr Neil Love.","date_published":"2022-09-29T09:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/d14dd3b8-a20f-4f9f-9601-4815bc500e64.mp3","mime_type":"audio/mpeg","size_in_bytes":46933020,"duration_in_seconds":2926}]},{"id":"528be69c-5cc0-42d3-b290-ba572d870693","title":"Management of Localized Non-Small Cell Lung Cancer with Dr Heather Wakelee","url":"https://oncologytoday.researchtopractice.com/131","content_text":"Dr Heather Wakelee from Stanford Cancer Institute in Palo Alto, California, discusses the management of localized non-small cell lung cancer.\n\nCME information and select publications here.","content_html":"Dr Heather Wakelee from Stanford Cancer Institute in Palo Alto, California, discusses the management of localized non-small cell lung cancer.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the management of localized non-small cell lung cancer with Dr Heather Wakelee, moderated by Dr Neil Love.","date_published":"2022-09-26T08:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/528be69c-5cc0-42d3-b290-ba572d870693.mp3","mime_type":"audio/mpeg","size_in_bytes":38987154,"duration_in_seconds":2434}]},{"id":"4850e19c-8e43-436a-9e97-d509b842c979","title":"Current and Future Management of Hodgkin Lymphoma with Dr Stephen Ansell","url":"https://oncologytoday.researchtopractice.com/130","content_text":"Dr Stephen Ansell from the Mayo Clinic in Rochester, Minnesota, reviews the evolution of the Hodgkin lymphoma treatment landscape.\n\nCME information and select publications here.","content_html":"Dr Stephen Ansell from the Mayo Clinic in Rochester, Minnesota, reviews the evolution of the Hodgkin lymphoma treatment landscape.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on current treatment and novel investigational strategies for the management of early-stage and advanced Hodgkin lymphoma with Dr Stephen Ansell, moderated by Dr Neil Love.","date_published":"2022-09-15T09:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/4850e19c-8e43-436a-9e97-d509b842c979.mp3","mime_type":"audio/mpeg","size_in_bytes":39394077,"duration_in_seconds":2455}]},{"id":"c2ed9d84-a538-440a-aeb7-9515c1803407","title":"Interstitial Lung Disease in Patients Receiving Anticancer Therapy with Dr Charles Powell","url":"https://oncologytoday.researchtopractice.com/129","content_text":"Dr Charles Powell from the Mount Sinai National Jewish Health Respiratory Institute in New York discusses the diagnosis and treatment of interstitial lung disease in patients receiving anticancer therapy.\n\nCME information and select publications here.","content_html":"Dr Charles Powell from the Mount Sinai National Jewish Health Respiratory Institute in New York discusses the diagnosis and treatment of interstitial lung disease in patients receiving anticancer therapy.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on interstitial lung disease associated with anticancer therapies with Dr Charles Powell, moderated by Dr Neil Love.","date_published":"2022-09-13T08:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/c2ed9d84-a538-440a-aeb7-9515c1803407.mp3","mime_type":"audio/mpeg","size_in_bytes":40867325,"duration_in_seconds":2553}]},{"id":"9bd85f80-4375-41d0-b759-3d186eac7b2d","title":"Endometrial Cancer Edition with Dr Mansoor Raza Mirza","url":"https://oncologytoday.researchtopractice.com/128","content_text":"Dr Mansoor Raza Mirza from Copenhagen University Hospital in Copenhagen, Denmark, discusses recent therapeutic advances in the care of patients with endometrial cancer.\n\nCME information and select publications here.","content_html":"Dr Mansoor Raza Mirza from Copenhagen University Hospital in Copenhagen, Denmark, discusses recent therapeutic advances in the care of patients with endometrial cancer.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent advances in the treatment of patients with endometrial cancer with Dr Mansoor Raza Mirza, moderated by Dr Neil Love.","date_published":"2022-09-08T09:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/9bd85f80-4375-41d0-b759-3d186eac7b2d.mp3","mime_type":"audio/mpeg","size_in_bytes":37136793,"duration_in_seconds":2317}]},{"id":"9494a737-ffe1-41ae-b248-2fb00744b3ac","title":"Ocular Toxicities in Patients Receiving Anticancer Therapy with Dr Asim Farooq","url":"https://oncologytoday.researchtopractice.com/127","content_text":"Dr Asim Farooq from The University of Chicago Medical Center in Chicago, Illinois, discusses common ocular toxicities associated with anticancer agents, including antibody-drug conjugates and EGFR, ALK, MEK and BRAF inhibitors.\n\nCME information and select publications here.","content_html":"Dr Asim Farooq from The University of Chicago Medical Center in Chicago, Illinois, discusses common ocular toxicities associated with anticancer agents, including antibody-drug conjugates and EGFR, ALK, MEK and BRAF inhibitors.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on ocular toxicities associated with anticancer therapies with Dr Asim Farooq, moderated by Dr Neil Love.","date_published":"2022-09-06T10:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/9494a737-ffe1-41ae-b248-2fb00744b3ac.mp3","mime_type":"audio/mpeg","size_in_bytes":27139268,"duration_in_seconds":1695}]},{"id":"de47fdd9-ebab-46b8-8662-fd2fbe0324f5","title":"Key Presentations in Lung Cancer from the 2022 ASCO Annual Meeting with Dr Joshua Sabari","url":"https://oncologytoday.researchtopractice.com/126","content_text":"Dr Joshua Sabari from the Perlmutter Cancer Center in New York discusses key presentations in lung cancer from the 2022 ASCO annual meeting.\n\nCME information and select publications here.","content_html":"Dr Joshua Sabari from the Perlmutter Cancer Center in New York discusses key presentations in lung cancer from the 2022 ASCO annual meeting.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the most exciting updates in the management of lung cancer from the 2022 ASCO annual meeting with Dr Joshua Sabari, moderated by Dr Neil Love.","date_published":"2022-08-24T13:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/de47fdd9-ebab-46b8-8662-fd2fbe0324f5.mp3","mime_type":"audio/mpeg","size_in_bytes":26292423,"duration_in_seconds":1640}]},{"id":"7f1339cd-5de3-42e0-a66b-4bd427623a47","title":"KRAS-Mutant Non-Small Cell Lung Cancer","url":"https://oncologytoday.researchtopractice.com/125","content_text":"Dr Alexander Spira of the Virginia Cancer Specialists Research Program in Fairfax, Virginia, discusses recent therapeutic advances in the care of patients with non-small cell lung cancer with KRAS mutations.\n\nCME information and select publications here.","content_html":"Dr Alexander Spira of the Virginia Cancer Specialists Research Program in Fairfax, Virginia, discusses recent therapeutic advances in the care of patients with non-small cell lung cancer with KRAS mutations.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent advances in the management of patients with non-small cell lung cancer with KRAS mutations with Dr Alexander Spira, moderated by Dr Neil Love.","date_published":"2022-08-18T09:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/7f1339cd-5de3-42e0-a66b-4bd427623a47.mp3","mime_type":"audio/mpeg","size_in_bytes":40762740,"duration_in_seconds":2545}]},{"id":"8df3ae54-2596-4371-bbfd-b0759c4737c2","title":"Advances in Gynecologic Cancers from the 2022 ASCO Annual Meeting with Dr Brian Slomovitz","url":"https://oncologytoday.researchtopractice.com/124","content_text":"Dr Brian Slomovitz from the Mount Sinai Medical Center in Miami, Florida, discusses key abstracts in gynecologic cancers presented at the 2022 ASCO annual meeting.\n\nCME information and select publications here.","content_html":"Dr Brian Slomovitz from the Mount Sinai Medical Center in Miami, Florida, discusses key abstracts in gynecologic cancers presented at the 2022 ASCO annual meeting.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on abstracts presented at the 2022 ASCO annual meeting on gynecologic cancers with Dr Brian Slomovitz, moderated by Dr Neil Love.","date_published":"2022-08-16T09:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/8df3ae54-2596-4371-bbfd-b0759c4737c2.mp3","mime_type":"audio/mpeg","size_in_bytes":44752047,"duration_in_seconds":2793}]},{"id":"4b1ee290-626f-433e-a881-7456433f76be","title":"Key Abstracts in Head, Neck and Thyroid Cancers from the 2022 ASCO Annual Meeting with Dr Ezra Cohen","url":"https://oncologytoday.researchtopractice.com/123","content_text":"Dr Ezra Cohen from the Moores Cancer Center at UC San Diego Health in La Jolla, California, discusses key abstracts presented in head, neck and thyroid cancers at the 2022 ASCO annual meeting.\n\nCME information and select publications here.","content_html":"Dr Ezra Cohen from the Moores Cancer Center at UC San Diego Health in La Jolla, California, discusses key abstracts presented in head, neck and thyroid cancers at the 2022 ASCO annual meeting.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on key abstracts in head, neck and thyroid cancers from the 2022 ASCO annual meeting with Dr Ezra Cohen, moderated by Dr Neil Love.","date_published":"2022-08-08T10:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/4b1ee290-626f-433e-a881-7456433f76be.mp3","mime_type":"audio/mpeg","size_in_bytes":43145895,"duration_in_seconds":2694}]},{"id":"b98b48c1-1d9f-4cf5-b42b-28a21c8e8281","title":"Recent Updates in the Management of HER2-Low Breast Cancer with Dr Shanu Modi","url":"https://oncologytoday.researchtopractice.com/122","content_text":"Dr Shanu Modi from Memorial Sloan Kettering Cancer Center in New York discusses recent therapeutic advances in HER2-low breast cancer.\n\nCME information and select publications here.","content_html":"Dr Shanu Modi from Memorial Sloan Kettering Cancer Center in New York discusses recent therapeutic advances in HER2-low breast cancer.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent advances in the treatment of HER2-low breast cancer with Dr Shanu Modi, moderated by Dr Neil Love.","date_published":"2022-08-02T12:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/b98b48c1-1d9f-4cf5-b42b-28a21c8e8281.mp3","mime_type":"audio/mpeg","size_in_bytes":57214254,"duration_in_seconds":3571}]},{"id":"d050658b-0b45-44a8-afa3-48238dc6e653","title":"Management of Unresectable Stage III Non-Small Cell Lung Cancer with Drs Jeffrey Bradley and David Spigel","url":"https://oncologytoday.researchtopractice.com/121","content_text":"Dr Jeffrey Bradley from the Emory University School of Medicine in Atlanta, Georgia, and Dr David Spigel from the Sarah Cannon Research Institute in Nashville, Tennessee, discuss the past, present and future management of unresectable Stage III non-small cell lung cancer.\n\nCME information and select publications here.","content_html":"Dr Jeffrey Bradley from the Emory University School of Medicine in Atlanta, Georgia, and Dr David Spigel from the Sarah Cannon Research Institute in Nashville, Tennessee, discuss the past, present and future management of unresectable Stage III non-small cell lung cancer.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on available research data, guideline endorsed algorithms and ongoing clinical trials relevant to the management of unresectable Stage III non-small cell lung cancer with Drs Jeffrey Bradley and David Spigel, moderated by Dr Neil Love.","date_published":"2022-08-01T11:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/d050658b-0b45-44a8-afa3-48238dc6e653.mp3","mime_type":"audio/mpeg","size_in_bytes":98458823,"duration_in_seconds":6151}]},{"id":"b673d2ff-509d-4d28-a990-6f4ad613c2f7","title":"Key Presentations on Genitourinary Cancers from the 2022 ASCO Annual Meeting with Dr Sandy Srinivas","url":"https://oncologytoday.researchtopractice.com/120","content_text":"Dr Sandy Srinivas from Stanford University in California discusses key abstracts across genitourinary cancers presented at the 2022 ASCO annual meeting.\n\nCME information and select publications here.","content_html":"Dr Sandy Srinivas from Stanford University in California discusses key abstracts across genitourinary cancers presented at the 2022 ASCO annual meeting.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on abstracts in genitourinary cancers presented at the 2022 ASCO annual meeting with Dr Sandy Srinivas, moderated by Dr Neil Love.","date_published":"2022-07-28T07:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/b673d2ff-509d-4d28-a990-6f4ad613c2f7.mp3","mime_type":"audio/mpeg","size_in_bytes":44258034,"duration_in_seconds":2763}]},{"id":"806f5077-089d-46c9-b4b6-e91f7fa64dd1","title":"Management of Cholangiocarcinoma and Other Biliary Tract Cancers with Professor Juan Valle","url":"https://oncologytoday.researchtopractice.com/119","content_text":"Professor Juan Valle from The Christie NHS Foundation Trust in Manchester, United Kingdom, discusses the evolving treatment landscape in biliary tract cancers.\n\nCME information and select publications here.","content_html":"Professor Juan Valle from The Christie NHS Foundation Trust in Manchester, United Kingdom, discusses the evolving treatment landscape in biliary tract cancers.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the incidence, presentation and management of cholangiocarcinoma and other biliary tract cancers with Professor Juan Valle, moderated by Dr Neil Love.","date_published":"2022-07-21T09:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/806f5077-089d-46c9-b4b6-e91f7fa64dd1.mp3","mime_type":"audio/mpeg","size_in_bytes":43426057,"duration_in_seconds":2712}]},{"id":"5b42559d-ec9c-498b-ad52-3d05137fd86a","title":"Key Presentations on Breast Cancer from the 2022 ASCO Annual Meeting with Dr Angela DeMichele","url":"https://oncologytoday.researchtopractice.com/118","content_text":"Dr Angela DeMichele from the University of Pennsylvania in Philadelphia discusses key abstracts in breast cancer presented at the 2022 ASCO annual meeting.\n\nCME information and select publications here.","content_html":"Dr Angela DeMichele from the University of Pennsylvania in Philadelphia discusses key abstracts in breast cancer presented at the 2022 ASCO annual meeting.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on abstracts in breast cancer presented at the 2022 ASCO annual meeting with Dr Angela DeMichele, moderated by Dr Neil Love.","date_published":"2022-07-18T11:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/5b42559d-ec9c-498b-ad52-3d05137fd86a.mp3","mime_type":"audio/mpeg","size_in_bytes":88069630,"duration_in_seconds":2749}]},{"id":"0b763971-8388-4c6d-9cfe-fbf38aeb17ca","title":"Recent Updates in HER2-Low Breast Cancer with Dr Adam Brufsky","url":"https://oncologytoday.researchtopractice.com/117","content_text":"Dr Adam Brufsky from the UPMC Hillman Cancer Center in Pittsburgh, Pennsylvania, discusses recent data in HER2-low breast cancer.\n\nCME information and select publications here.","content_html":"Dr Adam Brufsky from the UPMC Hillman Cancer Center in Pittsburgh, Pennsylvania, discusses recent data in HER2-low breast cancer.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent advances in the treatment of HER2-low breast cancer with Dr Adam Brufsky, moderated by Dr Neil Love.","date_published":"2022-07-07T09:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/0b763971-8388-4c6d-9cfe-fbf38aeb17ca.mp3","mime_type":"audio/mpeg","size_in_bytes":32766161,"duration_in_seconds":2042}]},{"id":"92bd7e1c-8310-45f7-927f-41937a7a3260","title":"Current and Future Management of Follicular Lymphoma with Dr Loretta Nastoupil","url":"https://oncologytoday.researchtopractice.com/116","content_text":"Dr Loretta Nastoupil from The University of Texas MD Anderson Cancer Center in Houston, Texas, discusses recent advances and future directions in the treatment of patients with follicular lymphoma.\n\nCME information and select publications here.","content_html":"Dr Loretta Nastoupil from The University of Texas MD Anderson Cancer Center in Houston, Texas, discusses recent advances and future directions in the treatment of patients with follicular lymphoma.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the evolving therapeutic landscape in follicular lymphoma with Dr Loretta Nastoupil, moderated by Dr Neil Love.","date_published":"2022-07-05T12:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/92bd7e1c-8310-45f7-927f-41937a7a3260.mp3","mime_type":"audio/mpeg","size_in_bytes":40866921,"duration_in_seconds":2547}]},{"id":"8dbd5568-cc2f-4615-966b-9cc63f2233e7","title":"Updates on Ovarian Cancer from SGO 2022 with Dr David O’Malley","url":"https://oncologytoday.researchtopractice.com/115","content_text":"Dr David O’Malley from The Ohio State University and The James Cancer Center in Columbus, Ohio, discusses trials in ovarian cancer presented at SGO 2022.\n\nCME information and select publications here.","content_html":"Dr David O’Malley from The Ohio State University and The James Cancer Center in Columbus, Ohio, discusses trials in ovarian cancer presented at SGO 2022.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on ovarian cancer presentations from SGO 2022 with Dr David O’Malley, moderated by Dr Neil Love.","date_published":"2022-05-04T08:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/8dbd5568-cc2f-4615-966b-9cc63f2233e7.mp3","mime_type":"audio/mpeg","size_in_bytes":41853480,"duration_in_seconds":2612}]},{"id":"50099eee-5db3-4065-bc5a-dc6637e3a9dd","title":"PARP Inhibitors in Breast Cancer with Dr Judy Garber","url":"https://oncologytoday.researchtopractice.com/114","content_text":"Dr Judy Garber from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent data with PARP inhibitors for breast cancer.\n\nCME information and select publications here.","content_html":"Dr Judy Garber from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent data with PARP inhibitors for breast cancer.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent advances in the treatment of breast cancer with PARP inhibitors with Dr Judy Garber, moderated by Dr Neil Love.\r\n","date_published":"2022-04-20T09:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/50099eee-5db3-4065-bc5a-dc6637e3a9dd.mp3","mime_type":"audio/mpeg","size_in_bytes":38342539,"duration_in_seconds":2391}]},{"id":"09b133f9-fee0-4f87-8d99-eedf60cea1ef","title":"Advances in Soft Tissue Sarcomas with Dr Mark Agulnik","url":"https://oncologytoday.researchtopractice.com/113","content_text":"Dr Mark Agulnik from City of Hope in Duarte, California, discusses recent therapeutic advances in soft tissue sarcoma.\n\nCME information and select publications here.","content_html":"Dr Mark Agulnik from City of Hope in Duarte, California, discusses recent therapeutic advances in soft tissue sarcoma.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent advances in the treatment of soft tissue sarcoma with Dr Mark Agulnik, moderated by Dr Neil Love.","date_published":"2022-03-14T08:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/09b133f9-fee0-4f87-8d99-eedf60cea1ef.mp3","mime_type":"audio/mpeg","size_in_bytes":40913902,"duration_in_seconds":2555}]},{"id":"548aa748-f964-45cb-a7d9-d99f9099119f","title":"Key Presentations on Multiple Myeloma from ASH 2021 with Dr Ajai Chari","url":"https://oncologytoday.researchtopractice.com/112","content_text":"Dr Ajai Chari from the Tisch Cancer Institute Clinical Trials Office in New York discusses recent therapeutic advances in multiple myeloma presented at the 2021 ASH annual meeting.\n\nCME information and select publications here.","content_html":"Dr Ajai Chari from the Tisch Cancer Institute Clinical Trials Office in New York discusses recent therapeutic advances in multiple myeloma presented at the 2021 ASH annual meeting.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent advances in the treatment of multiple myeloma from the 2021 ASH annual meeting with Dr Ajai Chari, moderated by Dr Neil Love.","date_published":"2022-03-10T09:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/548aa748-f964-45cb-a7d9-d99f9099119f.mp3","mime_type":"audio/mpeg","size_in_bytes":38942882,"duration_in_seconds":2427}]},{"id":"2cc0c7a3-6ece-45a6-b077-35913ba6cc74","title":"Key Presentations on Advances in Myeloproliferative Neoplasms from ASH 2021 with Dr Prithviraj Bose","url":"https://oncologytoday.researchtopractice.com/111","content_text":"Dr Prithviraj Bose from The University of Texas MD Anderson Cancer Center in Houston, Texas, discusses recent therapeutic advances in myeloproliferative neoplasms presented at the 2021 ASH annual meeting.\n\nCME information and select publications here.","content_html":"Dr Prithviraj Bose from The University of Texas MD Anderson Cancer Center in Houston, Texas, discusses recent therapeutic advances in myeloproliferative neoplasms presented at the 2021 ASH annual meeting.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent advances in the treatment of myeloproliferative neoplasms from the 2021 ASH annual meeting with Dr Prithviraj Bose, moderated by Dr Neil Love.","date_published":"2022-03-07T10:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/2cc0c7a3-6ece-45a6-b077-35913ba6cc74.mp3","mime_type":"audio/mpeg","size_in_bytes":38950389,"duration_in_seconds":2427}]},{"id":"f47f3eb3-96dc-4b47-af67-6b8f73bf6fa4","title":"Advances in the Treatment of Hodgkin and Non-Hodgkin Lymphomas from ASH 2021 with Dr Matthew Lunning","url":"https://oncologytoday.researchtopractice.com/110","content_text":"Dr Matthew Lunning from the University of Nebraska Medical Center in Omaha, Nebraska, discusses recent therapeutic advances in Hodgkin and non-Hodgkin lymphomas.\n\nCME information and select publications here.","content_html":"Dr Matthew Lunning from the University of Nebraska Medical Center in Omaha, Nebraska, discusses recent therapeutic advances in Hodgkin and non-Hodgkin lymphomas.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent advances in the treatment of Hodgkin and non-Hodgkin lymphomas with Dr Matthew Lunning, moderated by Dr Neil Love.","date_published":"2022-02-21T11:15:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/f47f3eb3-96dc-4b47-af67-6b8f73bf6fa4.mp3","mime_type":"audio/mpeg","size_in_bytes":41883150,"duration_in_seconds":2610}]},{"id":"698cfa22-611e-44ef-b8d7-1ab92cbcc54a","title":"Key Presentations on Acute Myeloid Leukemia and Myelodysplastic Syndromes from ASH 2021","url":"https://oncologytoday.researchtopractice.com/109","content_text":"Dr Andrew Brunner from the Massachusetts General Hospital Cancer Center in Boston, Massachusetts, discusses updates from ASH 2021 on the management of acute myeloid leukemia and myelodysplastic syndromes.\n\nCME information and select publications here.","content_html":"Dr Andrew Brunner from the Massachusetts General Hospital Cancer Center in Boston, Massachusetts, discusses updates from ASH 2021 on the management of acute myeloid leukemia and myelodysplastic syndromes.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on updates from the 2021 ASH annual meeting on the treatment of acute myeloid leukemia and myelodysplastic syndromes with Dr Andrew Brunner, moderated by Dr Neil Love.","date_published":"2022-02-17T12:45:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/698cfa22-611e-44ef-b8d7-1ab92cbcc54a.mp3","mime_type":"audio/mpeg","size_in_bytes":38696876,"duration_in_seconds":2411}]},{"id":"13dd8a1e-9a2d-47b8-8428-cd18172d0025","title":"Current Issues in the Research and Management of Localized Hormone Receptor-Positive Breast Cancer with Dr Sara Tolaney.","url":"https://oncologytoday.researchtopractice.com/108","content_text":"Dr Sara Tolaney from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses current issues in the research and management of localized estrogen receptor-positive breast cancer. \n\nCME information and select publications here.","content_html":"Dr Sara Tolaney from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses current issues in the research and management of localized estrogen receptor-positive breast cancer.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on some of the current major issues in the management of ER-positive breast cancer with Dr Sara Tolaney, moderated by Dr Neil Love.","date_published":"2022-02-11T11:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/13dd8a1e-9a2d-47b8-8428-cd18172d0025.mp3","mime_type":"audio/mpeg","size_in_bytes":38251216,"duration_in_seconds":2385}]},{"id":"6e6b51f8-5a68-4b95-953c-14810475abd9","title":"Recent Advances in the Treatment of Chronic Lymphocytic Leukemia with Dr Peter Hillmen","url":"https://oncologytoday.researchtopractice.com/107","content_text":"Dr Peter Hillmen from the University of Leeds in Leeds, England, discusses recent advances in the management of chronic lymphocytic leukemia.\n\nCME information and select publications here.","content_html":"Dr Peter Hillmen from the University of Leeds in Leeds, England, discusses recent advances in the management of chronic lymphocytic leukemia.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent advances in the management of chronic lymphocytic leukemia with Dr Peter Hillmen, moderated by Dr Neil Love.","date_published":"2022-02-09T08:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/6e6b51f8-5a68-4b95-953c-14810475abd9.mp3","mime_type":"audio/mpeg","size_in_bytes":38538809,"duration_in_seconds":2401}]},{"id":"940c6af2-f9eb-4dc7-8a2b-18df5411bf47","title":"Updates from the 2021 ASH Meeting on Chronic Lymphocytic Leukemia with Dr Matthew Davids","url":"https://oncologytoday.researchtopractice.com/106","content_text":"Dr Matthew Davids from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent therapeutic advances in chronic lymphocytic leukemia presented at ASH 2021.\n\nCME information and select publications here.","content_html":"Dr Matthew Davids from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent therapeutic advances in chronic lymphocytic leukemia presented at ASH 2021.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent advances in the treatment of chronic lymphocytic leukemia with Dr Matthew Davids, moderated by Dr Neil Love.","date_published":"2022-02-02T09:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/940c6af2-f9eb-4dc7-8a2b-18df5411bf47.mp3","mime_type":"audio/mpeg","size_in_bytes":39540027,"duration_in_seconds":2464}]},{"id":"49393dd3-98bf-42e5-bd1d-41d32620b45a","title":"Managing Transplant-Ineligible Newly Diagnosed Multiple Myeloma with Dr Saad Zafar Usmani","url":"https://oncologytoday.researchtopractice.com/105","content_text":"Dr Saad Zafar Usmani from the Memorial Sloan Kettering Cancer Center in New York, New York, discusses recent therapeutic advances in transplant-ineligible newly diagnosed multiple myeloma.\n\nCME information and select publications here.","content_html":"Dr Saad Zafar Usmani from the Memorial Sloan Kettering Cancer Center in New York, New York, discusses recent therapeutic advances in transplant-ineligible newly diagnosed multiple myeloma.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent advances in the treatment of patients with newly diagnosed multiple myeloma who are ineligible for transplant with Dr Saad Zafar Usmani, moderated by Dr Neil Love.","date_published":"2022-01-31T10:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/49393dd3-98bf-42e5-bd1d-41d32620b45a.mp3","mime_type":"audio/mpeg","size_in_bytes":39104679,"duration_in_seconds":2437}]},{"id":"0744cd7c-ece5-4b78-a447-a22bd37b22bb","title":"Novel Agents and Strategies for the Treatment of Metastatic Castration-Resistant Prostate Cancer with Dr Evan Yu","url":"https://oncologytoday.researchtopractice.com/104","content_text":"Dr Evan Yu from the Fred Hutchinson Cancer Research Center in Seattle, Washington, discusses recent therapeutic advances in metastatic castration-resistant prostate cancer\n\nCME information and select publications here.","content_html":"Dr Evan Yu from the Fred Hutchinson Cancer Research Center in Seattle, Washington, discusses recent therapeutic advances in metastatic castration-resistant prostate cancer
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent advances in the treatment of metastatic castration-resistant prostate cancer with Dr Evan Yu, moderated by Dr Neil Love.","date_published":"2022-01-21T08:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/0744cd7c-ece5-4b78-a447-a22bd37b22bb.mp3","mime_type":"audio/mpeg","size_in_bytes":39973958,"duration_in_seconds":2496}]},{"id":"a288c0f9-f26d-41dd-b4e0-52267bc46d58","title":"Biomarker-Directed Therapy for Colorectal Cancer with Dr Christopher Lieu","url":"https://oncologytoday.researchtopractice.com/103","content_text":"Dr Christopher Lieu from the University of Colorado Cancer Center in Aurora, Colorado, discusses recent therapeutic advances in the management of colorectal cancers.\n\nCME information and select publications here.","content_html":"Dr Christopher Lieu from the University of Colorado Cancer Center in Aurora, Colorado, discusses recent therapeutic advances in the management of colorectal cancers.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent advances in targeted therapies for colorectal cancers with Dr Christopher Lieu, moderated by Dr Neil Love.","date_published":"2022-01-14T11:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/a288c0f9-f26d-41dd-b4e0-52267bc46d58.mp3","mime_type":"audio/mpeg","size_in_bytes":50159514,"duration_in_seconds":2506}]},{"id":"655cf16c-f880-4b33-a6fa-fcf8871da869","title":"PARP Inhibition in Pancreatic Cancer with Dr Michael Pishvaian","url":"https://oncologytoday.researchtopractice.com/102","content_text":"Dr Michael Pishvaian from the Johns Hopkins University School of Medicine in Washington, DC, discusses recent therapeutic advances in pancreatic cancer.\n\nCME information and select publications here.","content_html":"Dr Michael Pishvaian from the Johns Hopkins University School of Medicine in Washington, DC, discusses recent therapeutic advances in pancreatic cancer.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent advances in the treatment of pancreatic cancer with PARP with Dr Michael Pishvaian, moderated by Dr Neil Love.","date_published":"2022-01-12T11:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/655cf16c-f880-4b33-a6fa-fcf8871da869.mp3","mime_type":"audio/mpeg","size_in_bytes":46283194,"duration_in_seconds":2890}]},{"id":"6e5b4c4f-0e17-406f-a709-047a1c332933","title":"Modern Management of Metastatic Castration-Resistant Prostate Cancer with Dr Alan Bryce","url":"https://oncologytoday.researchtopractice.com/101","content_text":"Dr Alan Bryce from the Mayo Clinic in Phoenix, Arizona, discusses current practice patterns and recent advances in the management of metastatic castration-resistant prostate cancer.\n\nCME information and select publications here.","content_html":"Dr Alan Bryce from the Mayo Clinic in Phoenix, Arizona, discusses current practice patterns and recent advances in the management of metastatic castration-resistant prostate cancer.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent advances in the therapeutic landscape of metastatic castration-resistant prostate cancer with Dr Alan Bryce, moderated by Dr Neil Love.","date_published":"2022-01-03T11:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/6e5b4c4f-0e17-406f-a709-047a1c332933.mp3","mime_type":"audio/mpeg","size_in_bytes":37500314,"duration_in_seconds":2341}]},{"id":"6973b141-1ef7-48a9-884e-5beb7d818cc3","title":"Advances in Genetic Profiling and Targeted Therapies for Colorectal Cancer with Dr Arvind Dasari","url":"https://oncologytoday.researchtopractice.com/100","content_text":"Dr Arvind Dasari from the University of Texas MD Anderson Cancer Center discusses recent advances and future directions for the management of early-stage and advanced colorectal cancers.\n\nCME information and select publications here.","content_html":"Dr Arvind Dasari from the University of Texas MD Anderson Cancer Center discusses recent advances and future directions for the management of early-stage and advanced colorectal cancers.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent advances in the therapeutic landscape of colorectal cancer with Dr Arvind Dasari, moderated by Dr Neil Love.","date_published":"2021-12-20T08:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/6973b141-1ef7-48a9-884e-5beb7d818cc3.mp3","mime_type":"audio/mpeg","size_in_bytes":54390210,"duration_in_seconds":2716}]},{"id":"2eeed54f-491a-4e1e-8856-ee42d17ca586","title":"Ovarian Cancer with Dr Bradley Monk","url":"https://oncologytoday.researchtopractice.com/99","content_text":"Dr Bradley Monk from the University of Arizona College of Medicine in Phoenix discusses the management of advanced ovarian cancers.\n\nCME information and select publications here.","content_html":"Dr Bradley Monk from the University of Arizona College of Medicine in Phoenix discusses the management of advanced ovarian cancers.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the management of advanced ovarian cancers with Dr Bradley Monk, moderated by Dr Neil Love.","date_published":"2021-12-17T12:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/2eeed54f-491a-4e1e-8856-ee42d17ca586.mp3","mime_type":"audio/mpeg","size_in_bytes":42292581,"duration_in_seconds":2639}]},{"id":"75a3204f-82f6-4449-9826-3235f7379eff","title":"NSCLC with EGFR Exon 20 Insertion Mutations with Dr Gregory Riely","url":"https://oncologytoday.researchtopractice.com/98","content_text":"Dr Gregory Riely from the Memorial Sloan Kettering Cancer Center in New York City discusses recent advances and future directions in the management of patients with NSCLC and EGFR exon 20 insertion mutations.\n\nCME information and select publications here.","content_html":"Dr Gregory Riely from the Memorial Sloan Kettering Cancer Center in New York City discusses recent advances and future directions in the management of patients with NSCLC and EGFR exon 20 insertion mutations.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on advances in the treatment of patients with NSCLC harboring an EGFR exon 20 insertion mutations with Dr Gregory Riely, moderated by Dr Neil Love.","date_published":"2021-12-17T10:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/75a3204f-82f6-4449-9826-3235f7379eff.mp3","mime_type":"audio/mpeg","size_in_bytes":34596524,"duration_in_seconds":2159}]},{"id":"d9615e91-a110-4745-93ab-bcf54cce0678","title":"Novel Immunotherapeutic Strategies in Melanoma with Dr Adil Daud","url":"https://oncologytoday.researchtopractice.com/96","content_text":"Dr Adil Daud from the UCSF Helen Diller Family Comprehensive Cancer Center discusses recent advances and future directions in the use of immunotherapy for the management of wild-type and BRAF-mutant melanoma.\n\nCME information and select publications here.","content_html":"Dr Adil Daud from the UCSF Helen Diller Family Comprehensive Cancer Center discusses recent advances and future directions in the use of immunotherapy for the management of wild-type and BRAF-mutant melanoma.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent advances in immunotherapeutic approaches for patients with melanoma with Dr Adil Daud, moderated by Dr Neil Love.","date_published":"2021-12-13T12:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/d9615e91-a110-4745-93ab-bcf54cce0678.mp3","mime_type":"audio/mpeg","size_in_bytes":34167815,"duration_in_seconds":2128}]},{"id":"b02c85e1-a44f-45ac-9e06-ef94639a3621","title":"Optimal Management of Hodgkin Lymphoma in Younger and Older Patients with Dr Neil Love","url":"https://oncologytoday.researchtopractice.com/95","content_text":"Dr Andrew Evens from the Rutgers Cancer Institute in New Jersey discusses the management of newly diagnosed and advanced Hodgkin lymphoma in younger and older patients.\n\nCME information and select publications here.","content_html":"Dr Andrew Evens from the Rutgers Cancer Institute in New Jersey discusses the management of newly diagnosed and advanced Hodgkin lymphoma in younger and older patients.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the management of Hodgkin lymphoma in younger and older patients with Dr Andrew Evens, moderated by Dr Neil Love.","date_published":"2021-12-09T12:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/b02c85e1-a44f-45ac-9e06-ef94639a3621.mp3","mime_type":"audio/mpeg","size_in_bytes":36030972,"duration_in_seconds":2245}]},{"id":"256d0833-4a89-4dc3-b8c1-1b21fa0a753f","title":"Advances in Endometrial Cancer with Dr Matthew Powell","url":"https://oncologytoday.researchtopractice.com/97","content_text":"Dr Matthew Powell from the Washington University School of Medicine in St Louis, Missouri, discusses therapeutic advances and novel investigational strategies for the management of endometrial cancer.\n\nCME information and select publications here.","content_html":"Dr Matthew Powell from the Washington University School of Medicine in St Louis, Missouri, discusses therapeutic advances and novel investigational strategies for the management of endometrial cancer.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent advances in the therapeutic landscape of endometrial cancer with Dr Matthew Powell, moderated by Dr Neil Love. ","date_published":"2021-12-08T11:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/256d0833-4a89-4dc3-b8c1-1b21fa0a753f.mp3","mime_type":"audio/mpeg","size_in_bytes":34535963,"duration_in_seconds":2155}]},{"id":"685acfdf-453f-4839-aaa6-7bd55fca1ce9","title":"Chronic Lymphocytic Leukemia with Professor Dr Arnon Kater","url":"https://oncologytoday.researchtopractice.com/94","content_text":"Dr Arnon Kater from the Amsterdam University Medical Centers in Amsterdam discusses recent advances in the management of chronic lymphocytic leukemia.\n\nCME information and select publications here.","content_html":"Dr Arnon Kater from the Amsterdam University Medical Centers in Amsterdam discusses recent advances in the management of chronic lymphocytic leukemia.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the management of chronic lymphocytic leukemia with Dr Arnon Kater, moderated by Dr Neil Love.","date_published":"2021-11-22T10:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/685acfdf-453f-4839-aaa6-7bd55fca1ce9.mp3","mime_type":"audio/mpeg","size_in_bytes":36669399,"duration_in_seconds":2285}]},{"id":"353abbfe-3657-44d5-ba97-b83d2bfd1a41","title":"Myelodysplastic Syndromes with Dr Michael Savona ","url":"https://oncologytoday.researchtopractice.com/93","content_text":"Dr Michael Savona from Vanderbilt University School of Medicine in Nashville, Tennessee, discusses recent advances and future directions in the management of myelodysplastic syndromes.\n\nCME information and select publications here.","content_html":"Dr Michael Savona from Vanderbilt University School of Medicine in Nashville, Tennessee, discusses recent advances and future directions in the management of myelodysplastic syndromes.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the management of myelodysplastic syndromes with Dr Michael Savona, moderated by Dr Neil Love.","date_published":"2021-11-15T14:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/353abbfe-3657-44d5-ba97-b83d2bfd1a41.mp3","mime_type":"audio/mpeg","size_in_bytes":38603445,"duration_in_seconds":2406}]},{"id":"1fd62c99-4794-4f3c-9f7b-d3bd0b6e0ebd","title":"CAR T-Cell Therapy in Non-Hodgkin Lymphoma with Dr Jonathon Cohen","url":"https://oncologytoday.researchtopractice.com/92","content_text":"Dr Jonathon Cohen from the Winship Cancer Institute of Emory University in Atlanta discusses recent advances and future directions in the use of CAR T-cell therapy for the management of non-Hodgkin lymphoma.\n\nCME information and select publications here.","content_html":"Dr Jonathon Cohen from the Winship Cancer Institute of Emory University in Atlanta discusses recent advances and future directions in the use of CAR T-cell therapy for the management of non-Hodgkin lymphoma.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the advances in CAR T-cell therapy for non-Hodgkin lymphoma with Dr Jonathon Cohen, moderated by Dr Neil Love.","date_published":"2021-11-08T09:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/1fd62c99-4794-4f3c-9f7b-d3bd0b6e0ebd.mp3","mime_type":"audio/mpeg","size_in_bytes":38784423,"duration_in_seconds":2417}]},{"id":"1b57bc41-590d-4891-89e2-ddac0cb4bcba","title":"Head and Neck Cancer with Dr Cristina Rodriguez","url":"https://oncologytoday.researchtopractice.com/91","content_text":"Dr Cristina Rodriguez from the Fred Hutchinson Cancer Research Center in Seattle discusses the current management of head and neck cancers.\n\nCME information and select publications here.","content_html":"Dr Cristina Rodriguez from the Fred Hutchinson Cancer Research Center in Seattle discusses the current management of head and neck cancers.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the management of head and neck cancers with Dr Cristina Rodriguez, moderated by Dr Neil Love. ","date_published":"2021-11-05T12:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/1b57bc41-590d-4891-89e2-ddac0cb4bcba.mp3","mime_type":"audio/mpeg","size_in_bytes":37388376,"duration_in_seconds":2334}]},{"id":"96229ef7-cfc2-4e4c-a87f-81f415e0d430","title":"Myeloproliferative Neoplasms with Dr Ruben Mesa","url":"https://oncologytoday.researchtopractice.com/90","content_text":"Dr Ruben Mesa from the Mays Cancer Center in San Antonio, Texas, discusses the pathogenesis and management of myeloproliferative neoplasms.\n\nCME information and select publications here.","content_html":"Dr Ruben Mesa from the Mays Cancer Center in San Antonio, Texas, discusses the pathogenesis and management of myeloproliferative neoplasms.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the management of myeloproliferative neoplasms with Dr Ruben Mesa, moderated by Dr Neil Love. ","date_published":"2021-11-01T10:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/96229ef7-cfc2-4e4c-a87f-81f415e0d430.mp3","mime_type":"audio/mpeg","size_in_bytes":42127929,"duration_in_seconds":2626}]},{"id":"307216b4-16db-4714-a87b-08143789bb49","title":"Chronic Myeloid Leukemia with Dr Michael Mauro","url":"https://oncologytoday.researchtopractice.com/89","content_text":"Dr Michael Mauro from the Memorial Sloan Kettering Cancer Center in New York City, New York, discusses the management of chronic myeloid leukemia. \n\nCME information and select publications here.","content_html":"Dr Michael Mauro from the Memorial Sloan Kettering Cancer Center in New York City, New York, discusses the management of chronic myeloid leukemia.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the management of chronic myeloid leukemia with Dr Michael Mauro, moderated by Dr Neil Love. ","date_published":"2021-10-26T15:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/307216b4-16db-4714-a87b-08143789bb49.mp3","mime_type":"audio/mpeg","size_in_bytes":37265830,"duration_in_seconds":2322}]},{"id":"d3ad7cb7-64a5-4a69-adc3-a71062a8f214","title":"Renal Cell Carcinoma with Dr Sumanta Pal","url":"https://oncologytoday.researchtopractice.com/88","content_text":"Dr Sumanta Pal from the City of Hope Comprehensive Cancer Center in Duarte, California discusses the management of advanced renal cell carcinoma.\n\nCME information and select publications here.","content_html":"Dr Sumanta Pal from the City of Hope Comprehensive Cancer Center in Duarte, California discusses the management of advanced renal cell carcinoma.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the management of advanced renal cell carcinoma with Dr Sumanta Pal, moderated by Dr Neil Love. ","date_published":"2021-10-08T10:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/d3ad7cb7-64a5-4a69-adc3-a71062a8f214.mp3","mime_type":"audio/mpeg","size_in_bytes":40987268,"duration_in_seconds":2559}]},{"id":"aa7f0e8d-116e-4e68-8bed-2145814134fe","title":"Thyroid Cancer with Dr Marcia Brose","url":"https://oncologytoday.researchtopractice.com/87","content_text":"Dr Marcia Brose from the Sidney Kimmel Cancer Center in Philadelphia discusses the latest clinical data on targeted therapeutic approaches for the management of advanced thyroid cancer. \n\nCME information and select publications here.","content_html":"Dr Marcia Brose from the Sidney Kimmel Cancer Center in Philadelphia discusses the latest clinical data on targeted therapeutic approaches for the management of advanced thyroid cancer.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on new targeted approaches for advanced thyroid cancer with Dr Marcia Brose, moderated by Dr Neil Love. ","date_published":"2021-10-04T13:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/aa7f0e8d-116e-4e68-8bed-2145814134fe.mp3","mime_type":"audio/mpeg","size_in_bytes":42126330,"duration_in_seconds":2630}]},{"id":"b6e782aa-0b18-401d-93ef-3668226c0856","title":"Gastroesophageal Cancers with Dr Samuel Klempner","url":"https://oncologytoday.researchtopractice.com/86","content_text":"Dr Samuel Klempner from Massachusetts General Hospital in Boston, Massachusetts discusses recent updates on immunotherapy and targeted therapy for gastroesophageal cancers. \n\nCME information and select publications here.","content_html":"Dr Samuel Klempner from Massachusetts General Hospital in Boston, Massachusetts discusses recent updates on immunotherapy and targeted therapy for gastroesophageal cancers.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent advances in the therapeutic landscape of upper gastrointestinal tumors with Dr Samuel Klempner, moderated by Dr Neil Love. ","date_published":"2021-09-23T11:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/b6e782aa-0b18-401d-93ef-3668226c0856.mp3","mime_type":"audio/mpeg","size_in_bytes":65991865,"duration_in_seconds":4122}]},{"id":"303cd35f-1fb4-4f1b-b545-4f996af08937","title":"Management of HER2-Low Breast Cancer with Dr Ian Krop","url":"https://oncologytoday.researchtopractice.com/85","content_text":"Dr Ian Krop from the Dana-Farber Cancer Institute in Boston discusses recently published and emerging research on the treatment of HER2-low breast cancer.\n\nCME information and select publications here.","content_html":"Dr Ian Krop from the Dana-Farber Cancer Institute in Boston discusses recently published and emerging research on the treatment of HER2-low breast cancer.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent data on the treatment of HER2-low breast cancer with Dr Ian Krop, moderated by Dr Neil Love.","date_published":"2021-09-23T09:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/303cd35f-1fb4-4f1b-b545-4f996af08937.mp3","mime_type":"audio/mpeg","size_in_bytes":41690587,"duration_in_seconds":2600}]},{"id":"02f78a4d-e865-488f-8dc1-3719ed6016b5","title":"Key Presentations on Gynecologic Cancers from the 2021 ASCO Annual Meeting with Dr Kathleen Moore","url":"https://oncologytoday.researchtopractice.com/84","content_text":"Dr Kathleen Moore from the University of Oklahoma Health Sciences Center in Oklahoma City, Oklahoma, discusses key presentations on gynecologic cancers from the 2021 ASCO Annual Meeting.\n\nCME information and select publications here.","content_html":"Dr Kathleen Moore from the University of Oklahoma Health Sciences Center in Oklahoma City, Oklahoma, discusses key presentations on gynecologic cancers from the 2021 ASCO Annual Meeting.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on important datasets on gynecologic cancers from the 2021 ASCO Annual Meeting with Dr Kathleen Moore, moderated by Dr Neil Love. ","date_published":"2021-09-02T13:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/02f78a4d-e865-488f-8dc1-3719ed6016b5.mp3","mime_type":"audio/mpeg","size_in_bytes":45907971,"duration_in_seconds":2865}]},{"id":"8a7d9814-33c6-42fe-b834-e3b3ae7a27e2","title":"Thyroid Cancer with Dr Lori Wirth","url":"https://oncologytoday.researchtopractice.com/83","content_text":"Dr Lori Wirth from the Massachusetts General Hospital in Boston discusses the latest clinical data and ongoing investigations on targeted therapeutic approaches for the management of RET-altered and NTRK fusion-positive thyroid cancers.\n\nCME information and select publications here.","content_html":"Dr Lori Wirth from the Massachusetts General Hospital in Boston discusses the latest clinical data and ongoing investigations on targeted therapeutic approaches for the management of RET-altered and NTRK fusion-positive thyroid cancers.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on targeted approaches for RET-driven and NTRK fusion-positive thyroid cancers with Dr Lori Wirth, moderated by Dr Neil Love. ","date_published":"2021-08-19T14:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/8a7d9814-33c6-42fe-b834-e3b3ae7a27e2.mp3","mime_type":"audio/mpeg","size_in_bytes":49426749,"duration_in_seconds":3086}]},{"id":"cae56925-6a8d-401c-be6b-120aaf61b57b","title":"Key Presentations on Lung Cancer from the 2021 ASCO Annual Meeting with Dr Joel Neal","url":"https://oncologytoday.researchtopractice.com/82","content_text":"Dr Joel Neal from Stanford University in Stanford, California, discusses key presentations on lung cancer from the 2021 ASCO Annual Meeting. \n\nCME information and select publications here.","content_html":"Dr Joel Neal from Stanford University in Stanford, California, discusses key presentations on lung cancer from the 2021 ASCO Annual Meeting.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on important datasets on lung cancer from the 2021 ASCO Annual Meeting with Dr Joel Neal, moderated by Dr Neil Love. ","date_published":"2021-08-10T18:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/cae56925-6a8d-401c-be6b-120aaf61b57b.mp3","mime_type":"audio/mpeg","size_in_bytes":54031643,"duration_in_seconds":3374}]},{"id":"c19d761c-824c-4bd7-8607-8c48da7d85ed","title":"CAR T-Cell Therapy in Multiple Myeloma with Dr Jesús Berdeja","url":"https://oncologytoday.researchtopractice.com/81","content_text":"Dr Jesús Berdeja from the Sarah Cannon Research Institute in Nashville, Tennessee, discusses recent advances and future directions in the use of CAR T-cell therapy for the management of multiple myeloma.\n\nCME information and select publications here.","content_html":"Dr Jesús Berdeja from the Sarah Cannon Research Institute in Nashville, Tennessee, discusses recent advances and future directions in the use of CAR T-cell therapy for the management of multiple myeloma.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on advances in anti-BCMA CAR T-cell therapy in patients with multiple myeloma with Dr Jesús Berdeja, moderated by Dr Neil Love.","date_published":"2021-08-05T09:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/c19d761c-824c-4bd7-8607-8c48da7d85ed.mp3","mime_type":"audio/mpeg","size_in_bytes":46696164,"duration_in_seconds":2911}]},{"id":"3a9372eb-d077-4a9d-b46f-835d20bf34f9","title":"Key Presentations on Gastrointestinal Cancers from the 2021 ASCO Annual Meeting with Dr Kristen Ciombor","url":"https://oncologytoday.researchtopractice.com/80","content_text":"Dr Kristen Ciombor from the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, discusses key presentations on gastrointestinal cancers from the 2021 ASCO Annual Meeting. \n\nCME information and select publications here.","content_html":"Dr Kristen Ciombor from the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, discusses key presentations on gastrointestinal cancers from the 2021 ASCO Annual Meeting.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on important datasets on gastrointestinal cancers from the 2021 ASCO Annual Meeting with Dr Kristen Ciombor, moderated by Dr Neil Love.","date_published":"2021-07-30T10:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/3a9372eb-d077-4a9d-b46f-835d20bf34f9.mp3","mime_type":"audio/mpeg","size_in_bytes":53549755,"duration_in_seconds":2675}]},{"id":"7261f7fe-568b-4096-b15c-f5b6b09d6e6b","title":"Key Presentations on Breast Cancer from the 2021 ASCO Annual Meeting with Dr Sara Tolaney ","url":"https://oncologytoday.researchtopractice.com/79","content_text":"Dr Sara Tolaney from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses key presentations on breast cancer from the 2021 ASCO Annual meeting. \n\nCME information and select publications here.","content_html":"Dr Sara Tolaney from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses key presentations on breast cancer from the 2021 ASCO Annual meeting.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on important data sets on breast cancer from the 2021 ASCO Annual meeting with Dr Sara Tolaney, moderated by Dr Neil Love. ","date_published":"2021-07-23T09:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/7261f7fe-568b-4096-b15c-f5b6b09d6e6b.mp3","mime_type":"audio/mpeg","size_in_bytes":54096510,"duration_in_seconds":3376}]},{"id":"3d4981f5-1266-42c8-86d0-e0c1fa15c59b","title":"Gastroesophageal Cancers with Dr Jaffer Ajani","url":"https://oncologytoday.researchtopractice.com/78","content_text":"Dr Jaffer Ajani from MD Anderson Cancer Center in Houston, Texas discusses the latest clinical data on immune checkpoint inhibitors and other novel agents in the management of gastroesophageal cancers. \n\nCME information and select publications here.","content_html":"Dr Jaffer Ajani from MD Anderson Cancer Center in Houston, Texas discusses the latest clinical data on immune checkpoint inhibitors and other novel agents in the management of gastroesophageal cancers.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent advances in the therapeutic landscape of upper gastrointestinal tumors with Dr Jaffer Ajani, moderated by Dr Neil Love.","date_published":"2021-07-22T14:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/3d4981f5-1266-42c8-86d0-e0c1fa15c59b.mp3","mime_type":"audio/mpeg","size_in_bytes":39752594,"duration_in_seconds":2482}]},{"id":"74327870-c04b-4e4d-b88d-9f3a1dd2c1f6","title":"Key Presentations on Genitourinary Cancers from the 2021 ASCO Annual Meeting with Dr Arjun Balar","url":"https://oncologytoday.researchtopractice.com/77","content_text":"Dr Arjun Balar from the NYU Perlmutter Cancer Center in New York discusses key presentations on genitourinary cancers from the 2021 ASCO Annual Meeting. \n\nCME information and select publications here.","content_html":"Dr Arjun Balar from the NYU Perlmutter Cancer Center in New York discusses key presentations on genitourinary cancers from the 2021 ASCO Annual Meeting.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on important data sets on genitourinary cancers from the 2021 ASCO Annual Meeting with Dr Arjun Balar, moderated by Dr Neil Love.","date_published":"2021-07-15T12:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/74327870-c04b-4e4d-b88d-9f3a1dd2c1f6.mp3","mime_type":"audio/mpeg","size_in_bytes":61779877,"duration_in_seconds":3087}]},{"id":"87689f1d-6ee2-479b-a888-52e8c92c5e4f","title":"Progress in Myelodysplastic Syndromes with Dr Guillermo Garcia-Manero","url":"https://oncologytoday.researchtopractice.com/76","content_text":"Dr Guillermo Garcia-Manero from the MD Anderson Cancer Center discusses clinical data with new and emerging approaches for the management of myelodysplastic syndromes.\n\nCME information and select publications here.","content_html":"Dr Guillermo Garcia-Manero from the MD Anderson Cancer Center discusses clinical data with new and emerging approaches for the management of myelodysplastic syndromes.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent advances in the management of myelodysplastic syndromes with Dr Guillermo Garcia-Manero, moderated by Dr Neil Love.","date_published":"2021-07-13T10:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/87689f1d-6ee2-479b-a888-52e8c92c5e4f.mp3","mime_type":"audio/mpeg","size_in_bytes":53923539,"duration_in_seconds":2690}]},{"id":"5e8b3add-6a2d-4841-b877-24432857fcc0","title":"HER2-Positive Localized Breast Cancer with Dr Adam Brufsky","url":"https://oncologytoday.researchtopractice.com/75","content_text":"Dr Adam Brufsky from the University of Pittsburgh discusses the latest clinical data on HER2-targeted therapy for the management of HER2-positive localized breast cancer.\n\nCME information and select publications here.","content_html":"Dr Adam Brufsky from the University of Pittsburgh discusses the latest clinical data on HER2-targeted therapy for the management of HER2-positive localized breast cancer.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on personalized targeted approaches for the management of HER2-positive localized breast cancer with Dr Adam Brufsky, moderated by Dr Neil Love. ","date_published":"2021-05-11T10:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/5e8b3add-6a2d-4841-b877-24432857fcc0.mp3","mime_type":"audio/mpeg","size_in_bytes":42027948,"duration_in_seconds":2621}]},{"id":"6a255eda-5ca9-4e10-a809-d69964370dbc","title":"Genomic Assays in Early Breast Cancer","url":"https://oncologytoday.researchtopractice.com/74","content_text":"Dr Kevin Kalinsky from Emory University in Atlanta discusses the role of genomic assays in treatment decision-making for patients with hormone receptor-positive, HER2-negative, early-stage breast cancer.\n\nCME information and select publications here.","content_html":"Dr Kevin Kalinsky from Emory University in Atlanta discusses the role of genomic assays in treatment decision-making for patients with hormone receptor-positive, HER2-negative, early-stage breast cancer.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent data on the use of genomic assays in early breast cancer with Dr Kevin Kalinsky, moderated by Dr Neil Love.","date_published":"2021-05-06T08:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/6a255eda-5ca9-4e10-a809-d69964370dbc.mp3","mime_type":"audio/mpeg","size_in_bytes":80315766,"duration_in_seconds":4011}]},{"id":"9f9d73cb-1e76-4ad3-aa62-4a99f09aa7b0","title":"Advances in the Management of Amyloid Light Chain Amyloidosis with Dr Morie Gertz","url":"https://oncologytoday.researchtopractice.com/73","content_text":"Dr Morie Gertz from the Mayo Clinic in Rochester, Minnesota, discusses the diagnosis and management of amyloid light chain amyloidosis.\n\nCME information and select publications here.","content_html":"Dr Morie Gertz from the Mayo Clinic in Rochester, Minnesota, discusses the diagnosis and management of amyloid light chain amyloidosis.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent advances in the treatment of amyloid light chain amyloidosis with Dr Morie Gertz, moderated by Dr Neil Love.","date_published":"2021-04-30T09:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/9f9d73cb-1e76-4ad3-aa62-4a99f09aa7b0.mp3","mime_type":"audio/mpeg","size_in_bytes":54895217,"duration_in_seconds":3424}]},{"id":"4c7f3009-2e7b-41ef-a709-30a8788f403d","title":"Advances in the Management of Cholangiocarcinoma with Dr Mitesh Borad","url":"https://oncologytoday.researchtopractice.com/72","content_text":"Mitesh Borad from the Mayo Clinic Comprehensive Cancer Center in Scottsdale, Arizona, discusses the biology of cholangiocarcinoma and clinical data with new and emerging targeted approaches for patients with this disease.\n\nCME information and select publications here.","content_html":"Mitesh Borad from the Mayo Clinic Comprehensive Cancer Center in Scottsdale, Arizona, discusses the biology of cholangiocarcinoma and clinical data with new and emerging targeted approaches for patients with this disease.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on novel targeted approaches in the management of cholangiocarcinoma with Dr Mitesh Borad, moderated by Dr Neil Love.","date_published":"2021-04-29T10:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/4c7f3009-2e7b-41ef-a709-30a8788f403d.mp3","mime_type":"audio/mpeg","size_in_bytes":38540718,"duration_in_seconds":2406}]},{"id":"c458dd90-72fc-440e-bc2f-55ba54816038","title":"Management of Localized Non-Small Cell Lung Cancer with EGFR Tumor Mutations with Dr Roy Herbst","url":"https://oncologytoday.researchtopractice.com/70","content_text":"Dr Roy Herbst from the Yale Cancer Center discusses the clinical data on and optimal use of adjuvant osimertinib for patients with resected non-small cell lung cancer and an EGFR mutation.\n\nCME information and select publications here.","content_html":"Dr Roy Herbst from the Yale Cancer Center discusses the clinical data on and optimal use of adjuvant osimertinib for patients with resected non-small cell lung cancer and an EGFR mutation.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the latest advances in adjuvant therapy for early-stage non-small cell lung cancer with EGFR tumor mutations with Dr Roy Herbst, moderated by Dr Neil Love. ","date_published":"2021-04-12T12:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/c458dd90-72fc-440e-bc2f-55ba54816038.mp3","mime_type":"audio/mpeg","size_in_bytes":37501763,"duration_in_seconds":2341}]},{"id":"0d5e37ac-debd-46cf-aa3f-aeb620b5a792","title":"Key Presentations on Non-Hodgkin and Hodgkin Lymphomas from the 2020 ASH Annual Meeting with Dr Laurie Sehn","url":"https://oncologytoday.researchtopractice.com/69","content_text":"Dr Laurie Sehn from the BC Cancer Center for Lymphoid Cancer in Vancouver, Canada, discusses the latest clinical research findings on non-Hodgkin and Hodgkin lymphomas from the 2020 ASH Annual Meeting.\n\nCME information and select publications here.","content_html":"Dr Laurie Sehn from the BC Cancer Center for Lymphoid Cancer in Vancouver, Canada, discusses the latest clinical research findings on non-Hodgkin and Hodgkin lymphomas from the 2020 ASH Annual Meeting.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on selected data sets in non-Hodgkin and Hodgkin lymphomas from the 2020 ASH Annual Meeting with Dr Laurie Sehn, moderated by Dr Neil Love.","date_published":"2021-04-07T09:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/0d5e37ac-debd-46cf-aa3f-aeb620b5a792.mp3","mime_type":"audio/mpeg","size_in_bytes":60161939,"duration_in_seconds":3753}]},{"id":"17c8280b-7fef-4942-83d9-70b3bf72b1fc","title":"Key Presentations on Multiple Myeloma, Waldenström Macroglobulinemia and Amyloidosis from the 2020 ASH Annual Meeting with Dr Natalie Callander","url":"https://oncologytoday.researchtopractice.com/68","content_text":"Dr Natalie Callander from the University of Wisconsin Carbone Cancer Center discusses key presentations on multiple myeloma, Waldenström macroglobulinemia and amyloidosis from the 2020 ASH Annual Meeting.\n\nCME information and select publications here.","content_html":"Dr Natalie Callander from the University of Wisconsin Carbone Cancer Center discusses key presentations on multiple myeloma, Waldenström macroglobulinemia and amyloidosis from the 2020 ASH Annual Meeting.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on important data sets on multiple myeloma, Waldenström macroglobulinemia and amyloidosis from the 2020 ASH Annual Meeting with Dr Natalie Callander, moderated by Dr Neil Love.","date_published":"2021-04-02T12:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/17c8280b-7fef-4942-83d9-70b3bf72b1fc.mp3","mime_type":"audio/mpeg","size_in_bytes":61250298,"duration_in_seconds":3821}]},{"id":"0ebe0626-c791-48a1-9185-74599f1704df","title":"Side Effects of Hormonal Therapy in Prostate Cancer with Dr Roberto Iacovelli","url":"https://oncologytoday.researchtopractice.com/67","content_text":"Dr Roberto Iacovelli from the Fondazione Policlinico Universitario A Gemelli in Rome discusses the spectrum and management of side effects with hormonal therapies in prostate cancer.\n\nCME information and select publications here.","content_html":"Dr Roberto Iacovelli from the Fondazione Policlinico Universitario A Gemelli in Rome discusses the spectrum and management of side effects with hormonal therapies in prostate cancer.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on hormonal therapies and the associated side effects in prostate cancer with Dr Roberto Iacovelli, moderated by Dr Neil Love.","date_published":"2021-03-29T10:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/0ebe0626-c791-48a1-9185-74599f1704df.mp3","mime_type":"audio/mpeg","size_in_bytes":45741068,"duration_in_seconds":2856}]},{"id":"652a4017-5053-42a8-b98a-d69be465ba21","title":"Key Presentations on Acute Myeloid Leukemia and Myelodysplastic Syndromes from the 2020 ASH Annual Meeting with Dr Harry Erba","url":"https://oncologytoday.researchtopractice.com/66","content_text":"Dr Harry Erba from Duke University in Durham, North Carolina, discusses key presentations on acute myeloid leukemia and myelodysplastic syndromes from the 2020 AS Annual Meeting.\n\nCME information and select publications here.","content_html":"Dr Harry Erba from Duke University in Durham, North Carolina, discusses key presentations on acute myeloid leukemia and myelodysplastic syndromes from the 2020 AS Annual Meeting.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on important data sets on acute myeloid leukemia and myelodysplastic syndromes from the 2020 ASH Annual Meeting with Dr Harry Erba, moderated by Dr Neil Love.","date_published":"2021-03-26T11:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/652a4017-5053-42a8-b98a-d69be465ba21.mp3","mime_type":"audio/mpeg","size_in_bytes":63661809,"duration_in_seconds":3972}]},{"id":"d0fb49c0-0d46-42b3-8afb-dd5ba75a653a","title":"Management of CNS Metastases in Patients with Non-Small Cell Lung Cancer with Dr Manmeet Ahluwalia","url":"https://oncologytoday.researchtopractice.com/65","content_text":"Dr Manmeet Ahluwalia from the Miami Cancer Institute of Baptist Health South Florida discusses recently published and emerging research on the management of CNS metastases in patients with non-small cell lung cancer.\n\nCME information and select publications here.","content_html":"Dr Manmeet Ahluwalia from the Miami Cancer Institute of Baptist Health South Florida discusses recently published and emerging research on the management of CNS metastases in patients with non-small cell lung cancer.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent data on the treatment of CNS metastases in patients with non-small cell lung cancer with Dr Manmeet Ahluwalia, moderated by Dr Neil Love.","date_published":"2021-03-23T13:30:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/d0fb49c0-0d46-42b3-8afb-dd5ba75a653a.mp3","mime_type":"audio/mpeg","size_in_bytes":62342870,"duration_in_seconds":3894}]},{"id":"347b0db0-3067-4cf9-84ae-34384c85b1e2","title":"Novel and Emerging Strategies for Diffuse Large B-Cell Lymphoma with Dr Gilles Salles","url":"https://oncologytoday.researchtopractice.com/64","content_text":"Dr Gilles Salles from Memorial Sloan Kettering Cancer Center in New York discusses recently published and emerging research on the treatment of diffuse large B-cell lymphoma.\n\nCME information and select publications here.","content_html":"Dr Gilles Salles from Memorial Sloan Kettering Cancer Center in New York discusses recently published and emerging research on the treatment of diffuse large B-cell lymphoma.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent data on the treatment of diffuse large B-cell lymphoma with Dr Gilles Salles, moderated by Dr Neil Love.","date_published":"2021-03-22T14:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/347b0db0-3067-4cf9-84ae-34384c85b1e2.mp3","mime_type":"audio/mpeg","size_in_bytes":87114114,"duration_in_seconds":4350}]},{"id":"12494e73-b732-4e46-abd7-f6bc43571c78","title":"Management of Acute Myeloid Leukemia Not Eligible for Intensive Induction Therapy with Dr Andrew Wei","url":"https://oncologytoday.researchtopractice.com/63","content_text":"Dr Andrew Wei from the Alfred Hospital and Monash University in Melbourne, Australia, discusses recently published and emerging research on the treatment of acute myeloid leukemia not eligible for intensive induction therapy.\n\nCME information and select publications here.","content_html":"Dr Andrew Wei from the Alfred Hospital and Monash University in Melbourne, Australia, discusses recently published and emerging research on the treatment of acute myeloid leukemia not eligible for intensive induction therapy.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent data on the treatment of acute myeloid leukemia not eligible for intensive induction therapy with Dr Andrew Wei, moderated by Dr Neil Love.","date_published":"2021-03-19T10:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/12494e73-b732-4e46-abd7-f6bc43571c78.mp3","mime_type":"audio/mpeg","size_in_bytes":65214764,"duration_in_seconds":3255}]},{"id":"b6402f2d-278c-4102-90d6-2a678e9fe56b","title":"PARP Inhibitors in Ovarian Cancer with Dr Antonio González-Martín","url":"https://oncologytoday.researchtopractice.com/62","content_text":"Dr Antonio González-Martín from the Clínica Universidad de Navarra in Madrid discusses the latest clinical data on and optimal integration of PARP inhibitors in ovarian cancer.\n\nCME information and select publications here.","content_html":"Dr Antonio González-Martín from the Clínica Universidad de Navarra in Madrid discusses the latest clinical data on and optimal integration of PARP inhibitors in ovarian cancer.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the use of PARP inhibitors in ovarian cancer with Dr Antonio González-Martín, moderated by Dr Neil Love. ","date_published":"2021-03-12T12:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/b6402f2d-278c-4102-90d6-2a678e9fe56b.mp3","mime_type":"audio/mpeg","size_in_bytes":42959781,"duration_in_seconds":2681}]},{"id":"fc3234e9-5d0b-47ab-ba48-97411e2fd6f6","title":"Predictors of Response to Cancer Immunotherapy with Prof Solange Peters","url":"https://oncologytoday.researchtopractice.com/61","content_text":"Professor Solange Peters from Lausanne University Hospital in Switzerland discusses existing and emerging biomarkers of response to cancer immunotherapy.\n\nCME information and select publications here.","content_html":"Professor Solange Peters from Lausanne University Hospital in Switzerland discusses existing and emerging biomarkers of response to cancer immunotherapy.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on predictors of response to cancer immunotherapy with Prof Solange Peters, moderated by Dr Neil Love.","date_published":"2021-03-12T10:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/fc3234e9-5d0b-47ab-ba48-97411e2fd6f6.mp3","mime_type":"audio/mpeg","size_in_bytes":86213205,"duration_in_seconds":4308}]},{"id":"4d5cb25c-990e-4634-8337-3cdeb9fe6794","title":"Recently Approved Agents in Multiple Myeloma with Dr Joseph Mikhael","url":"https://oncologytoday.researchtopractice.com/60","content_text":"Dr Joseph Mikhael from the Translational Genomics Research Institute in Phoenix, Arizona, discusses agents that have been recently approved for the treatment of multiple myeloma.\n\nCME information and select publications here.","content_html":"Dr Joseph Mikhael from the Translational Genomics Research Institute in Phoenix, Arizona, discusses agents that have been recently approved for the treatment of multiple myeloma.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on newly approved agents in multiple myeloma with Dr Joseph Mikhael, moderated by Dr Neil Love. ","date_published":"2021-03-10T12:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/4d5cb25c-990e-4634-8337-3cdeb9fe6794.mp3","mime_type":"audio/mpeg","size_in_bytes":44149962,"duration_in_seconds":2752}]},{"id":"5024f662-0705-4d6d-be3c-b29847afe971","title":"Current and Emerging Strategies for Patients with Non-Small Cell Lung Cancer Harboring an EGFR Exon 20 Insertion Mutation with Dr Zofia Piotrowska","url":"https://oncologytoday.researchtopractice.com/59","content_text":"Dr Zofia Piotrowska from the Massachusetts General Hospital in Boston discusses emerging strategies for patients with non-small cell lung cancer and EGFR exon 20 insertion mutations.\n\nCME information and select publications here.","content_html":"Dr Zofia Piotrowska from the Massachusetts General Hospital in Boston discusses emerging strategies for patients with non-small cell lung cancer and EGFR exon 20 insertion mutations.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on new targets in non-small cell lung cancer with Dr Zofia Piotrowska, moderated by Dr Neil Love.","date_published":"2021-03-08T11:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/5024f662-0705-4d6d-be3c-b29847afe971.mp3","mime_type":"audio/mpeg","size_in_bytes":78633037,"duration_in_seconds":3929}]},{"id":"38f4c5d0-1d7e-42f6-8be6-dd9d1c3477f2","title":"Newly Approved Agents in HER2-Positive Metastatic Breast Cancer with Dr Mark Pegram","url":"https://oncologytoday.researchtopractice.com/58","content_text":"Dr Mark Pegram from the Stanford University School of Medicine discusses the latest clinical data on and optimal use of newly approved therapies for HER2-positive metastatic breast cancer.\n\nCME information and select publications here.","content_html":"Dr Mark Pegram from the Stanford University School of Medicine discusses the latest clinical data on and optimal use of newly approved therapies for HER2-positive metastatic breast cancer.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on newly approved and emerging therapies for HER2-positive metastatic breast cancer with Dr Mark Pegram, moderated by Dr Neil Love.","date_published":"2021-03-03T13:30:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/38f4c5d0-1d7e-42f6-8be6-dd9d1c3477f2.mp3","mime_type":"audio/mpeg","size_in_bytes":62560231,"duration_in_seconds":3905}]},{"id":"f01b99db-c288-4a84-9564-d940dc5b6cda","title":"Current Role of Minimal Residual Disease Assessment in the Management of Multiple Myeloma and Chronic Lymphocytic Leukemia with Drs Shaji Kumar and Philip Thompson","url":"https://oncologytoday.researchtopractice.com/57","content_text":"Dr Shaji Kumar from the Mayo Clinic in Rochester, Minnesota, and Dr Philip Thompson from the University of Texas MD Anderson Cancer Center discuss the role of minimal residual disease assessment in the management of multiple myeloma and chronic lymphocytic leukemia.\n\nCME information and select publications here.","content_html":"Dr Shaji Kumar from the Mayo Clinic in Rochester, Minnesota, and Dr Philip Thompson from the University of Texas MD Anderson Cancer Center discuss the role of minimal residual disease assessment in the management of multiple myeloma and chronic lymphocytic leukemia.
\n\nCME information and select publications here.
","summary":"Featuring discussions on the role of minimal residual disease evaluation in the management of multiple myeloma and chronic lymphocytic leukemia with Drs Shaji Kumar and Philip Thompson, moderated by Dr Neil Love.","date_published":"2021-03-01T14:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/f01b99db-c288-4a84-9564-d940dc5b6cda.mp3","mime_type":"audio/mpeg","size_in_bytes":74053866,"duration_in_seconds":4621}]},{"id":"16a1cedf-3459-469f-b0f9-6f09e9876057","title":"New Targets in Non-Small Cell Lung Cancer with Dr Justin Gainor","url":"https://oncologytoday.researchtopractice.com/56","content_text":"Dr Justin Gainor from the Massachusetts General Hospital in Boston discusses emerging targets in non-small cell lung cancer.\n\nCME and select publications here.","content_html":"Dr Justin Gainor from the Massachusetts General Hospital in Boston discusses emerging targets in non-small cell lung cancer.
\n\nCME and select publications here.
","summary":"Featuring a discussion on new targets in non-small cell lung cancer with Dr Justin Gainor, moderated by Dr Neil Love.","date_published":"2021-02-26T12:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/16a1cedf-3459-469f-b0f9-6f09e9876057.mp3","mime_type":"audio/mpeg","size_in_bytes":55010801,"duration_in_seconds":2748}]},{"id":"a37aae62-9e83-457a-9330-7cd556590bff","title":"ER-Positive Metastatic Breast Cancer with Dr Erika Hamilton","url":"https://oncologytoday.researchtopractice.com/55","content_text":"Dr Erika Hamilton from the Sarah Cannon Research Institute in Nashville discusses the latest clinical data on and optimal management of ER-positive metastatic breast cancer.\n\nCME and select publications here.","content_html":"Dr Erika Hamilton from the Sarah Cannon Research Institute in Nashville discusses the latest clinical data on and optimal management of ER-positive metastatic breast cancer.
\n\nCME and select publications here.
","summary":"Featuring a discussion on the selection and sequencing of available and emerging therapies for ER-positive metastatic breast cancer with Dr Erika Hamilton, moderated by Dr Neil Love.","date_published":"2021-02-24T13:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/a37aae62-9e83-457a-9330-7cd556590bff.mp3","mime_type":"audio/mpeg","size_in_bytes":41502982,"duration_in_seconds":2589}]},{"id":"b5e20786-9346-47bf-b36d-49ea7fb07f89","title":"Key Presentations on Chronic Lymphocytic Leukemia and Follicular Lymphoma from the 2020 ASH Annual Meeting with Dr Ann LaCasce","url":"https://oncologytoday.researchtopractice.com/53","content_text":"Dr Ann LaCasce from the Dana-Farber Cancer Institute discusses key presentations on chronic lymphocytic leukemia and follicular lymphoma from the 2020 ASH Annual Meeting.\n\nCME information and select publications here.","content_html":"Dr Ann LaCasce from the Dana-Farber Cancer Institute discusses key presentations on chronic lymphocytic leukemia and follicular lymphoma from the 2020 ASH Annual Meeting.
\n\nCME information and select publications here.
","summary":"Featuring discussion on important data sets in chronic lymphocytic leukemia and follicular lymphoma from the 2020 ASH Annual Meeting with Dr Ann LaCasce, moderated by Dr Neil Love.","date_published":"2021-02-19T12:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/b5e20786-9346-47bf-b36d-49ea7fb07f89.mp3","mime_type":"audio/mpeg","size_in_bytes":58508076,"duration_in_seconds":3650}]},{"id":"bbb6b234-f692-48c5-8686-03f247ec41f8","title":"Current and Future Treatment Strategies for Advanced Ovarian Cancer with Dr Kathleen Moore ","url":"https://oncologytoday.researchtopractice.com/54","content_text":"Dr Kathleen Moore from the University of Oklahoma Health Sciences Center discusses key 2020 presentations on the role of PARP inhibitors and other treatment strategies in the management of advanced ovarian cancer.\n\nCME information and select publications here.","content_html":"Dr Kathleen Moore from the University of Oklahoma Health Sciences Center discusses key 2020 presentations on the role of PARP inhibitors and other treatment strategies in the management of advanced ovarian cancer.
\n\nCME information and select publications here.
","summary":"Featuring a presentation and discussion of recent research on the role of PARP inhibitors and other treatment strategies in the management of advanced ovarian cancer with Dr Kathleen Moore, moderated by Dr Neil Love. ","date_published":"2021-02-19T10:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/bbb6b234-f692-48c5-8686-03f247ec41f8.mp3","mime_type":"audio/mpeg","size_in_bytes":63764269,"duration_in_seconds":3981}]},{"id":"6e3d003c-8a1b-4710-b15e-c9e1b1549d87","title":"Front-Line Treatment of Chronic Lymphocytic Leukemia with Dr Steven Coutre","url":"https://oncologytoday.researchtopractice.com/52","content_text":"Dr Steven Coutre from Stanford Medicine in California discusses recently published and emerging research in the front-line treatment of chronic lymphocytic leukemia. \n\nCME information and select publications here.","content_html":"Dr Steven Coutre from Stanford Medicine in California discusses recently published and emerging research in the front-line treatment of chronic lymphocytic leukemia.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent advances in the first-line treatment of chronic lymphocytic leukemia with Dr Steven Coutre, moderated by Dr Neil Love. ","date_published":"2021-02-16T12:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/6e3d003c-8a1b-4710-b15e-c9e1b1549d87.mp3","mime_type":"audio/mpeg","size_in_bytes":74407028,"duration_in_seconds":4643}]},{"id":"8354d84a-c897-48a4-833e-fc5412a731eb","title":"Key Presentations on Myeloproliferative Neoplasms from the 2020 ASH Annual Meeting with Dr Aaron T Gerds","url":"https://oncologytoday.researchtopractice.com/51","content_text":"Dr Aaron Gerds from the Cleveland Clinic Taussig Cancer Institute discusses key presentations on myeloproliferative neoplasms from the 2020 ASH Annual Meeting.\n\nCME information and select publications here.","content_html":"Dr Aaron Gerds from the Cleveland Clinic Taussig Cancer Institute discusses key presentations on myeloproliferative neoplasms from the 2020 ASH Annual Meeting.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on important data sets on myeloproliferative neoplasms from the 2020 ASH Annual Meeting with Dr Aaron Gerds, moderated by Dr Neil Love.","date_published":"2021-02-12T14:15:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/8354d84a-c897-48a4-833e-fc5412a731eb.mp3","mime_type":"audio/mpeg","size_in_bytes":102065754,"duration_in_seconds":4248}]},{"id":"842062f8-8a3a-4c7a-8dbb-07e90f1078bf","title":"Newly Approved Agents in the Management of Urothelial Bladder Carcinoma with Dr Matthew Galsky","url":"https://oncologytoday.researchtopractice.com/50","content_text":"Dr Matthew Galsky from the Icahn School of Medicine at Mount Sinai in New York discusses recently published and emerging data on newly approved agents for urothelial bladder carcinoma.\n\nCME information and select publications here ","content_html":"Dr Matthew Galsky from the Icahn School of Medicine at Mount Sinai in New York discusses recently published and emerging data on newly approved agents for urothelial bladder carcinoma.
\n\nCME information and select publications here
","summary":"Featuring a discussion on recently approved agents in the treatment of urothelial bladder carcinoma with Dr Matthew Galsky, moderated by Dr Neil Love.","date_published":"2021-02-05T10:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/842062f8-8a3a-4c7a-8dbb-07e90f1078bf.mp3","mime_type":"audio/mpeg","size_in_bytes":58111891,"duration_in_seconds":2419}]},{"id":"bf82a290-c963-445c-89e9-4269d2f5a17e","title":"Role of Immune Checkpoint Inhibitors in the Management of Metastatic NSCLC without Actionable Mutations with Dr Corey Langer","url":"https://oncologytoday.researchtopractice.com/49","content_text":"Dr Corey Langer from the Abramson Cancer Center at the University of Pennsylvania discusses recently published and emerging data on the role of immune checkpoint inhibitors in the treatment of metastatic non-small cell lung cancer without actionable mutations.\n\nCME information and select publications here ","content_html":"Dr Corey Langer from the Abramson Cancer Center at the University of Pennsylvania discusses recently published and emerging data on the role of immune checkpoint inhibitors in the treatment of metastatic non-small cell lung cancer without actionable mutations.
\n\nCME information and select publications here
","summary":"The second issue of this program on the role of immune checkpoint inhibitors in the treatment of metastatic NSCLC without targetable alterations features a discussion with Dr Corey Langer, moderated by Dr Neil Love.","date_published":"2021-01-29T14:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/bf82a290-c963-445c-89e9-4269d2f5a17e.mp3","mime_type":"audio/mpeg","size_in_bytes":56214508,"duration_in_seconds":2340}]},{"id":"8721382f-0463-4c21-8ca3-7caa01d713ad","title":"The Evolving Role of PARP Inhibition in the Management of Ovarian Cancer with Dr Shannon Westin","url":"https://oncologytoday.researchtopractice.com/48","content_text":"Dr Shannon Westin from the MD Anderson Cancer Center in Houston, Texas, discusses the role of PARP inhibition in the management of ovarian cancer. \n\nCME information and select publications here ","content_html":"Dr Shannon Westin from the MD Anderson Cancer Center in Houston, Texas, discusses the role of PARP inhibition in the management of ovarian cancer.
\n\nCME information and select publications here
","summary":"Featuring a discussion on the evolving role of PARP inhibition in the management of ovarian cancer with Dr Shannon N Westin, moderated by Dr Neil Love.","date_published":"2021-01-19T14:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/8721382f-0463-4c21-8ca3-7caa01d713ad.mp3","mime_type":"audio/mpeg","size_in_bytes":63207340,"duration_in_seconds":3947}]},{"id":"64b2fcff-7698-4605-9113-07418bee9d94","title":"Key Presentations on the Treatment of Multiple Myeloma from the 2020 ASH Annual Meeting with Dr Sagar Lonial ","url":"https://oncologytoday.researchtopractice.com/47","content_text":"Dr Sagar Lonial from the Winship Cancer Institute in Atlanta, Georgia, discuses key presentations on the management of multiple myeloma from the 2020 ASH Annual Meeting. \n\nCME information and select publications here ","content_html":"Dr Sagar Lonial from the Winship Cancer Institute in Atlanta, Georgia, discuses key presentations on the management of multiple myeloma from the 2020 ASH Annual Meeting.
\n\nCME information and select publications here
","summary":"Featuring a discussion of important multiple myeloma data sets from the 2020 ASH Annual Meeting with Dr Sagar Lonial, moderated by Dr Neil Love. ","date_published":"2021-01-15T11:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/64b2fcff-7698-4605-9113-07418bee9d94.mp3","mime_type":"audio/mpeg","size_in_bytes":61607791,"duration_in_seconds":3843}]},{"id":"92909d72-9f88-421d-8130-15f6d1f816ff","title":"Current Challenges of COVID-19 in Southern California with Dr David Quinn","url":"https://oncologytoday.researchtopractice.com/46","content_text":"Dr David Quinn from the University of Southern California in Los Angeles discusses the impact of COVID-19 on the management of cancer and the current challenges he is experiencing as a physician caring for patients at the front line of the pandemic.\n\nAdditional resources\n\n\nLee LYW et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: A prospective cohort study. Lancet 2020;395(10241):1919-26. Abstract\nMalek AE et al. Cancer and COVID-19. Lancet 2020;396(10257):1066-7. Abstract\nPoortmans P et al. Cancer and COVID-19: What do we really know? Lancet 2020;395(10241):1884-5. Abstract\nXia Y et al. Risk of COVID-19 for patients with cancer. Lancet Oncol 2020;21(4):e180. Abstract\nYang F et al. Clinical characteristics and outcomes of cancer patients with COVID-19. _J Med Virol _2020;92(10):2067-73. Abstract\n","content_html":"Dr David Quinn from the University of Southern California in Los Angeles discusses the impact of COVID-19 on the management of cancer and the current challenges he is experiencing as a physician caring for patients at the front line of the pandemic.
\n\nAdditional resources
\n\nDr Marjorie Zauderer from Memorial Sloan Kettering Cancer Center in New York discusses recently published and emerging research in the management of mesothelioma.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent advances in the treatment of mesothelioma with Dr Marjorie Zauderer, moderated by Dr Neil Love.","date_published":"2020-12-30T12:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/25d73f3f-5326-44bb-b74b-66c55be36cbb.mp3","mime_type":"audio/mpeg","size_in_bytes":41353753,"duration_in_seconds":2582}]},{"id":"579e21ac-aae9-4cb0-bf87-b9856b257b87","title":"The Role of Immunotherapy Combination Approaches in the Management of Metastatic Non-Small Cell Lung Cancer with Dr Stephen Liu","url":"https://oncologytoday.researchtopractice.com/44","content_text":"Dr Stephen Liu from Georgetown University Hospital in Washington, DC, discusses recently published and emerging research on the role of immunotherapy combination approaches in the treatment of metastatic non-small cell lung cancer.\n\nCME information and select publications here.","content_html":"Dr Stephen Liu from Georgetown University Hospital in Washington, DC, discusses recently published and emerging research on the role of immunotherapy combination approaches in the treatment of metastatic non-small cell lung cancer.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent data on the role of immunotherapy combination approaches in the management of metastatic non-small cell lung cancer with Dr Stephen Liu, moderated by Dr Neil Love.","date_published":"2020-12-22T16:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/579e21ac-aae9-4cb0-bf87-b9856b257b87.mp3","mime_type":"audio/mpeg","size_in_bytes":47994895,"duration_in_seconds":2997}]},{"id":"c8d6eae1-4358-4841-9798-3f5a71732956","title":"The Role of PARP Inhibition in the Management of Ovarian Cancer with Dr Ursula Matulonis","url":"https://oncologytoday.researchtopractice.com/42","content_text":"Dr Ursula Matulonis discusses the role of PARP inhibitors in the treatment of ovarian cancer.\n\nCME information and select publications here.","content_html":"Dr Ursula Matulonis discusses the role of PARP inhibitors in the treatment of ovarian cancer.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent data with PARP inhibitors in the treatment of ovarian cancer with Dr Ursula Matulonis, moderated by Neil Love, MD.","date_published":"2020-12-21T15:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/c8d6eae1-4358-4841-9798-3f5a71732956.mp3","mime_type":"audio/mpeg","size_in_bytes":87210545,"duration_in_seconds":2179}]},{"id":"1bb2bf49-fbfb-480c-95f5-ea9c00356eb4","title":"The Role of PARP Inhibition in the Management of Breast Cancer with Dr Hope Rugo","url":"https://oncologytoday.researchtopractice.com/43","content_text":"Dr Hope Rugo discusses the role of PARP inhibitors in the treatment of breast cancer.\n\nCME information and select publications here.","content_html":"Dr Hope Rugo discusses the role of PARP inhibitors in the treatment of breast cancer.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent data with PARP inhibitors in the treatment of breast cancer with Dr Hope Rugo, moderated by Neil Love, MD.","date_published":"2020-12-21T15:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/1bb2bf49-fbfb-480c-95f5-ea9c00356eb4.mp3","mime_type":"audio/mpeg","size_in_bytes":52649754,"duration_in_seconds":2632}]},{"id":"b9676153-73aa-42e5-8c06-77080afda64e","title":"The Role of PARP Inhibition in the Management of Pancreatic Cancer with Dr Philip A Philip","url":"https://oncologytoday.researchtopractice.com/41","content_text":"Dr Philip A Philip discusses the role of PARP inhibitors in the treatment of pancreatic cancer.\n\nCME information and select publications here.","content_html":"Dr Philip A Philip discusses the role of PARP inhibitors in the treatment of pancreatic cancer.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent data with PARP inhibitors in the treatment of pancreatic cancer with Dr Philip A Philip, moderated by Neil Love, MD.","date_published":"2020-12-21T14:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/b9676153-73aa-42e5-8c06-77080afda64e.mp3","mime_type":"audio/mpeg","size_in_bytes":88193585,"duration_in_seconds":2204}]},{"id":"bd913e3c-995d-4d8d-abb8-d949235ebe94","title":"The Role of PARP Inhibition in the Management of Prostate Cancer with Dr Maha Hussain","url":"https://oncologytoday.researchtopractice.com/40","content_text":"Dr Maha Hussain discusses the role of PARP inhibitors in the treatment of prostate cancer.\n\nCME information and select publications here.","content_html":"Dr Maha Hussain discusses the role of PARP inhibitors in the treatment of prostate cancer.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent data with PARP inhibitors in the treatment of prostate cancer with Dr Maha Hussain, moderated by Neil Love, MD.","date_published":"2020-12-21T14:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/bd913e3c-995d-4d8d-abb8-d949235ebe94.mp3","mime_type":"audio/mpeg","size_in_bytes":96627185,"duration_in_seconds":2415}]},{"id":"c6dee7fd-2b71-407a-98f9-3e7de8f3559e","title":"Immune Checkpoint Inhibitors in Urothelial Bladder Carcinoma with Dr Joaquim Bellmunt","url":"https://oncologytoday.researchtopractice.com/39","content_text":"Dr Joaquim Bellmunt from the Beth Israel Deaconess Medical Center in Boston discusses the use of immune checkpoint inhibitors in urothelial bladder carcinoma.\n\nCME information and select publications here.","content_html":"Dr Joaquim Bellmunt from the Beth Israel Deaconess Medical Center in Boston discusses the use of immune checkpoint inhibitors in urothelial bladder carcinoma.
\n\nCME information and select publications here.
","summary":"Featuring a discussion of immune checkpoint inhibitors in urothelial bladder carcinoma with Dr Joaquim Bellmunt, moderated by Neil Love, MD.","date_published":"2020-12-15T13:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/c6dee7fd-2b71-407a-98f9-3e7de8f3559e.mp3","mime_type":"audio/mpeg","size_in_bytes":40563303,"duration_in_seconds":2533}]},{"id":"7c5cc70c-b7d1-48d2-ae5b-1afc2f3bdcf5","title":"Current and Future Role of Immune Checkpoint Inhibitors and Other Novel Therapies in the Management of Gynecologic Cancers with Dr David O'Malley","url":"https://oncologytoday.researchtopractice.com/38","content_text":"Dr David O’Malley from the Ohio State University and The James Cancer Center in Columbus discusses the current and future roles of immune checkpoint inhibitors and other novel therapies in the management of gynecologic cancers.\n\nCME information and select publications here.","content_html":"Dr David O’Malley from the Ohio State University and The James Cancer Center in Columbus discusses the current and future roles of immune checkpoint inhibitors and other novel therapies in the management of gynecologic cancers.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on the current and future role of immune checkpoint inhibitors and other novel therapies in the management of gynecologic cancers with Dr David O’Malley, moderated by Neil Love, MD.","date_published":"2020-12-10T15:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/7c5cc70c-b7d1-48d2-ae5b-1afc2f3bdcf5.mp3","mime_type":"audio/mpeg","size_in_bytes":43767634,"duration_in_seconds":2732}]},{"id":"28388d81-ab16-447e-a654-aad1fa1e6474","title":"Management of Pancreatic Cancer with Dr Andrew Ko","url":"https://oncologytoday.researchtopractice.com/37","content_text":"Dr Andrew Ko from the University of California, San Francisco discusses recently published and emerging research in the management of pancreatic cancer.\n\nCME information and select publications here.","content_html":"Dr Andrew Ko from the University of California, San Francisco discusses recently published and emerging research in the management of pancreatic cancer.
\n\nCME information and select publications here.
","summary":"Featuring a discussion of recent data on the treatment of pancreatic cancer with Dr Andrew Ko, moderated by Neil Love, MD.","date_published":"2020-12-09T11:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/28388d81-ab16-447e-a654-aad1fa1e6474.mp3","mime_type":"audio/mpeg","size_in_bytes":48236129,"duration_in_seconds":3012}]},{"id":"9819cd5a-99a3-434c-a7d8-cb040ef9d103","title":"Key Recent Data Sets in Gastrointestinal Cancers with Dr Philip A Philip","url":"https://oncologytoday.researchtopractice.com/36","content_text":"Dr Philip A Philip from the Karmanos Cancer Institute in Detroit, Michigan, discusses recent data sets in gastrointestinal cancers from the ASCO and ESMO 2020 meetings that are most likely to have an impact on clinical practice.\n\nFaculty information and select publications here.","content_html":"Dr Philip A Philip from the Karmanos Cancer Institute in Detroit, Michigan, discusses recent data sets in gastrointestinal cancers from the ASCO and ESMO 2020 meetings that are most likely to have an impact on clinical practice.
\n\nFaculty information and select publications here.
","summary":"Featuring a discussion on recent data sets in gastrointestinal cancers with Dr Philip A Philip, moderated by Neil Love, MD.","date_published":"2020-12-07T18:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/9819cd5a-99a3-434c-a7d8-cb040ef9d103.mp3","mime_type":"audio/mpeg","size_in_bytes":18541488,"duration_in_seconds":1158}]},{"id":"85a7bbeb-e6a9-40a8-b5a8-17ceadab5945","title":"Immune Checkpoint Inhibition in Breast Cancer with Dr Sylvia Adams","url":"https://oncologytoday.researchtopractice.com/35","content_text":"Dr Sylvia Adams from the Perlmutter Cancer Center in New York discusses recently published and emerging research on the use of immune checkpoint inhibition in breast cancer.\n\nCME information and select publications here.","content_html":"Dr Sylvia Adams from the Perlmutter Cancer Center in New York discusses recently published and emerging research on the use of immune checkpoint inhibition in breast cancer.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent data on the use of immune checkpoint inhibition in breast cancer with Dr Sylvia Adams, moderated by Neil Love, MD.","date_published":"2020-12-07T12:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/85a7bbeb-e6a9-40a8-b5a8-17ceadab5945.mp3","mime_type":"audio/mpeg","size_in_bytes":43287866,"duration_in_seconds":2700}]},{"id":"e79ef67e-1f4d-4f27-9941-4c733cff8a32","title":"The Role of Liquid Biopsy for Cancer Screening with Dr Eric Klein","url":"https://oncologytoday.researchtopractice.com/34","content_text":"Dr Eric Klein from the Cleveland Clinic Lerner College of Medicine in Cleveland, Ohio, discusses the role of liquid biopsy for cancer detection, including his experience with the Circulating Cell-Free Genome Atlas study.\n\nFaculty information and select publications here.","content_html":"Dr Eric Klein from the Cleveland Clinic Lerner College of Medicine in Cleveland, Ohio, discusses the role of liquid biopsy for cancer detection, including his experience with the Circulating Cell-Free Genome Atlas study.
\n\nFaculty information and select publications here.
","summary":"Featuring a discussion on liquid biopsy for cancer screening with Dr Eric Klein, moderated by Neil Love, MD.","date_published":"2020-12-02T12:30:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/e79ef67e-1f4d-4f27-9941-4c733cff8a32.mp3","mime_type":"audio/mpeg","size_in_bytes":31430541,"duration_in_seconds":1964}]},{"id":"decd4fc9-ea0c-456b-81fb-4f34f0320699","title":"Novel Agents Under Investigation in Multiple Myeloma with Dr Peter Voorhees","url":"https://oncologytoday.researchtopractice.com/33","content_text":"Dr Peter Voorhees from the Levine Cancer Institute in Charlotte, North Carolina, discusses novel agents under investigation in multiple myeloma.\n\nCME information and select publications here.","content_html":"Dr Peter Voorhees from the Levine Cancer Institute in Charlotte, North Carolina, discusses novel agents under investigation in multiple myeloma.
\n\nCME information and select publications here.
","summary":"Featuring a discussion of novel agents under investigation in multiple myeloma with Dr Peter Voorhees, moderated by Neil Love, MD.\r\n","date_published":"2020-12-01T12:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/decd4fc9-ea0c-456b-81fb-4f34f0320699.mp3","mime_type":"audio/mpeg","size_in_bytes":48023599,"duration_in_seconds":2994}]},{"id":"1eb1cdf8-f473-4b29-ae32-880b4ab43c34","title":" Adjuvant Therapy for ER-Positive Breast Cancer with Prof Stephen Johnston","url":"https://oncologytoday.researchtopractice.com/32","content_text":"Professor Stephen Johnston from The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research in London discusses the role of CDK4/6 inhibitors in adjuvant therapy for ER-positive breast cancer.\n\nCME information and select publications here.","content_html":"Professor Stephen Johnston from The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research in London discusses the role of CDK4/6 inhibitors in adjuvant therapy for ER-positive breast cancer.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent data with CDK4/6 inhibitors in adjuvant therapy for ER-positive breast cancer with Prof Stephen Johnston, moderated by Neil Love, MD.","date_published":"2020-11-19T11:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/1eb1cdf8-f473-4b29-ae32-880b4ab43c34.mp3","mime_type":"audio/mpeg","size_in_bytes":37498606,"duration_in_seconds":2338}]},{"id":"236573a1-6a7e-429d-8998-8efa61ab1e7a","title":"Management of Non-Small Cell Lung Cancer with ALK and ROS1 Rearrangements with Dr Ross Camidge","url":"https://oncologytoday.researchtopractice.com/31","content_text":"Dr Ross Camidge from the University of Colorado in Denver discusses recently published and emerging research in the management of non-small cell lung cancer with ALK and ROS1 rearrangements.\n\nCME information and select publications here.","content_html":"Dr Ross Camidge from the University of Colorado in Denver discusses recently published and emerging research in the management of non-small cell lung cancer with ALK and ROS1 rearrangements.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent data on the treatment of non-small cell lung cancer with ALK and ROS1 rearrangements with Dr Ross Camidge, moderated by Neil Love, MD.","date_published":"2020-11-18T10:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/236573a1-6a7e-429d-8998-8efa61ab1e7a.mp3","mime_type":"audio/mpeg","size_in_bytes":37482978,"duration_in_seconds":2340}]},{"id":"03eab149-3998-473c-9923-d81a121f7cba","title":"Management of Gastroesophageal Cancers with Dr Daniel Catenacci","url":"https://oncologytoday.researchtopractice.com/30","content_text":"Dr Daniel Catenacci from the University of Chicago Medicine and Biological Sciences discusses recently published and emerging research in the management of gastroesophageal cancers.\n\nCME information and select publications here.","content_html":"Dr Daniel Catenacci from the University of Chicago Medicine and Biological Sciences discusses recently published and emerging research in the management of gastroesophageal cancers.
\n\nCME information and select publications here.
","summary":"Featuring a discussion of recent data on the treatment of gastroesophageal cancers with Dr Daniel Catenacci, moderated by Neil Love, MD.","date_published":"2020-11-16T15:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/03eab149-3998-473c-9923-d81a121f7cba.mp3","mime_type":"audio/mpeg","size_in_bytes":41103761,"duration_in_seconds":2566}]},{"id":"19b928ec-9c89-4868-80a6-2cc41530d73c","title":"Current and Future Role of Immune Checkpoint Inhibitors and Other Novel Therapies in Urothelial Bladder Cancer with Dr Ashish Kamat","url":"https://oncologytoday.researchtopractice.com/29","content_text":"Dr Ashish Kamat from the University of Texas MD Anderson Cancer Center in Houston discusses recently published and emerging research on the use of immune checkpoint inhibitors and other novel therapies for patients with urothelial bladder cancer.\n\nCME information and select publications here.","content_html":"Dr Ashish Kamat from the University of Texas MD Anderson Cancer Center in Houston discusses recently published and emerging research on the use of immune checkpoint inhibitors and other novel therapies for patients with urothelial bladder cancer.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent clinical trial data on the use of immune checkpoint inhibitors and other novel therapies in the management of urothelial bladder cancer with Dr Ashish Kamat, moderated by Neil Love, MD.","date_published":"2020-11-05T12:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/19b928ec-9c89-4868-80a6-2cc41530d73c.mp3","mime_type":"audio/mpeg","size_in_bytes":49817784,"duration_in_seconds":3111}]},{"id":"a2f7e314-7fae-4c93-ab07-81b5ed98f1ed","title":"Renal Cell Carcinoma","url":"https://oncologytoday.researchtopractice.com/28","content_text":"For this special edition of Oncology Today, I met with Dr Chung-Han Lee from the Memorial Sloan Kettering Cancer Center in New York to discuss recently published and emerging research on the management of renal cell carcinoma.\n\nCME information and select publications here.","content_html":"For this special edition of Oncology Today, I met with Dr Chung-Han Lee from the Memorial Sloan Kettering Cancer Center in New York to discuss recently published and emerging research on the management of renal cell carcinoma.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent data on the management of renal cell carcinoma with Dr Chung-Han Lee, moderated by Neil Love, MD.","date_published":"2020-11-04T13:00:00.000-05:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/a2f7e314-7fae-4c93-ab07-81b5ed98f1ed.mp3","mime_type":"audio/mpeg","size_in_bytes":43404613,"duration_in_seconds":2710}]},{"id":"f2759c40-4863-4add-96e0-62039f75f7be","title":"Acute Myeloid Leukemia with FLT3 Mutations","url":"https://oncologytoday.researchtopractice.com/27","content_text":"For this special edition of Oncology Today, I met with Dr Keith Pratz from the University of Pennsylvania in Philadelphia to discuss recently published and emerging research in the use of FLT3 inhibitors for patients with acute myeloid leukemia.\n\nCME information and select publications here.","content_html":"For this special edition of Oncology Today, I met with Dr Keith Pratz from the University of Pennsylvania in Philadelphia to discuss recently published and emerging research in the use of FLT3 inhibitors for patients with acute myeloid leukemia.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent clinical trial data on the use of FLT3 inhibitors in the management of acute myeloid leukemia with Dr Keith Pratz, moderated by Neil Love, MD.","date_published":"2020-10-30T10:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/f2759c40-4863-4add-96e0-62039f75f7be.mp3","mime_type":"audio/mpeg","size_in_bytes":36678986,"duration_in_seconds":2285}]},{"id":"b3c920d0-13bb-4e57-a942-092dac07eea2","title":"Chimeric Antigen Receptor T-Cell Therapy in Non-Hodgkin Lymphoma","url":"https://oncologytoday.researchtopractice.com/26","content_text":"For this special edition of Oncology Today, I met with Dr Tanya Siddiqi from the City of Hope National Medical Center in Duarte, California, to discuss recently published and emerging research in the use of chimeric antigen receptor T-cell therapy for patients with non-Hodgkin lymphoma.\n\nCME information and select publications here.","content_html":"For this special edition of Oncology Today, I met with Dr Tanya Siddiqi from the City of Hope National Medical Center in Duarte, California, to discuss recently published and emerging research in the use of chimeric antigen receptor T-cell therapy for patients with non-Hodgkin lymphoma.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent clinical trial data on the use of CAR T-cell therapy in the management of non-Hodgkin lymphoma with Dr Tanya Siddiqi, moderated by Neil Love, MD.","date_published":"2020-10-27T09:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/b3c920d0-13bb-4e57-a942-092dac07eea2.mp3","mime_type":"audio/mpeg","size_in_bytes":48470495,"duration_in_seconds":3022}]},{"id":"145c3a44-000d-4ee5-b51d-ce40afc1f6ab","title":"PARP Inhibition in the Management of Pancreatic Cancer","url":"https://oncologytoday.researchtopractice.com/25","content_text":"For this special edition of Oncology Today, I met with Dr Kim Reiss Binder from the Abramson Cancer Center in Philadelphia to discuss recently published and emerging research on the use of PARP inhibitors in pancreatic cancer.\n\nCME information and select publications here.","content_html":"For this special edition of Oncology Today, I met with Dr Kim Reiss Binder from the Abramson Cancer Center in Philadelphia to discuss recently published and emerging research on the use of PARP inhibitors in pancreatic cancer.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent advances in the use of PARP inhibitors in pancreatic cancer with Dr Kim Reiss Binder, moderated by Neil Love, MD.","date_published":"2020-10-23T15:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/145c3a44-000d-4ee5-b51d-ce40afc1f6ab.mp3","mime_type":"audio/mpeg","size_in_bytes":44839373,"duration_in_seconds":2800}]},{"id":"a28e96d2-7686-40c4-8a80-d45d5f807289","title":"Management of Acute Myeloid Leukemia Not Eligible for Intensive Induction Therapy","url":"https://oncologytoday.researchtopractice.com/24","content_text":"For this special edition of Oncology Today, I met with Dr Courtney DiNardo from the MD Anderson Cancer Center in Houston, Texas, to discuss recently published and emerging research on the management of acute myeloid leukemia not eligible for intensive induction therapy.\n\nCME information and select publications here.","content_html":"For this special edition of Oncology Today, I met with Dr Courtney DiNardo from the MD Anderson Cancer Center in Houston, Texas, to discuss recently published and emerging research on the management of acute myeloid leukemia not eligible for intensive induction therapy.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent data on the management of acute myeloid leukemia not eligible for intensive induction therapy with Dr Courtney DiNardo, moderated by Neil Love, MD.","date_published":"2020-10-21T10:15:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/a28e96d2-7686-40c4-8a80-d45d5f807289.mp3","mime_type":"audio/mpeg","size_in_bytes":34396456,"duration_in_seconds":2143}]},{"id":"98f317b7-07e0-419f-9341-6eb9d82b4b15","title":"Front-Line Treatment of Chronic Lymphocytic Leukemia","url":"https://oncologytoday.researchtopractice.com/23","content_text":"For this special edition of Oncology Today, I met with Dr John Pagel from the Swedish Cancer Institute in Seattle to discuss recently published and emerging research in the front-line treatment of chronic lymphocytic leukemia.\n\nCME information and select publications here.","content_html":"For this special edition of Oncology Today, I met with Dr John Pagel from the Swedish Cancer Institute in Seattle to discuss recently published and emerging research in the front-line treatment of chronic lymphocytic leukemia.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent advances in the first-line treatment of chronic lymphocytic leukemia with Dr John Pagel, moderated by Neil Love, MD.","date_published":"2020-10-13T16:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/98f317b7-07e0-419f-9341-6eb9d82b4b15.mp3","mime_type":"audio/mpeg","size_in_bytes":78324828,"duration_in_seconds":3259}]},{"id":"81d018fe-ee4f-409f-be61-392e9745a74e","title":"Hodgkin Lymphoma","url":"https://oncologytoday.researchtopractice.com/22","content_text":"For this special edition of Oncology Today, I met with Dr Craig Moskowitz from the University of Miami Sylvester Comprehensive Cancer Center to discuss recently published and emerging research for the treatment of Hodgkin lymphoma.\n\nCME information and select publications here.","content_html":"For this special edition of Oncology Today, I met with Dr Craig Moskowitz from the University of Miami Sylvester Comprehensive Cancer Center to discuss recently published and emerging research for the treatment of Hodgkin lymphoma.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent advances in the treatment of Hodgkin lymphoma with Dr Craig Moskowitz, moderated by Neil Love, MD.","date_published":"2020-10-02T15:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/81d018fe-ee4f-409f-be61-392e9745a74e.mp3","mime_type":"audio/mpeg","size_in_bytes":39464674,"duration_in_seconds":2459}]},{"id":"e589044d-1608-4aa1-9b25-103bcba9fbdc","title":"Novel Induction and Maintenance Strategies in Acute Myeloid Leukemia Edition","url":"https://oncologytoday.researchtopractice.com/21","content_text":"For this special edition of Oncology Today, I met with Dr Jeffrey Lancet from the Moffitt Cancer Center in Tampa, Florida, to discuss recently published and emerging research on induction and maintenance strategies for patients with acute myeloid leukemia.\n\nCME information and select publications here.","content_html":"For this special edition of Oncology Today, I met with Dr Jeffrey Lancet from the Moffitt Cancer Center in Tampa, Florida, to discuss recently published and emerging research on induction and maintenance strategies for patients with acute myeloid leukemia.
\n\nCME information and select publications here.
","summary":"Featuring a discussion of recent data with induction and maintenance therapy for acute myeloid leukemia with Jeffrey E Lancet, MD moderated by Neil Love, MD.","date_published":"2020-09-30T11:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/e589044d-1608-4aa1-9b25-103bcba9fbdc.mp3","mime_type":"audio/mpeg","size_in_bytes":50356586,"duration_in_seconds":3140}]},{"id":"490038ec-c3ae-4cc8-a2a9-4104604fee04","title":"PARP Inhibitors in Breast Cancer Edition","url":"https://oncologytoday.researchtopractice.com/20","content_text":"For this special edition of Oncology Today, I met with Dr Susan Domchek from the University of Pennsylvania in Philadelphia to discuss recently published and emerging research on the use of PARP inhibitors in breast cancer.\n\nCME information and select publications here.","content_html":"For this special edition of Oncology Today, I met with Dr Susan Domchek from the University of Pennsylvania in Philadelphia to discuss recently published and emerging research on the use of PARP inhibitors in breast cancer.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent advances in the use of PARP inhibitors in breast cancer with Dr Susan Domchek, moderated by Neil Love, MD.","date_published":"2020-09-23T09:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/490038ec-c3ae-4cc8-a2a9-4104604fee04.mp3","mime_type":"audio/mpeg","size_in_bytes":56609220,"duration_in_seconds":3533}]},{"id":"9a84aace-6c47-4aed-bab7-9d8180d881a3","title":"Oncology Today with Dr Neil Love: Myeloproliferative Neoplasms Edition","url":"https://oncologytoday.researchtopractice.com/19","content_text":"For this special edition of Oncology Today, I met with Dr Srdan Verstovsek from the MD Anderson Cancer Center in Houston, Texas, to discuss recently published and emerging research in the management of myeloproliferative neoplasms.\n\nCME information and select publications here.","content_html":"For this special edition of Oncology Today, I met with Dr Srdan Verstovsek from the MD Anderson Cancer Center in Houston, Texas, to discuss recently published and emerging research in the management of myeloproliferative neoplasms.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent advances in the treatment of myeloproliferative neoplasms with Dr Srdan Verstovsek, moderated by Neil Love, MD.","date_published":"2020-09-21T15:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/9a84aace-6c47-4aed-bab7-9d8180d881a3.mp3","mime_type":"audio/mpeg","size_in_bytes":40075451,"duration_in_seconds":2498}]},{"id":"21cfcbcf-7a7d-450d-a54b-40bba2e6d3ca","title":"Oncology Today with Dr Neil Love: EGFR Mutation-Positive Non-Small Cell Lung Cancer Edition","url":"https://oncologytoday.researchtopractice.com/18","content_text":"For this special edition of Oncology Today, I met with Dr Pasi Jänne from the Dana-Farber Cancer Institute in Boston, Massachusetts to discuss recently published and emerging research in the management of EGFR mutation-positive non-small cell lung cancer.\n\nCME information and select publications here.","content_html":"For this special edition of Oncology Today, I met with Dr Pasi Jänne from the Dana-Farber Cancer Institute in Boston, Massachusetts to discuss recently published and emerging research in the management of EGFR mutation-positive non-small cell lung cancer.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent advances in the treatment of EGFR mutation-positive non-small cell lung cancer with Dr Pasi Jänne, moderated by Neil Love, MD.","date_published":"2020-09-17T14:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/21cfcbcf-7a7d-450d-a54b-40bba2e6d3ca.mp3","mime_type":"audio/mpeg","size_in_bytes":49758260,"duration_in_seconds":3107}]},{"id":"7032b7a2-a700-4e31-99aa-672bb1b9627b","title":"Oncology Today with Dr Neil Love: CAR T-Cell Therapy in Multiple Myeloma Edition","url":"https://oncologytoday.researchtopractice.com/17","content_text":"For this special edition of Oncology Today, I met with Dr Nikhil Munshi from the Dana-Farber Cancer Institute in Boston to discuss recently published and emerging research on the use of CAR T-cell therapy in multiple myeloma.\n\nCME information and select publications here.","content_html":"For this special edition of Oncology Today, I met with Dr Nikhil Munshi from the Dana-Farber Cancer Institute in Boston to discuss recently published and emerging research on the use of CAR T-cell therapy in multiple myeloma.
\n\nCME information and select publications here.
","summary":"For this special edition of Oncology Today, I met with Dr Nikhil Munshi from the Dana-Farber Cancer Institute in Boston to discuss recently published and emerging research on the use of CAR T-cell therapy in multiple myeloma.","date_published":"2020-09-15T16:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/7032b7a2-a700-4e31-99aa-672bb1b9627b.mp3","mime_type":"audio/mpeg","size_in_bytes":41289338,"duration_in_seconds":2573}]},{"id":"220ef333-b9da-4d6f-9569-919dd6e7a6e2","title":"Oncology Today with Dr Neil Love: Immunotherapy for Urothelial Bladder Carcinoma Edition","url":"https://oncologytoday.researchtopractice.com/16","content_text":"For this special edition of Oncology Today, I met with Dr Petros Grivas from the Fred Hutchinson Cancer Research Center in Seattle to discuss recently published and emerging research on the use of immunotherapy in the management of urothelial bladder carcinoma.\n\nCME information and select publications here.","content_html":"For this special edition of Oncology Today, I met with Dr Petros Grivas from the Fred Hutchinson Cancer Research Center in Seattle to discuss recently published and emerging research on the use of immunotherapy in the management of urothelial bladder carcinoma.
\n\nCME information and select publications here.
","summary":"Featuring a discussion on recent advances in the use of immunotherapy for urothelial bladder cancer with Dr Petros Grivas, moderated by Neil Love, MD.","date_published":"2020-09-11T09:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/220ef333-b9da-4d6f-9569-919dd6e7a6e2.mp3","mime_type":"audio/mpeg","size_in_bytes":44766620,"duration_in_seconds":2795}]},{"id":"109240b9-7d91-42e6-92e6-5a88ab366623","title":"Oncology Today with Dr Neil Love: Cutaneous Squamous Cell Carcinoma Edition","url":"https://oncologytoday.researchtopractice.com/15","content_text":"For this special edition of Oncology Today, I met with Dr Nikhil Khushalani from the Moffitt Cancer Center in Tampa, Florida, to discuss recently published and emerging research including the use of the immune checkpoint inhibitors cemiplimab and pembrolizumab in the management of cutaneous squamous cell carcinoma.\n\nCME information and select publications here.","content_html":"For this special edition of Oncology Today, I met with Dr Nikhil Khushalani from the Moffitt Cancer Center in Tampa, Florida, to discuss recently published and emerging research including the use of the immune checkpoint inhibitors cemiplimab and pembrolizumab in the management of cutaneous squamous cell carcinoma.
\n\nCME information and select publications here.
","summary":"For this special edition of Oncology Today, I met with Dr Nikhil Khushalani from Moffitt Cancer Center to discuss recent data and optimal management of cutaneous squamous cell carcinoma.\r\n","date_published":"2020-09-04T13:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/109240b9-7d91-42e6-92e6-5a88ab366623.mp3","mime_type":"audio/mpeg","size_in_bytes":38117791,"duration_in_seconds":2379}]},{"id":"847fbb6b-3afa-4f38-9622-0e57a6ff79c2","title":"Oncology Today with Dr Neil Love: Small Cell Lung Cancer Edition","url":"https://oncologytoday.researchtopractice.com/14","content_text":"For this special edition of Oncology Today, I met with Dr Charles Rudin from Memorial Sloan Kettering Cancer Center in New York to discuss recently published and emerging research in the management of small cell lung cancer (SCLC), including the recent approval of lurbinectedin as second-line treatment for extensive-stage SCLC.\n\nCME information and select publications here.","content_html":"For this special edition of Oncology Today, I met with Dr Charles Rudin from Memorial Sloan Kettering Cancer Center in New York to discuss recently published and emerging research in the management of small cell lung cancer (SCLC), including the recent approval of lurbinectedin as second-line treatment for extensive-stage SCLC.
\n\nCME information and select publications here.
","summary":"For this special edition of Oncology Today, I met with Dr Charles Rudin from Memorial Sloan Kettering Cancer Center in New York to discuss recently published and emerging research in the management of small cell lung cancer.","date_published":"2020-08-28T13:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/847fbb6b-3afa-4f38-9622-0e57a6ff79c2.mp3","mime_type":"audio/mpeg","size_in_bytes":43645874,"duration_in_seconds":2725}]},{"id":"25d67907-5e60-49a3-afe2-3ec55ea2ef26","title":"Follicular Lymphoma Roundtable – Drs Carla Casulo and John P Leonard","url":"https://oncologytoday.researchtopractice.com/13","content_text":"For this special edition of Oncology Today, Dr Neil Love discusses recently published and emerging research in follicular lymphoma with Drs Carla Casulo from the University of Rochester Wilmot Cancer Center and John P Leonard from the Weill Medical College of Cornell.\n\nCME information and select publications here.","content_html":"For this special edition of Oncology Today, Dr Neil Love discusses recently published and emerging research in follicular lymphoma with Drs Carla Casulo from the University of Rochester Wilmot Cancer Center and John P Leonard from the Weill Medical College of Cornell.
\n\nCME information and select publications here.
","summary":"Featuring a roundtable discussion on recent data and optimal management of follicular lymphoma with Drs Carla Casulo and John P Leonard moderated by Neil Love, MD.","date_published":"2020-08-18T16:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/25d67907-5e60-49a3-afe2-3ec55ea2ef26.mp3","mime_type":"audio/mpeg","size_in_bytes":83169610,"duration_in_seconds":5191}]},{"id":"347166c4-d772-4425-b9de-e04841b0507b","title":"Oncology Today Special Roundtable: Colorectal Cancer ","url":"https://oncologytoday.researchtopractice.com/12","content_text":"Featuring a roundtable discussion with Drs Axel Grothey and Michael J Overman moderated by Neil Love, MD.\n\nCME information and select publications here.","content_html":"Featuring a roundtable discussion with Drs Axel Grothey and Michael J Overman moderated by Neil Love, MD.
\n\nCME information and select publications here.
","summary":"Featuring a roundtable discussion with Drs Axel Grothey and Michael J Overman moderated by Neil Love, MD.","date_published":"2020-08-05T12:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/347166c4-d772-4425-b9de-e04841b0507b.mp3","mime_type":"audio/mpeg","size_in_bytes":87362822,"duration_in_seconds":5458}]},{"id":"441b19d3-44ad-4ecf-9765-2836ae67322e","title":"Dr John Heymach on Angiogenesis Inhibition in Lung Cancer and COVID-19 at MD Anderson","url":"https://oncologytoday.researchtopractice.com/11","content_text":"Dr John Heymach from the MD Anderson Cancer Center discusses the role of anti-angiogenic agents in NSCLC and the status of clinical research for and treatment of lung cancer at MD Anderson during the COVID-19 pandemic.\n\nRTP Lung Cancer Summit: https://www.researchtopractice.com/LungCancerSummit20/\n\nAdditional Resources\n\n\nCalabro L et al. Challenges in lung cancer therapy during the COVID-19 pandemic. Lancet Respir Med 2020;8(6):542-4. Abstract\nDingemans AC et al. Treatment guidance for patients with lung cancer during the coronavirus 2019 pandemic. J Thorac Oncol 2020;15(7):1119-36. Abstract\nDi Noia V et al. Immune checkpoint inhibitors in SARS-CoV-2 infected cancer patients: The spark that ignites the fire? Lung Cancer 2020;145:208-10. Abstract\nSingh AP et al. Management of lung cancer during the COVID-19 pandemic. JCO Oncol Pract 2020:OP2000286. Abstract\nZhao Z et al. Recommendations of individualized medical treatment and common adverse events management for lung cancer patients during the outbreak of COVID-19 epidemic. Thorac Cancer 2020;11(6):1752-7. Abstract\n","content_html":"Dr John Heymach from the MD Anderson Cancer Center discusses the role of anti-angiogenic agents in NSCLC and the status of clinical research for and treatment of lung cancer at MD Anderson during the COVID-19 pandemic.
\n\nRTP Lung Cancer Summit: https://www.researchtopractice.com/LungCancerSummit20/
\n\nAdditional Resources
\n\nIs it worthwhile to treat pancreatic cancer? Dr Michael Pishvaian from Johns Hopkins University discusses the use of the PARP inhibitor olaparib and other new developments in the disease.
\n\nAdditional Resources
\n\nDr Jeff Sharman from the Willamette Valley Cancer Institute and Research Center discusses clinical trials evaluating the use of Bruton tyrosine kinase inhibitors as treatment for patients with SARS-CoV-2.
\n\nAdditional Resources
\n\nOncology nurse practitioner Kelly Goodwin discusses current treatment practices at Massachusetts General Hospital, the challenges encountered treating patients with cancer during COVID-19, and the use of telemedicine in oncology care.
\n\nAdditional Resources
\n\nDr Benjamin Levy from Johns Hopkins comments on changes to the surgical and targeted treatment of lung cancer during COVID-19 and challenges in the management of immune-related adverse events with immune checkpoint inhibitors.
\n\nRTP Lung Cancer Summit Presentations
\n\nAdditional Resources
\n\nBanna G et al. How we treat patients with lung cancer during the SARS-CoV-2 pandemic: primum non nocere. ESMO Open 2020;5(2). Abstract
Kumar S et al. Alternative multidisciplinary management options for locally advanced non-small cell lung cancer during the COVID-19 global pandemic. J Thorac Oncol 2020;[Online ahead of print]. Abstract
Thoracic Surgery Outcomes Research Network, Inc. COVID-19 guidance for triage of operations for thoracic malignancies: A consensus statement from Thoracic Surgery Outcomes Research Network. Ann Thorac Surg 2020;[Online ahead of print]. Abstract
Dr Kathleen Moore from the Stephenson Cancer Cetner and co-chair of the SGO 2020 Annual Meeting discusses COVID guidelines and the impact of the pandemic on clinical research and the treatment of ovarian cancer.
\n\nDr Julie Gralow, Director of Breast Medical Oncology at the Seattle Cancer Care Alliance, reviews how telemedicine and the screening, diagnosis and treatment of breast cancer have rapidly adapted based on resource limitations and risk factors related to COVID-19.
\n\nAdditional Resources
\n\nDr Leora Horn of Vanderbilt University Medical Center discusses outcomes for patients with lung cancer and COVID-19 as well as the human implications of social distancing.
\n\nAdditional Resources
\n\nDr Harold Burstein discusses how breast cancer is currently being managed at the Dana-Farber Cancer Institute with the constraints of social distancing and other COVID-19 considerations.
\n\nCOVID-19-Related Resources in Breast Cancer
\n\nDietz JR et al. Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. The COVID-19 pandemic breast cancer consortium. Breast Cancer Res Treat 2020;[Online ahead of print]. Abstract
\n\nBraunstein LZ et al. Breast radiotherapy under COVID-19 pandemic resource constraints —Approaches to defer or shorten treatment from a Comprehensive Cancer Center in the United States. Adv Radiat Oncol 2020;[Online ahead of print]. Abstract
\n\nColes CE et al. International guidelines on radiation therapy for breast cancer during the COVID-19 pandemic. Clin Oncol (R Coll Radiol) 2020;32(5):279-81. https://www.clinicaloncologyonline.net/article/S0936-6555(20)30122-9/pdf
\n\nESMO. ESMO management and treatment adapted recommendations in the COVID-19 era: Breast Cancer. https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic/breast-cancer-in-the-covid-19-era
","summary":"Dr Harold Burstein discusses how breast cancer is currently being managed at the Dana-Farber Cancer Institute with the constraints of social distancing and other COVID-19 considerations.","date_published":"2020-04-24T09:00:00.000-04:00","attachments":[{"url":"https://dts.podtrac.com/redirect.mp3/aphid.fireside.fm/d/1437767933/705f838e-4a61-494a-8050-bbbc7743dcc2/a06c60a5-def5-4f55-a071-4ede007bccb2.mp3","mime_type":"audio/mpeg","size_in_bytes":41547573,"duration_in_seconds":1730}]},{"id":"77eb719b-96f2-4c9b-9832-db2b376e414d","title":"Dr Tom Lynch on Adjuvant EGFR TKIs in Lung Cancer and COVID-19 in Seattle","url":"https://oncologytoday.researchtopractice.com/2","content_text":"In this second episode of our new podcast series, Dr Tom Lynch, who began his position as director of the Fred Hutchinson Cancer Research Center as Seattle became the first epicenter of the COVID-19 pandemic in the United States, comments on the current status of oncology research and data soon to be presented from a Phase III trial evaluating the EGFR TKI osimertinib as adjuvant therapy for patients with non-small cell lung cancer and EGFR tumor mutations.\n\nAdditional resources:\n\n\nLynch TJ et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350(21):2129-39. Abstract\nAstraZeneca. [Osimertinib] Phase III ADAURA trial will be unblinded early after overwhelming efficacy in the adjuvant treatment of patients with EGFR-mutated lung cancer [press release]. April 10, 2020.\nNational Comprehensive Cancer Network. Short-term recommendations for non-small cell lung cancer management during the COVID-19 pandemic. COVID-19 NCCN guidelines.\n","content_html":"In this second episode of our new podcast series, Dr Tom Lynch, who began his position as director of the Fred Hutchinson Cancer Research Center as Seattle became the first epicenter of the COVID-19 pandemic in the United States, comments on the current status of oncology research and data soon to be presented from a Phase III trial evaluating the EGFR TKI osimertinib as adjuvant therapy for patients with non-small cell lung cancer and EGFR tumor mutations.
\n\nAdditional resources:
\n\nOn this inaugural episode of our new podcast series, we address the treatment of prostate cancer in the era of COVID-19. Featuring interviews with Drs Neeraj Agarwal, Emmanuel Antonarakis and A Oliver Sartor.
\n\nAdditional Resources
\n\n